Here you are: IMGT Web resources > IMGT Repertoire (IG and TR) > Genes and clinical entities

Monoclonal antibodies with clinical indications

Definitions

Monoclonal antibodies and immunoadhesins approved for therapeutic or diagnostic use and are on the market (in 2013)

- 7 Mouse muromonab-CD3
(1992)
ORTHOCLONE OKT3® 		edrecolomab
(1995)
PANOREX® 		capromab
(1996)
PROSTASCINT® 		ibritumomab tiuxetan
(2002)
ZEVALIN® 		tositumomab
(2003)
BEXXAR® 		catumaxomab
(2009)
REMOVAB® 		besilesomab
(2010)
SCINTIMUN®
- 1 Rat catumaxomab
(2009)
REMOVAB®
- 6 Chimeric abciximab
(1993)
REOPRO® 		rituximab
(1997)
MABTHERA® /
RITUXAN® 		basiliximab
(1998)
SIMULECT® 		infliximab
(1998)
REMICADE® 		cetuximab
(2004)
ERBITUX® 		brentuximab vedotin
(2011)
ADCETRIS™
- 13 Humanized palivizumab
(1998)
SYNAGIS® 		trastuzumab
(1998)
HERCEPTIN® 		alemtuzumab
(2001)
CAMPATH® /
MABCAMPATH® /
LEMTRADA™ 		omalizumab
(2003)
XOLAIR® 		bevacizumab
(2004)
AVASTIN® 		nimotuzumab
(2004)
THERACIM® 		natalizumab
(2004)
TYSABRI® /
ANTEGREN® (formerly) 		ranibizumab
(2006)
LUCENTIS® 		eculizumab
(2007)
SOLIRIS™ 		tocilizumab
(2008)
ACTEMRA™ /
RoACTEMRA® 		certolizumab pegol
(2008)
CIMZIA® 		mogamulizumab
(2012)
POTELIGEO® 		pertuzumab
(2012)
PERJETA™
- 14 Human etanercept
(1998)
ENBREL® 		adalimumab
(2002)
HUMIRA® /
TRUDEXA® 		alefacept
(2003)
AMEVIVE® 		abatacept
(2005)
ORENCIA® 		panitumumab
(2006)
VECTIBIX™ 		rilonacept
(2008)
ARCALYST™ 		romiplostim
(2008)
Nplate® 		ustekinumab
(2009)
STELARA™ 		ofatumumab
(2009)
ARZERRA™ 		golimumab
(2009)
SIMPONI™ 		canakinumab
(2009)
ILARIS® 		belimumab
(2011)
BENLYSTA® 		aflibercept
(2011)
ZALTRAP™ /
EYLEA® 		raxibacumab
(2012)
ABthrax®

The INN is followed by the date of first FDA approval and the commercial mark(s).

Development status

These phases are defined by the FDA in the Code of Federal Regulations.

print To print these tables please use Internet Explorer and print in Landscape format and A3 paper size.

Mouse

Number of results: 68

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA, RPI, CPCA chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Development Technology Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain Clinical trials FDA / EMA / NCI number or ATC code Citations/ Notes/ References Biosimilars
111 abagovomab 8659 95
(2006)		 57
(2007)		 ACA125,
MEN-2234		 IG Mus musculus IgG1 - kappa

8659 MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125) (idiotope) [Homo sapiens] Mus musculus 3D5 Menarini (Florence Italy) Therapeutic Ovarian cancers Phase III Oncology 3 studies found, 0 recruiting
128 afelimomab 7340 72
(1994)		 35
(1995)		 MAK-195F IG Mus musculus F(ab')2 - G3 - kappa

TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus Abbott Laboratories (Abbott Park IL USA) / Knoll Pharmaceutical (Mount Olive NJ USA) Sepsis toxic shock Phase III Infectiology 0 studies found, 0 recruiting [a] [b] [e] (108)
312 altumomab 7046 68
(1992)		 33
(1993)		 ZCE025 HYBRI-CEAKER™ IG Mus musculus IgG1 - nd conjugated with chelator pentetate (DPTA)

radiolabelled with Indium-111, In-111		 CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Eli Lilly (Indianapolis IN USA) / Hybritech Inc. (San Diego CA USA) Diagnostic Colorectal cancers Discontinued Oncology 0 studies found, 0 recruiting (99) (116)
287 anatumomab mafenatox 7655 79
(1998)		 41
(1999)		 ABR-214936,
pMB125		 IG Mus musculus IgG1 - nd conjugated with Staphylococcus aureus enterotoxin A

 tumour associated glycoprotein 72 (TAG-72, TAG, HMW mucin-like glycoprotein, CA 72-4) [Homo sapiens] Unknown Renal cell carcinoma (RCC) Phase II Oncology 0 studies found, 0 recruiting
113 arcitumomab 7417 74
(1995)		 36
(1996)		 CEA-Scan,
IMMU-4		 CEA-SCAN™ IG Mus musculus Fab' - G1 - nd

radiolabelled with Technetium-99m, Tc-99m		 CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus NP4, IMMU-4 Immunomedics Inc. (Morris Plains NJ USA) Diagnostic Colorectal cancers (radiodiagnostic imaging of tumors) Withdrawn EC withdrawal (on holders request) November 14, 2005, EC approval October 04, 1996, FDA approval June 28, 1996 Murine ascites, pepsin digestion Oncology 1 studies found, 0 recruiting FDA: (BLA) 103425

 [b] [n]
306 bectumomab 7514 75
(1996)		 37
(1997)		 99mTc-IMMU-LL2 Lymphoscan® IG Mus musculus Fab' - G2a - kappa

CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] LL2 (IgG2a) Immunomedics Inc. (Morris Plains NJ USA) Diagnostic Non-Hodgkin's lymphoma (NHL) Oncology 0 studies found, 0 recruiting
258 besilesomab 8451 92
(2004)		 54
(2005)		 BW250/183 SCINTIMUN® (EU) IG Mus musculus IgG1 - kappa

radiolabelled with Technetium-99m, Tc-99m		 CEACAM8 (carcinoembryonic antigen-related cell adhesion molecule 8, NCA-95, nonspecific cross-reacting antigen 95 kDa, granulocyte cell antigen, CGM6, CD66b) [Homo sapiens] Iba Molecular Imaging (Louvain-la-Neuve Belgium) Diagnostic Peripheral bone infections Phase M EMA approval January 11, 2010 Osteology 1 studies found, 1 recruiting EMA: H-C-001045
Diagnostic Diagnosis of ostomyelitis Phase M EMA approval January 11, 2010 Osteology
Diagnostic Bone marrow scintigraphy Phase M EMA approval January 11, 2010 Osteology
131 biciromab 6867 66
(1991)		 32
(1992)		 Indium (111In) biciromab,
TT2G1		 FibriScint™ IG Mus musculus Fab' - G - nd

radiolabelled with Indium-111, In-111		 fibrin II beta chain (NH2 terminus) [Homo sapiens] Mus musculus T2G1 Centocor Inc. (Horsham PA USA) Diagnostic Cardiovascular thrombosis (in vivo imaging agent) Withdrawn FDA withdrawal (PLA withdrawal, on holders request) June 01, 1993 Cardiovascular diseases 0 studies found, 0 recruiting [b] (31)
101 blinatumomab 9028 100
(2008)		 62
(2009)		 AMG103,
BITE MT-103,
bscCD19xCD3,
MEDI-538,
MT103		 IG Mus musculus (scFv - kappa - heavy) - (scFv - heavy - kappa)

9028 CD19 (B lymphocyte surface antigen B4, Leu-12) [Homo sapiens] ;
CD3E (CD3 epsilon) [Homo sapiens] ;
bispecific [Homo sapiens] 		Homo sapiens Amgen (Thousand Oaks CA USA) (US) / MedImmune Inc. (Gaithersburg MD USA) (US) Therapeutic B cell lymphoma Phase II FDA Orphan drug (for indolent B cell lymphoma) January 01, 2006 Oncology 9 studies found, 4 recruiting [p] (36) (119)
115 capromab 7201 70
(1993)		 34
(1994)		 7E11-C5.3 radiolabelled,
capromab pendetide,
Indium In1111 ProstaScint®		 PROSTASCINT® IG Mus musculus IgG1 - kappa conjugated with chelator pendetide (GYK-DPTA)

radiolabelled with Indium-111, In-111		 FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA) [Homo sapiens] Mus musculus 7E11-C5.3 EUSA Pharma (Doylestown PA USA) Diagnostic Prostate cancers Phase M FDA approval October 28, 1996 Oncology 5 studies found, 1 recruiting FDA: (BLA) 103608

 [b] [d] [n] (31)
218 catumaxomab 8406 93
(2005)		 55
(2006)		 Mus mus. anti-EPCAM (Ho-3/TP-A-01/TPBs01) G2a kappa / Rat sp. anti-CD3E (26/II/6-1.2/TPBs01) G2b lambda,
TPBs01		 REMOVAB® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a - kappa / G2b - lambda

CD3E (CD3 epsilon) [Homo sapiens] ;
EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] ;
bispecific [Homo sapiens] 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Gastric cancers Phase II/III EC Orphan drug November 03, 2006 Oncology 14 studies found, 5 recruiting ATC: L01XC09

 [o] (28) (36)
Therapeutic Malignant ascites Phase M EMA approval April 20, 2009 Oncology
Therapeutic Ovarian cancers Phase II/III Oncology
313 detumomab 7156 70
(1993)		 34
(1994)		 SPECIFID IG Mus musculus

Unknown Cancers Oncology 20 studies found, 3 recruiting
207 dorlimomab aritox 6516 66
(1991)		 32
(1992)		 4197X-RA,
MDX-RA (Ricin A)		 IG Mus musculus conjugated with Ricinus communis ricin A

 Houston Biotechnology (The Woodlands TX USA) / Medarex (Princeton NJ USA) Therapeutic Secondary cataract, Secondary cataract
(Prevention)
Phase III Ophthalmology 0 studies found, 0 recruiting [b] [e] (29) (74)
118 edobacomab 7056 69
(1993)		 34
(1994)		 E5,
XMMEN-0E5		 IG Mus musculus IgM - nd

Mus musculus Pfizer (New York NY USA) / Xoma (Berkeley CA USA) Therapeutic Gram-negative sepsis Phase III Infectiology 212 studies found, 41 recruiting [e] (57)
Therapeutic Septic shock, MSS (meningococcal septic shock) Phase I Infectiology
119 edrecolomab 7471 74
(1995)		 36
(1996)		 17-1A PANOREX® IG Mus musculus IgG2a - kappa

EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Colon cancers Phase M approval (Germany) January 01, 1995 Sp2/0 mouse myeloma cells Oncology 5 studies found, 2 recruiting ATC: L01XC01

NCI: C1554

 [a] [e] [90]
268 elsilimomab 8371 89
(2003)		 51
(2004)		 B-E8 IG Mus musculus IgG1 - nd

IL6 (interleukin 6, IL-6) [Homo sapiens] Unknown Cancers Oncology 0 studies found, 0 recruiting
120 enlimomab 6964 70
(1993)		 34
(1994)		 BIRR-1 IG Mus musculus IgG2a - nd

ICAM1 (intercellular adhesion molecule 1, ICAM-1, CD54) [Homo sapiens] Mus musculus Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) Therapeutic Thermal injury Phase II Hematology 0 studies found, 0 recruiting [a] [e]
Therapeutic Stroke Phase II/III Cardiology
317 enlimomab pegol 7525 77
(1997)		 39
(1998)		 IG Mus musculus Fab' - G2a - nd conjugated with pegol

 ICAM1 (intercellular adhesion molecule 1, ICAM-1, CD54) [Homo sapiens] Mus musculus BI-RR-1 Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) Therapeutic Renal transplant rejection Phase I Immunology 0 studies found, 0 recruiting [70]
303 epitumomab 7833 82
(1999)		 44
(2000)		 B1R1 IG Mus musculus IgG2a - nd

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
269 epitumomab cituxetan 8372 89
(2003)		 51
(2004)		 IG Mus musculus IgG1 - kappa conjugated with chelator cituxetan

radiolabelled with Yttrium-90, Y-90		 MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus HMFG-1 Unknown Therapeutic Epithelial Ovarian cancers Phase III Oncology 0 studies found, 0 recruiting
219 ertumaxomab 8407 93
(2005)		 55
(2006)		 Murine G2a 250A/TP-A-02 (anti-ERBB2) / Rat sp. G2b lambda 26/II/6-1.2 (anti-CD3E),
TPBs03		 REXOMUN® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a - nd / G2b - nd

CD3E (CD3 epsilon) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] ;
bispecific [Homo sapiens] 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Breast cancers Phase II Oncology 4 studies found, 1 recruiting [o] (28) (36)
305 faralimomab 7496 76
(1996)		 38
(1997)		 64G12 IG Mus musculus IgG1 - nd

IFNA1 (interferon alpha1, IFN alpha, IFN alpha 1/13, IFN 13) [Homo sapiens] Medarex (Princeton NJ USA) Systemic lupus erythematosus (SLE) Immunology 0 studies found, 0 recruiting (74)
Rheumatoid arthritis (RA) Immunology
112 gavilimomab 8060 84
(2000)		 46
(2001)		 ABX-CBL IG Mus musculus IgM - nd

BSG (basigin, Ok blood group, CD147) [Homo sapiens] Mus musculus Abgenix (Fremont CA USA) Therapeutic Graft-versus-host disease (GvHD) (steroid-refractory) Phase III Immunology 1 studies found, 0 recruiting [a] [b] [52]
Therapeutic Allograft rejection Phase II Immunology
122 ibritumomab tiuxetan 7873 81
(1999)		 43
(2000)		 In-111 Zevalin,
Y-90 Zevalin		 ZEVALIN® IG Mus musculus IgG1 - kappa conjugated with chelator tiuxetan

radiolabelled with Yttrium-90, Y-90 (Therapeutic) and Indium-111, In-111 (Diagnostic)		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus IDEC-Y2B8 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Schering AG (Berlin Germany) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase M FDA approval February 19, 2002 CHO (Chinese Hamster Ovary) cells Oncology 99 studies found, 32 recruiting FDA: (BLA) 125019

 [j] [n] (31)
123 igovomab 7433 77
(1997)		 39
(1998)		 Indimacis 125,
OC125 chelator DTPA		 IG Mus musculus F(ab')2 - G1 - nd conjugated with chelator pentetate (DPTA)

radiolabelled with Indium-111, In-111		 MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125) [Homo sapiens] Mus musculus CIS Bio international (Bagnols/C France) Diagnostic Ovarian cancers Withdrawn EC withdrawal (on holders request) September 01, 1999, FDA approval September 01, 1996 Oncology 0 studies found, 0 recruiting [d] [n] (31)
124 imciromab 6605 66
(1991)		 32
(1992)		 R1D10 pentetate MYOSCINT® IG Mus musculus Fab - G2a - kappa conjugated with chelator pentetate (DPTA)

radiolabelled with Indium-111, In-111		 myosin, cardiac [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / Eli Lilly (Indianapolis IN USA) Diagnostic Myocardial infection (imaging agent) Withdrawn FDA withdrawal (too expensive to manufacture) February 01, 1999, FDA approval July 03, 1996 Murine ascites, pepsin digestion Cardiology 0 studies found, 0 recruiting FDA: (BLA) 103634

 [b] [d] [n] (31)
126 inolimomab 7253 71
(1994)		 35
(1995)		 IG Mus musculus

IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Mus musculus OPI (Orphan Pharma International) (Dardilly France) Therapeutic Graft versus-host disease (GvHD), acute Phase II/III Immunology 0 studies found, 0 recruiting
281 lemalesomab 8046 84
(2000)		 46
(2001)		 78NCA-90, IMMU-MN3 IG Mus musculus IgG1 - nd

NCA-90 (nonspecific cross-reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [Homo sapiens] Unknown Diagnostic Inflammatory lesions Immunology 0 studies found, 0 recruiting
318 maslimomab 6614 66
(1991)		 32
(1992)		 IG Mus musculus IgG2b - nd

T cell receptor (TR, TR alpha_beta) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
309 minretumomab 7821 80
(1998)		 42
(1999)		 Mab CC-49 IG Mus musculus IgG1 - nd

tumour associated glycoprotein 72 (TAG-72, TAG, HMW mucin-like glycoprotein, CA 72-4) [Homo sapiens] Unknown Unknown Unknown 3 studies found, 0 recruiting
130 mitumomab 7934 82
(1999)		 44
(2000)		 BEC2 IG Mus musculus IgG2b - kappa

ganglioside GD3 [Homo sapiens] Mus musculus BEC2 ImClone Systems Inc. (Somerville NJ USA) / Memorial Sloan-Kettering Cancer Center (New York NY USA) / Merck KgaA (Darmstadt Germany) Therapeutic Melanoma Phase III Oncology 3 studies found, 0 recruiting [a] [e] (9)
Therapeutic Small cell lung cancers (SCLC) Phase III Oncology
198 moxetumomab pasudotox 9236 102
(2009)		 64
(2010)		 CAT-8015,
GCR-8015,
HA22		 IG Mus musculus Fv , disulfide stabilized conjugated with Pseudomonas aeruginosa exotoxin A

 9236 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Acute lymphocytic leukemia (ALL) Phase I Hematology, Oncology 11 studies found, 6 recruiting NCI: C68819

 (29)
Therapeutic Hairy cell leukemia (HCL) Phase I Hematology, Oncology
Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Hematology, Oncology
132 muromonab-CD3 6281 59
(1988)		 29
(1989)		 OKT3 ORTHOCLONE OKT3® IG Mus musculus IgG2a - kappa

1sy6 CD3E (CD3 epsilon) [Homo sapiens] Mus musculus Centocor Ortho Biotech Products LP (Raritan NJ USA) Therapeutic Heart transplant rejection (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology 46 studies found, 7 recruiting FDA: (BLA) 103463

ATC: L04AA02

NCI: C1321

 [a] [b] [d] [j] [n]
Therapeutic Liver transplantation (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology
Therapeutic Acute kidney transplant rejection (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology
316 nacolomab tafenatox 7227 71
(1994)		 35
(1995)		 r-c242Fab-SEA IG Mus musculus IgG1 - nd conjugated with Staphylococcus aureus enterotoxin A

 MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242) [Homo sapiens] Mus musculus pK941 Unknown Unknown Unknown 0 studies found, 0 recruiting
65 naptumomab estafenatox 8598 96
(2006)		 58
(2007)		 ABR-217620,
ANYARA,
TTS CD3		 IG Mus musculus Fab - G1 - kappa conjugated with Staphylococcus aureus enterotoxin E SEA/E120 superantigen (synthetic)

 8598 TPBG (trophoblast glycoprotein, 5T4) [Homo sapiens] Mus musculus 5T4 Active Biotech AB (Lund Sweden) Therapeutic Non-small lung carcinomia Phase III Oncology 3 studies found, 0 recruiting (29)
Therapeutic Renal cell carcinoma (RCC) Phase III Oncology
307 nerelimomab 7546 76
(1996)		 38
(1997)		 BAYX1351 IG Mus musculus IgG1 - nd

TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
134 odulimomab 7364 73
(1995)		 36
(1996)		 afolimomab,
anti-LFA1		 ANTILFA® IG Mus musculus F(ab')2 - G1 - nd

ITGAL (integrin alpha L subunit, lymphocyte function associated antigen 1, CD11a) [Homo sapiens] Mus musculus 25.3 Pasteur M (Lyon France) Therapeutic Allograft rejection Phase III not renewed April 01, 2000, ATU (Temporary Authorizations for Use) August 01, 1994 Immunology 0 studies found, 0 recruiting [a] [n]
136 oregovomab 8183 86
(2002)		 48
(2002)		 MAB-B43.13,
oregovamab		 OVAREX® IG Mus musculus IgG1 - kappa

MUC16 (mucin 16, MUC-16, cancer antigen 125, CA125) [Homo sapiens] Mus musculus B43.13 AltaRex Corp. (Edmonton AB Canada) Therapeutic Ovarian cancers Phase II Oncology 8 studies found, 1 recruiting NCI: C1784

 [a]
225 racotumomab 8998 100
(2008)		 62
(2009)		 1E10 IG Mus musculus IgG1 - kappa

8998 anti-idiopatic, anti-N-glycolyl GM3 ganglioside Mus musculus IgM-kappa P3 (N-glycolylneuraminic -NGNA GM3- acid GM3 gangliosides, NeuGcGM3) [Homo sapiens] Mus musculus CMI (Center of Molecular Immunology) (Playa Cuba) Therapeutic Melanoma Preclinical Oncology 5 studies found, 3 recruiting
Therapeutic Breast cancers Preclinical Oncology
138 satumomab 6977 68
(1992)		 33
(1993)		 Indium (111In) satumomab pendetide,
OncoScint CR/OV,
OncoScint CR103		 ONCOSCINT® IG Mus musculus IgG1 - kappa conjugated with chelator pendetide (GYK-DPTA)

radiolabelled with Indium-111, In-111		 tumour associated glycoprotein 72 (TAG-72, TAG, HMW mucin-like glycoprotein, CA 72-4) [Homo sapiens] Mus musculus B72.3 Cytogen Corp. (Princeton NJ USA) / Lonza Biologics (Basel Switzerland) Diagnostic Colorectal cancers Withdrawn FDA approval December 01, 1992 Oncology 0 studies found, 0 recruiting [b] [n] (31) (38)
Diagnostic Ovarian cancers Withdrawn FDA approval December 01, 1992 Oncology
405 solitomab 9537 106
(2011)		 68
(2012)		 MT110 IG Mus musculus (scFv - kappa - heavy) - (scFv - heavy - kappa)

9537 CD3E (CD3 epsilon) [Homo sapiens] ;
EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] ;
bispecific [Homo sapiens] 		Micromet AG (Munich Germany) Solid tumors Phase I Oncology 1 studies found, 1 recruiting [88]
139 sulesomab 7519 75
(1996)		 37
(1997)		 IMMU-MN3,
Technetium (99mTc) sulesomab, LeukoScan		 LEUKOSCAN® IG Mus musculus Fab' - G1 - nd

radiolabelled with Technetium-99m, Tc-99m		 NCA-90 (nonspecific cross-reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [Homo sapiens] Mus musculus IMMU-MN3 Immunomedics Inc. (Morris Plains NJ USA) Diagnostic Acute atypical appendicitis Immunology 0 studies found, 0 recruiting [b] [d] (10) (31)
Diagnostic Osteomyelitis Immunology
282 taplitumomab paptox 8047 84
(2000)		 46
(2001)		 IG Mus musculus IgG1 - kappa conjugated with Phytolacca americana (pokeweed) antiviral protein PAP

 CD19 (B lymphocyte surface antigen B4, Leu-12) [Homo sapiens] B43 Unknown Therapeutic Cancers Oncology 0 studies found, 0 recruiting
140 technetium (99mTc) fanolesomab 8150 86
(2002)		 48
(2002)		 NeutroSpec IG Mus musculus IgM - nd

radiolabelled with Technetium-99m, Tc-99m		 CD15 (3-fucosyl-N-acetyl-lactosamine, Lewis x, stage-specific embryonic antigen 1, SSEA-1) [Homo sapiens] Mus musculus RB5 Palatin Technologies Inc. (Cranbury NJ USA) Diagnostic Appendicitis (Radionuclide imaging) Withdrawn FDA withdrawal (life-threatening adverse events) December 01, 2005, FDA approval July 02, 2004 Inflammation 0 studies found, 0 recruiting [j] (31)
133 technetium (99mTc) nofetumomab merpentan 7542 76
(1996)		 38
(1997)		 VERLUMA® IG Mus musculus Fab - G2b - kappa conjugated with chelator merpentan

radiolabelled with Technetium-99m, Tc-99m		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus NR-LU-10 Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) / DuPont Merck Pharmaceutical (Billerica MA USA) / NeoRx Corp. (Seattle WA USA) Diagnostic Small cell lung cancers (SCLC) Withdrawn FDA approval August 20, 1996 Oncology 0 studies found, 0 recruiting [b] [d] [n] (31)
286 technetium (99mTc) pintumomab 7513 75
(1996)		 37
(1997)		 170 IG Mus musculus IgG1 - kappa

radiolabelled with Technetium-99m, Tc-99m		 adenocarcinoma antigen [Homo sapiens] Mus musculus 170 Unknown Diagnostic Adenocarcinoma Oncology 365 studies found, 97 recruiting (31)
320 telimomab aritox 6345 66
(1991)		 32
(1992)		 T101-ricin A chain immunotoxin, T101-RTA IG Mus musculus Fab - nd - nd conjugated with Ricinus communis ricin A

 CD5 (T1, LEU-1) [Homo sapiens] Mus musculus T101 Unknown Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Discontinued Hematology, Oncology 0 studies found, 0 recruiting
226 tenatumomab 8832 98
(2007)		 60
(2008)		 ST2146 IG Mus musculus IgG2b - nd

8832 TNC (tenascin C, hexabrachion, HXB) [Homo sapiens] Mus musculus SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (Pomezia Italy) Therapeutic Cancers Oncology 4 studies found, 0 recruiting
142 tositumomab 7827 80
(1998)		 42
(1999)		 BEXXAR® IG Mus musculus IgG2a - lambda

radiolabelled with Iodine-131, I-131		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Corixa Corp. (Seattle WA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Non-Hodgkin's lymphoma (NHL) (follicular, CD20 positive, following chemotherapy relapse) Phase M FDA approval June 27, 2003 Hybridoma Oncology 98 studies found, 21 recruiting FDA: (BLA) 125011

NCI: C2543

Drugnum: 834

 [j] [n] (31)
310 vepalimomab 7757 80
(1998)		 42
(1999)		 1B2 IG Mus musculus IgM - nd

AOC3 (amine oxidase copper concaining 3) [Homo sapiens] Unknown Unknown Unknown 75 studies found, 15 recruiting
314 zolimomab aritox 7055 69
(1993)		 34
(1994)		 H65-ricin A chain immunotoxin, H65-RTA IG Mus musculus conjugated with Ricinus communis ricin A

 CD5 (T1, LEU-1) [Homo sapiens] Mus musculus H65 Unknown Therapeutic Cutaneous T cell lymphoma (CTCL) Phase I Discontinued Oncology 0 studies found, 0 recruiting
Therapeutic Systemic lupus erythematosus (SLE) Phase I Discontinued Immunology
Therapeutic Graft-versus-host disease (GvHD) Phase I Discontinued Immunology
1 0.5B,
0.5beta		 IG Mus musculus IgG1 - kappa

1qnz HIV-1 (human immunodeficiency virus) IIIB gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus Kaketsuken (the Chemo-Sero-Therapeutic Research Institute) (Kumamoto Japan) / MRC Technology (London UK) HIV-1 infection, AIDS
(Prevention and treatment)
Preclinical COS cells transient expression Infectiology [c] [k] (1) (100) [1]
125 131I-IMMU-LL2,
ImmuRAIT-LL2		 IG Mus musculus IgG2a - kappa

radiolabelled with Iodine-131, I-131		 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] Mus musculus LL2 (IgG2a) Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I/II Oncology [e] (31) (54)
108 14F7 IG Mus musculus IgG1 - kappa

1rih ganglioside N-glycolyl GM3 (N-glycolylneuraminic acid -NeuGc, NGNA- GM3 ganglioside, NeuGcGM3) [Homo sapiens] Mus musculus 14F7 Centre of Molecular Immunology (Havana Cuba) Diagnostic Cancers Oncology [p]
109 14G2a IG Mus musculus IgG2a - nd

ganglioside GD2 [Homo sapiens] Mus musculus National Cancer Institute (Bethesda MD USA) Solid tumors Phase I Oncology [e]
Melanoma Phase I Oncology
110 177 Lu-J591,
HuJ591-GS		 IG Mus musculus

radiolabelled with Lutetium-177, Lu-177		 FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA) [Homo sapiens] Mus musculus Weill Cornell Medical (New York NY USA) Therapeutic Prostate cancers, metastatic (androgen-Independent) Phase I/II Oncology (23) (31) (37)
141 225.28S,
Tecnemab-K-1		 IG Mus musculus F(ab')2, Fab/Fab2 mix

radiolabelled with Technetium-99m, Tc-99m		 CSPG4 (chondroitin sulfate proteoglycan 4, high molecular weight-melanoma-associated antigen, HMW-MAA) [Homo sapiens] Mus musculus Sorin Radiofarmaci S.R.L. (Milan Italy) Cutaneous melanoma lesions Withdrawn EC withdrawal (on holders request) February 01, 2000, EC approval April 01, 1997, FDA approval September 01, 1996 Oncology [d] [n] (31)
99 4D5 and UCHT1,
trastuzumab coupled with UCHT1 F(ab')2		 IG Homo sapiens
Mus musculus
Hybrid		 IgG1 - kappa / F(ab')2

CD3E (CD3 epsilon) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] ;
bispecific [Homo sapiens] 		Mus musculus Charing Cross Sunley Research Centre (UK) / Genentech Inc. (S. San Francisco CA USA) / ICRF (UK) Cancers (overexpressing ERBB2) Oncology [c] (36) [42]
137 CC49 RIGScan™ IG Mus musculus

radiolabelled with Iodine-125, I-125		 tumour associated glycoprotein 72 (TAG-72, TAG, HMW mucin-like glycoprotein, CA 72-4) [Homo sapiens] Neoprobe Corp. (Dublin OH USA) Diagnostic Rectal cancers Phase III Oncology [j] (31) (115)
Diagnostic Colon cancers Phase III Oncology
Diagnostic Breast cancers Phase III Oncology
116 COL-1 IG Mus musculus IgG2 - kappa

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus National Cancer Institute (Bethesda MD USA) Gastric cancers Phase I Oncology [e]
Colorectal cancers Phase I Oncology
117 CYT-356-Y-90 ONCOLTAD® IG Mus musculus

Mus musculus Cytogen Corp. (Princeton NJ USA) Prostate cancers (targeted radiotherapy) Phase II Oncology [e]
121 HNK20 IG Mus musculus IgA - nd

glycoprotein F RSV [Respiratory syncytial virus] hybridoma of BALB/c Mus musculus OraVax Inc. (Cambridge MA USA) Respiratory Syncytial Virus (RSV) disease Phase III Infectiology, Pulmonary, Respiratory diseases [a] [n] (102) [94]
159 Iodine 131-ILym-1,
Lym-1,
Oncolym		 ONCOLYM® IG Mus musculus IgG2a - nd

radiolabelled with Iodine-131, I-131		 HLA-DR10 (DRB1*1001) [Homo sapiens] Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Discontinued FDA Orphan drug (for NHL) November 27, 1998 Oncology [e] [p] (19) (31) (55)
70 ME361 IG Mus musculus IgG3 - nd

ganglioside GD2 [Homo sapiens] Mus musculus Merck KgaA (Darmstadt Germany) / MRC Technology (London UK) Cancers Oncology (112)
129 MEDI-500,
T10B9,
T10B9.1A-31		 IG Mus musculus IgM - kappa

T cell receptor (TR, TR alpha_beta) [Homo sapiens] Mus musculus MedImmune Inc. (Gaithersburg MD USA) Graft-versus-host disease (GvHD) Phase III Immunology [a]
7 muMAb VEGF A.4.6.1,
muMAb VEGF A4.6.1,
muMAb-VEGF		 IG Mus musculus IgG1 - nd

VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Cancers Oncology [c] [6]
409 CaroRx™ IG Mus musculus IgG/A

streptococcal antigen (SA) [Streptococcus mutans] Mus musculus Guy's 13 Planet Biotechnology (Hayward California USA) Therapeutic dental caries Phase II Infectiology (88) (89)
114 AVICIDIN™ IG Mus musculus

radiolabelled with Yttrium-90, Y-90		 EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Mus musculus NeoRx Corp. (Seattle WA USA) Therapeutic Colon cancers Phase II Withdrawn December 29, 1998 Oncology [e] (31) (35) (86) (87)

up

Rat

Number of results: 2

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA, RPI, CPCA chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Development Technology Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain Clinical trials FDA / EMA / NCI number or ATC code Citations/ Notes/ References Biosimilars
218 catumaxomab 8406 93
(2005)		 55
(2006)		 Mus mus. anti-EPCAM (Ho-3/TP-A-01/TPBs01) G2a kappa / Rat sp. anti-CD3E (26/II/6-1.2/TPBs01) G2b lambda,
TPBs01		 REMOVAB® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a - kappa / G2b - lambda

CD3E (CD3 epsilon) [Homo sapiens] ;
EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] ;
bispecific [Homo sapiens] 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Gastric cancers Phase II/III EC Orphan drug November 03, 2006 Oncology 14 studies found, 5 recruiting ATC: L01XC09

 [o] (28) (36)
Therapeutic Malignant ascites Phase M EMA approval April 20, 2009 Oncology
Therapeutic Ovarian cancers Phase II/III Oncology
219 ertumaxomab 8407 93
(2005)		 55
(2006)		 Murine G2a 250A/TP-A-02 (anti-ERBB2) / Rat sp. G2b lambda 26/II/6-1.2 (anti-CD3E),
TPBs03		 REXOMUN® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a - nd / G2b - nd

CD3E (CD3 epsilon) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] ;
bispecific [Homo sapiens] 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Breast cancers Phase II Oncology 4 studies found, 1 recruiting [o] (28) (36)

up

Chimeric

Number of results: 37

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA, RPI, CPCA chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Development Technology Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain Clinical trials FDA / EMA / NCI number or ATC code Citations/ Notes/ References Biosimilars
146 abciximab 7200 70
(1993)		 34
(1994)		 c7E3 REOPRO® IG Chimeric Fab - G1 - kappa

ITGA2B_ITGB3 (integrin alpha2b_beta3, integrin αIIbβ3, GPIIbIIIa, fibrinogen receptor, CD41_CD61) [Homo sapiens] Mus musculus 7E3 Centocor Inc. (Horsham PA USA) / Eli Lilly (Indianapolis IN USA) Therapeutic Refractory unstable angina when percutaneous coronary intervention is planned Phase M FDA approval November 05, 1997 Sp2/0 mouse myeloma cells Cardiology 60 studies found, 9 recruiting FDA: (BLA) 103575

Drugnum: 332

 [a] [b] [e] [f] [j]
Therapeutic Anti-platelet prevention of blood clots in the setting of high risk percutaneous transluminal coronary angioplasty Phase M FDA approval December 16, 1993 Sp2/0 mouse myeloma cells Cardiology
64 amatuximab 9343 104
(2010)		 66
(2011)		 MORAb-009 IG Chimeric IgG1 - kappa

9343 MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte potentiating factor, MPF, CAK1) [Homo sapiens] Homo sapiens Morphotek Inc. (Exton PA USA) Therapeutic Malignant pleural mesothelioma Phase II Parental A431 cells and A431-K5 cells (expressing mesothelin) Oncology 6 studies found, 2 recruiting [91]
Therapeutic Pancreatic cancers Phase II EC Orphan drug April 01, 2008 Oncology
148 basiliximab 7578 76
(1996)		 38
(1997)		 CHI621 SIMULECT® IG Chimeric IgG1 - kappa

3iu3
1mim		 IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Mus musculus CHI621 Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Organ transplant rejection, acute
(Prevention)
Phase M FDA approval May 12, 1998 Immunology 107 studies found, 42 recruiting FDA: (BLA) 103764

ATC: L04AC02

Drugnum: 440

 [a] [b] [d] [f] [j] (53) [56]
Therapeutic Kidney transplant rejection, acute
(Prevention)
Phase M FDA approval January 02, 2003 Immunology
149 bavituximab 8734 95
(2006)		 57
(2007)		 Tarvacin ch3G4 IG Chimeric IgG1 - kappa

8734 phosphatidylserine [Homo sapiens] Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Therapeutic Hepatitis C Phase II Infectiology 16 studies found, 5 recruiting [p]
Therapeutic Non-small cell lung cancers (NSCLC) Phase II Oncology
Therapeutic Influenza Preclinical Infectiology
Therapeutic Breast cancers Phase II Oncology
324 brentuximab vedotin 9144 103
(2010)		 65
(2011)		 cAC10-Val-Cit-MMAE,
SGN-35		 ADCETRIS™ IG Chimeric IgG1 - kappa conjugated with monomethyl auristatin E (MMAE)

 9144 TNFRSF8 (tumor necrosis factor receptor (TNFR) superfamily member 8, CD30) [Homo sapiens] Mus musculus AC10, mAC10 (IgG2b) Seattle genetics, Inc. (Bothell WA USA) Therapeutic Cutaneous T cell lymphoma (CTCL) with mycosis fungoides (MF) or Sezary syndrome Phase II Oncology 42 studies found, 24 recruiting FDA: (BLA) 125388


FDA: (BLA) 125399

 (79)
Therapeutic Hodgkin lymphoma Phase M FDA approval August 19, 2011 Oncology
Therapeutic Anaplastic large cell lymphoma (ALCL) Phase M FDA approval August 19, 2011 Oncology
151 cetuximab 7906 82
(1999)		 44
(2000)		 Fab C225,
IMC-225		 ERBITUX® IG Chimeric IgG1 - kappa

7906 1yy8
1yy9		 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Mus musculus C225 ImClone Systems Inc. (Somerville NJ USA) (US) / Merck & Co., Inc. (Whitehouse Station NJ USA) (EU) Therapeutic Colorectal cancers, metastatic (EGFR positive) Phase M FDA approval February 12, 2004 Sp2/0 mouse myeloma cells Oncology 606 studies found, 183 recruiting FDA: (BLA) 125084

ATC: L01XC06

NCI: C1723

Drugnum: 850

 [a] [b] [e] [j]
152 clenoliximab 7615 77
(1997)		 39
(1998)		 CE9γ4PE,
IDEC-151		 PRIMATIZED® IG Chimeric IgG4 - lambda

CD4 (p55) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Rheumatoid arthritis (RA) Phase II Immunology 0 studies found, 0 recruiting [a] [b] (21)
Therapeutic Asthma Phase II Immunology
274 ecromeximab 8239 87
(2002)		 49
(2003)		 KM871 IG Chimeric IgG1 - nd

ganglioside GD3 [Homo sapiens] Ludwig Institute for Cancer Research (New York NY USA) Unknown Unknown 1 studies found, 1 recruiting (121)
349 ensituximab 9300 103
(2010)		 65
(2011)		 NPC-1C IG Chimeric IgG1 - kappa

9300 MUC5AC (mucin 5AC, mucin 5 subtypes A and C tracheobronchial/gastric) [Homo sapiens] Neogenix Oncology, Inc.'s (Rockville, MD 20850 Maryland USA) Therapeutic Pancreatic cancers Phase I Oncology 1 studies found, 1 recruiting
Therapeutic Colorectal cancers Phase I Oncology
419 futuximab 9612 107
(2011)		 69
(2013)		 DS 992,
Sym 004 (combinaison of zatuximab and futuximab)		 IG Chimeric IgG1 - kappa

9612 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) domain III [Homo sapiens] Symphogen (Lyngby Denmark) Head and Neck cancers Oncology 0 studies found, 0 recruiting
Colorectal cancers Phase I/II Oncology
154 galiximab 8339 89
(2003)		 51
(2004)		 IDEC-114 IG Chimeric IgG1 - lambda

CD80 (B7-1, CD28LG1) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Rheumatoid arthritis (RA) Immunology 7 studies found, 0 recruiting NCI: C26447

 [a] [g]
Therapeutic Psoriasis Phase II Immunology
Therapeutic Non-Hodgkin's lymphoma (NHL) Phase II Oncology
328 girentuximab 9116 101
(2009)		 63
(2010)		 cG250,
WX-G250		 RENCAREX® IG Chimeric IgG1 - kappa

9116 CA9 (carbonic anhydrase IX, CAIX, MN, G250) [Homo sapiens] Wilex AG (Munich Germany) Therapeutic Renal cell carcinoma (RCC)
(Treatment)
Phase III Oncology 12 studies found, 5 recruiting
389 indatuximab ravtansine 9486 105
(2011)		 67
(2012)		 BT062,
nBT062-DM4		 IG Chimeric IgG4 - kappa conjugated with maytansinoid DM4

 9486 SDC1 (syndecan-1, CD138) [Homo sapiens] Biotest AG (Dreieich Germany) Multiple myeloma (MM) Phase I Hematology, Immunology, Oncology 3 studies found, 2 recruiting [u]
156 infliximab 7602 77
(1997)		 39
(1998)		 cA2,
TA-650		 REMICADE® IG Chimeric IgG1 - kappa

7602 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus A2 Janssen Biotechn Inc. (Horsham PA USA) Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval September 26, 2006 Immunology 332 studies found, 100 recruiting FDA: (BLA) 103772

REMS

ATC: L04AB02

NCI: C1789

Drugnum: 703

Drugnum: 759

 [a] [b] [d] [f] [j] (83) (84) [53] [54] REMSIMA™, developed by Celltrion, Inc. (Incheon Korea), (CT-P13, biosimilar of REMICADE®), approved by KFDA on July 23, 2012, same clinical indications as REMICADE®
Therapeutic Ulcerative colitis (UC) Phase M FDA approval September 15, 2005 Immunology
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval May 18, 2005 Immunology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval November 10, 1999 Immunology
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval December 17, 2004 Immunology
Therapeutic Crohn's disease (CD)
(Treatment)
Phase M FDA approval August 24, 1998 Immunology
329 iodine (124I) girentuximab 9117 101
(2009)		 63
(2010)		 124I_cG250,
124I_WX-G250		 REDECTANE® IG Chimeric IgG1 - kappa

radiolabelled with Iodine-124, I-124		 9117 CA9 (carbonic anhydrase IX, CAIX, MN, G250) [Homo sapiens] Wilex AG (Munich Germany) Diagnostic Renal mass Urology 5 studies found, 2 recruiting (31)
Diagnostic Kidney tumours
(Treatment)
Phase III Oncology
157 keliximab 7560 76
(1996)		 38
(1997)		 IDEC CE9.1/SB-210396 IG Chimeric IgG1 - lambda

CD4 (p55) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Rheumatoid arthritis (RA)
(Treatment)
(chronic)		 Immunology 0 studies found, 0 recruiting (21)
158 lumiliximab 8443 90
(2004)		 52
(2004)		 IDEC-152,
P5E8		 IG Chimeric IgG1 - kappa

FCER2 (immunoglobulin E Fc receptor low affinity II, Fc epsilon RII, CD23) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Hematology, Oncology 5 studies found, 0 recruiting NCI: C26448

 [a] [h] [i]
Therapeutic Allergic asthma Phase I Immunology
235 otelixizumab 8864 98
(2007)		 60
(2008)		 ChAglyCD,
TRX4		 IG Hybrid
Chimeric
Humanized		 IgG1 - lambda

8864 CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. YTH12.5 GlaxoSmithKline (Brentford UK) Therapeutic Psoriasis Phase I Immunology 8 studies found, 1 recruiting
TolerRx (Cambridge CA USA) Therapeutic Type 1 diabetes Phase III Immunology
253 pagibaximab 8643 93
(2005)		 55
(2006)		 BSYX-A110,
PMAB		 IG Chimeric IgG1 - kappa

Staphylococcus epidermidis lipoteichoic acid [Staphylococcus epidermidis] Mus musculus MedImmune Inc. (Gaithersburg MD USA) Staphylococcal sepsis in infants with low birth weight
(Prevention)
Phase II/III Infectiology 7 studies found, 2 recruiting
160 priliximab 7263 72
(1994)		 35
(1995)		 cm-MT412 IG Chimeric IgG1 - kappa

CD4 (p55) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) Therapeutic Crohn's disease (CD) Phase II Immunology 0 studies found, 0 recruiting
459 pritoxaximab 9723 108
(2012)		 caStx1,
cαStx1		 IG Chimeric IgG1 - kappa

9723 Shiga toxin 2 (B-subunit) [Escherichia coli] Laboratoire Français du fractionnement et des Biotechnologies (LFB) (Courtabœuf France) / Thallion Pharmaceuticals Inc (Dorval Québec Canada) Therapeutic STEC (Shiga-like toxin-producing Escherichia coli or E. coli serotype O121) infection causing diarrhea and HUS (hemolytic-uremic syndrome)
(Treatment)
Phase II Infectiology 1 studies found, 0 recruiting
161 rituximab 7609 77
(1997)		 39
(1998)		 IDEC-C2B8 MABTHERA®
RITUXAN® (US, Canada and Japan) 		IG Chimeric IgG1 - kappa

7609 1l6x
2osl		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus IDEC-C2B8 CureTech (Yavne Israel) / IDEC Pharmaceuticals, Inc. (San Diego USA CA) Therapeutic Chronic lymphocytic leukemia (CLL) (CD20-positive, in combination with fludaraline and cyclophosphamide (FC) ) Phase M FDA approval (orphan drug) February 18, 2010 Hematology, Oncology 1275 studies found, 187 recruiting FDA: (BLA) 103705


FDA: (BLA) 103737

ATC: L01XC02

NCI: C1702

Drugnum: 349

 [a] [b] [d] [f] [j] [q] (18) (49) [55]
Genentech Inc. (S. San Francisco CA USA) / IDEC Pharmaceuticals, Inc. (San Diego USA CA) Therapeutic Non-Hodgkin's lymphoma (NHL)
(Treatment)
(follicular, CD20 positive, relapsed or refractory low grade)		 Phase M FDA approval November 01, 1997 Oncology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval February 28, 2006 Immunology
Therapeutic Wegener's Granulomatosis (WG) and Microscopic Polygamiitis (MPA), in combination with glucocorticoides Phase M FDA approval April 19, 2011 Hematology
460 setoxaximab 9724 108
(2012)		 caStx2,
cαStx2		 IG Chimeric IgG1 - kappa

9724 Shiga Toxin 2 (A-subunit) [Escherichia coli] Laboratoire Français du fractionnement et des Biotechnologies (LFB) (Courtabœuf France) / Thallion Pharmaceuticals Inc (Dorval Québec Canada) Therapeutic STEC (Shiga-like toxin-producing Escherichia coli or E. coli serotype O121) infection causing diarrhea and HUS (hemolytic-uremic syndrome)
(Treatment)
Phase II Infectiology 1 studies found, 0 recruiting
297 siltuximab 9051 100
(2008)		 62
(2009)		 CLLB8,
CNTO 328		 IG Chimeric IgG1 - kappa

9051 IL6 (interleukin 6, IL-6) [Homo sapiens] Centocor Inc. (Horsham PA USA) Therapeutic Neoplasms Phase I Oncology 18 studies found, 2 recruiting (117)
Therapeutic Renal cell carcinoma (RCC) Phase II Oncology
Therapeutic Multiple myeloma (MM) Phase II Hematology, Immunology, Oncology
276 teneliximab 8211 87
(2002)		 49
(2003)		 chi220 IG Chimeric IgG1 - nd

CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5, p50) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
372 ublituximab 9334 104
(2010)		 66
(2011)		 LFB-R603 IG Chimeric IgG1 - kappa

9334 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Laboratoire Français du fractionnement et des Biotechnologies (LFB) (Courtabœuf France) Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Hematology, Oncology 3 studies found, 2 recruiting [67]
277 vapaliximab 8207 87
(2002)		 49
(2003)		 2D10 IG Chimeric IgG2 - nd

AOC3 (amine oxidase copper concaining 3) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
256 volociximab 8600 93
(2005)		 55
(2006)		 IG Chimeric IgG4 - nd

ITGA5 (integrin alpha5 subunit, CD49e) [Homo sapiens] Mus musculus p200-M Unknown Unknown Unknown 10 studies found, 0 recruiting NCI: C48426
433 zatuximab 9613 107
(2011)		 DS 1024,
Sym 004 (combinaison of zatuximab and futuximab)		 IG Chimeric IgG1 - kappa

9613 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) domain III [Homo sapiens] Symphogen (Lyngby Denmark) Head and Neck cancers Phase I/II Oncology 2 studies found, 0 recruiting
Colorectal cancers Phase I/II Oncology
153 12D10 Fab,
12D10-Fab		 CORSEVIN™ M IG Chimeric Fab - nd - nd

F7, coagulation factor VII (coagulation serum prothrombin conversion accelerator) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / Corvas International Inc. (San Diego CA USA) Antithrombotic Discontinued Hematology [a] [e] (56)
143 131I-chTNT (Tumor Necrosis Therapy) -1/B COTARA® IG Chimeric

radiolabelled with Iodine-131, I-131		 Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Solid tumors Phase II Oncology [b] (31)
Malignant glioma (brain cancers) Phase II Oncology
Glioblastoma multiforme (GBM) Phase III Oncology
144 14,18 IG Chimeric

Mus musculus National Cancer Institute (Bethesda MD USA) Neuroblastoma Phase II NCI trial Oncology [b] [e]
Solid tumors Phase II NCI trial Oncology
Leukemia Phase II NCI trial Hematology, Oncology
Melanoma Phase II NCI trial Oncology
145 90Y-cT84.66 IG Chimeric

1J05 CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus Beckman Research Institute (Duarte CA USA) Cancers Phase I Oncology [p] [59]
147 ALG-991 IG Chimeric IgM - nd

urushiol (allergen) [Toxicodendron] Mus musculus Allergene (San Mateo CA USA) Poison oak Phase III Immunology [e] (118)
Poison ivy Phase III Immunology
150 BMS-182248,
BR96		 IG Chimeric conjugated with doxorubicin

1cly
1clz		 Mus musculus Bristol-Myers Squibb (Princeton NJ USA) Breast cancers Phase II Oncology [103]
Ovarian cancers Phase II Oncology
155 IC14 IG Chimeric

CD14 [Homo sapiens] Mus musculus 28C5 ICOS Corporation (Bothell WA USA) Sepsis toxic shock (severe) Phase I CHO (Chinese Hamster Ovary) cells Infectiology [a] [b]
179 IMC-1C11 IG Chimeric

VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Angiogenesis
(Prevention)
Oncology NCI: C2037

up

Humanized

Number of results: 172

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA, RPI, CPCA chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Development Technology Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain Clinical trials FDA / EMA / NCI number or ATC code Citations/ Notes/ References Biosimilars
233 alacizumab pegol 8976 98
(2007)		 60
(2008)		 CDP791,
g165 DFM-PEG		 IG Humanized di - Fab' conjugated with pegol

 8976 KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Therapeutic Cancers Oncology 1 studies found, 0 recruiting
11 alemtuzumab 8005 83
(2000)		 45
(2001)		 Campath-1H,
LDP-03		 CAMPATH® (US)
MABCAMPATH® (EU)
LEMTRADA™ 		IG Humanized IgG1 - kappa

8005 1bey
1ce1		 CD52 [Homo sapiens] Rattus norvegicus YTH34.5HL Berlex Inc. (Wayne NJ USA) (US) / Genzyme Corp. (Cambridge MA USA) (EU) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) (EU/US) Therapeutic Multiple sclerosis (MS) Phase I/II CHO (Chinese Hamster Ovary) cells Immunology 285 studies found, 97 recruiting FDA: (BLA) 103948

ATC: L01XC04

NCI: C1681

Drugnum: 702

 [a] [b] [c] (109) [19] [75] [76] [77] [78] [79] [80] [81] [82] [83]
Therapeutic Kidney transplant rejection Phase I/II CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Chronic lymphocytic leukemia (CLL) Phase M FDA approval May 07, 2001 CHO (Chinese Hamster Ovary) cells Hematology, Oncology
Sanofi-Aventis (Paris France) Therapeutic Multiple sclerosis (MS) Phase III Immunology
231 anrukinzumab 8942 98
(2007)		 60
(2008)		 IMA-638 IG Humanized IgG1 - nd

8942 IL13 (interleukin 13, IL-13) [Homo sapiens] Mus musculus IMA-638 Pfizer (New York NY USA) Ulcerative colitis (UC) Phase III Immunology 5 studies found, 1 recruiting
Wyeth Pharmaceuticals (Madison NJ USA) Therapeutic Asthma Phase II Immunology
18 apolizumab 8210 87
(2002)		 49
(2003)		 Hu1D10 REMITOGEN™
SMART™ 		IG Humanized IgG1 - nd

HLA-DRB (HLA-DR beta) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase II Oncology 6 studies found, 0 recruiting NCI: C2228

 [b]
Therapeutic Chronic lymphocytic leukemia (CLL) (refractory) Phase II Hematology, Oncology
272 aselizumab 8291 88
(2003)		 50
(2003)		 HuDreg-55 IG Humanized IgG4 - nd

SELL (L-selectin, CD62) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
252 bapineuzumab 8624 93
(2005)		 55
(2006)		 AAB-001 IG Humanized IgG1 - nd

amyloid beta (Abeta) [Homo sapiens] Mus musculus Johnson & Johnson (Langhorne PA USA) / Pfizer (New York NY USA) Therapeutic Alzheimer's disease Phase II Neurology 15 studies found, 0 recruiting (32) (33) (91)
Therapeutic Alzheimer's disease Discontinued Neurology
334 benralizumab 9233 102
(2009)		 64
(2010)		 BIW-8405,
MEDI-563		 IG Humanized IgG1 - kappa

9233 IL5RA (interleukin 5 receptor alpha subunit, CD125) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Asthma Phase II Immunology 6 studies found, 0 recruiting
24 bevacizumab 8017 83
(2000)		 45
(2001)		 12-IgG1,
F(ab)-12 IgG1,
Fab-12 IgG1,
rhuMAb-VEGF		 AVASTIN® IG Humanized IgG1 - kappa

8017 1bj1 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) (EU) Therapeutic Colorectal cancers, metastatic Phase M FDA approval February 26, 2004 CHO (Chinese Hamster Ovary) cells Oncology 1591 studies found, 190 recruiting FDA: (BLA) 125085

ATC: L01XC07

Drugnum: 851

 [a] [b] (20)
Therapeutic Glioblastoma Phase M FDA approval February 08, 2011 Oncology
Therapeutic Non-small cell lung cancers, metastatic Phase M FDA approval October 11, 2006 CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Renal cell carcinoma (RCC) Phase M FDA approval July 31, 2009 Oncology
Therapeutic Breast cancers (metastatic ERB2 negative) Phase M FDA approval February 22, 2008 CHO (Chinese Hamster Ovary) cells Oncology
283 bivatuzumab 7965 83
(2000)		 45
(2001)		 BIWA4 IG Humanized IgG1 - nd

CD44 (homing function and Indian blood group system, chondroitin sulfate proteoglycan 8, CSPG8) [Homo sapiens] Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) Therapeutic Squamous cancers Phase I Market discontinued (skin toxicity) February 01, 2005 Oncology 0 studies found, 0 recruiting
375 blosozumab 9440 105
(2011)		 67
(2012)		 LY2541546 IG Humanized IgG4 - kappa

9440 SOST (sclerostin) [Homo sapiens] Eli Lilly (Indianapolis IN USA) Therapeutic Postmenopausal women osteoporosis Phase II Osteology 3 studies found, 0 recruiting
52 cantuzumab mertansine 8223 89
(2003)		 51
(2004)		 huC242-DM1,
SB408075		 IG Humanized IgG1 - kappa conjugated with maytansinoid DM1

 MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242) [Homo sapiens] Mus musculus C242 GlaxoSmithKline (Brentford UK) / ImmunoGen Inc. (Cambridge MA USA) Therapeutic Pancreatic cancers Phase I/II Oncology 0 studies found, 0 recruiting [b]
Therapeutic Non-small cell lung cancers (NSCLC) Phase I/II Oncology
Therapeutic Colorectal cancers Phase I/II Oncology
387 cantuzumab ravtansine 9441 105
(2011)		 67
(2012)		 huC242-DM4,
IMGN242		 IG Humanized IgG1 - kappa conjugated with maytansinoid DM4

 9441 MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242) [Homo sapiens] ImmunoGen Inc. (Cambridge MA USA) GE Junction Cancer (metastatic or locally advanced) Phase II Oncology 2 studies found, 0 recruiting
Neoplasms (Stomach) Phase II Oncology
Gastric cancers (metastatic or locally advanced) Phase II Oncology
401 caplacizumab 9511 106
(2011)		 68
(2012)		 ALX-0081,
PMP12A2h1 - linker AAA - PMP12A2h1 		IG Humanized VH - VH

9511 VWF (von Willebrand factor) [Homo sapiens] Lama glama Ablynx (Ghent/Zwijnaarde Belgium) Acute coronary syndrome (ACS) Phase II Cardiology 1 studies found, 0 recruiting [v]
78 cedelizumab 7567 77
(1997)		 39
(1998)		 ORTHOCLONE OKT4 A IG Humanized IgG - nd

CD4 (p55) [Homo sapiens] Mus musculus Centocor Ortho Biotech Products LP (Raritan NJ USA) Therapeutic Autoimmune diseases, CD4 mediated
(Treatment)
Phase II Immunology 0 studies found, 0 recruiting [a] [b]
Therapeutic Allograft rejection
(Prevention)
Phase II Immunology
242 certolizumab pegol 8448 90
(2004)		 52
(2004)		 CDP870,
PHA-738144		 CIMZIA® IG Humanized Fab' - nd - nd conjugated with pegol

 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval May 13, 2009 Immunology 80 studies found, 26 recruiting FDA: (BLA) 125160

REMS

ATC: L04AB05

 (80)
Therapeutic Crohn's disease (CD) Phase M FDA approval April 22, 2008 Immunology
236 citatuzumab bogatox 9046 99
(2008)		 61
(2009)		 VB6-845 IG Humanized Fab - G1 - kappa conjugated with Bougainvillea spectabilis Willd bouganin

 9046 EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Mus musculus Viventia Biotechnologies Inc. (Mississauga ON Canada) Therapeutic Solid tumors Phase I Oncology 1 studies found, 0 recruiting (29)
447 concizumab 9636 108
(2012)		 Anti-TFPI,
mab2021,
NN7415		 IG Humanized IgG4 - kappa

9636 TFPI (Tissue factor pathway inhibitor, lipoprotein-associated coagualtion inhibitor) [Homo sapiens] Novo Nordisk (Bagsvaerd -1 Denmark) Therapeutic Hemophilia
(Prevention)
Phase I Hematology 1 studies found, 1 recruiting
378 crenezumab 9482 105
(2011)		 67
(2012)		 MABT5102A IG Humanized IgG4 - kappa

9482 amyloid beta (Abeta) peptides Aβ42 and Aβ40 [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Alzheimer's disease Phase II Neurology 5 studies found, 3 recruiting
232 dacetuzumab 8959 98
(2007)		 60
(2008)		 huS2C,
SGN-40		 IG Humanized IgG1 - nd

8959 CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5, p50) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) / Seattle genetics, Inc. (Bothell WA USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I Oncology 16 studies found, 3 recruiting [p]
Therapeutic Diffuse large B cell lymphoma (DLBCL) Phase II Oncology
Therapeutic Multiple myeloma (MM) Phase I Hematology, Immunology, Oncology
36 daclizumab 7164 78
(1997)		 40
(1998)		 ZENAPAX® (EC withdrawal 2009) IG Humanized IgG1 - nd

7164 3nfp
3nfs		 IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Mus musculus 1H4 F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) Therapeutic Kidney transplant rejection, acute
(Prevention)
Withdrawn EC withdrawal (on holders request whith effect from Jan 1, 2009) June 01, 2008, FDA approval December 10, 1997 Immunology 100 studies found, 14 recruiting FDA: (BLA) 103749

ATC: L04AC01

NCI: C1569

Drugnum: 359

 [b] [c] [j] (53) [46] [50]
PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Uveitis Phase I/II Ophthalmology
Therapeutic Psoriasis Phase II Immunology
Therapeutic Graft-versus-host disease (GvHD) Phase II Immunology
Therapeutic Ulcerative colitis (UC) Phase II Immunology
Therapeutic Pediatric kidney transplantation Phase I/II Immunology
Therapeutic Blood cancers Phase II Immunology, Oncology
Therapeutic Tropical spastic paraparesis (TSP model for multiple sclerosis) Phase I/II Immunology, Infectiology, Myelopathy
Therapeutic Liver transplantation Phase II Immunology
Therapeutic Asthma Phase II Immunology
333 dalotuzumab 9200 102
(2009)		 64
(2010)		 MK-0646 IG Humanized IgG1 - kappa

9200 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Merck & Co., Inc. (Whitehouse Station NJ USA) Therapeutic Solid tumors Phase I Oncology 22 studies found, 4 recruiting NCI: C70411
415 demcizumab 9572 107
(2011)		 69
(2013)		 OMP-21M18 IG Humanized IgG2 - kappa

9572 DLL4 (delta-like 4) [Homo sapiens] Oncomed Pharmaceuticals (Redwood City CA USA) Cancers Phase I Oncology 4 studies found, 2 recruiting
37 eculizumab 8231 87
(2002)		 49
(2003)		 5G1.1,
h5G1.1,
h5G1.1HuG2/G4		 SOLIRIS™ IG Humanized IgG2 / G4 - kappa

C5 (complement 5) [Homo sapiens] Mus musculus Alexion Pharmaceuticals Inc. (New Haven CT USA) Therapeutic Paroxysmal nocturnal hemoglobinuria (PNH) Phase M FDA approval March 16, 2007 Hematology 45 studies found, 18 recruiting FDA: (BLA) 125166

REMS

ATC: L04AA25

NCI: C48386

Drugnum: 945

 [a] [b] (81)
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Nephritis Phase II Urology
Therapeutic Psoriasis Phase I/II Immunology
Therapeutic Dermatomyositis Phase I/II Immunology
38 efalizumab 8122 85
(2001)		 47
(2002)		 hu1124 RAPTIVA® IG Humanized IgG1 - kappa

8122 3eo9
3eoa
3eob		 ITGAL (integrin alpha L subunit, lymphocyte function associated antigen 1, CD11a) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) (EU/US) / Merck Serono International S.A. (Geneva Switzerland) (EU) / Xoma (Berkeley CA USA) (US) Therapeutic Psoriasis (infection in chronic moderate to severe plaque) Withdrawn FDA withdrawal (risk of developing progressive multifocal leukoencephalopathy) March 13, 2009, FDA approval October 27, 2003 CHO (Chinese Hamster Ovary) cells Immunology 50 studies found, 2 recruiting FDA: (BLA) 125075

ATC: L04AA21

NCI: C68831

 [a] [b] [j]
291 elotuzumab 9074 100
(2008)		 62
(2009)		 HuLuc63,
PDL-063,
PDL063		 IG Humanized IgG1 - kappa

9074 SLAMF7 (SLAM family member 7, CD2 subset 1, CS1, CD2-like receptor-activating cytotoxic cells, CRACC, 19A24, CD319) [Homo sapiens] Homo sapiens Abbott Laboratories (Abbott Park IL USA) / Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Multiple myeloma (MM) Phase III Hematology, Immunology, Oncology 11 studies found, 5 recruiting
360 enavatuzumab 9354 104
(2010)		 66
(2011)		 PDL 192 IG Humanized IgG1 - kappa

9354 TNFRSF12A (tumor necrosis factor receptor (TNFR) superfamily member 12A, fibroblast growth factor FGF-inducible 14 kDa protein, Fn14, TNF-like weak inducer of apoptosis (Tweak) receptor, Tweak receptor, TweakR, CD266) [Homo sapiens] Mus musculus Facet Biotech (Redwood City CA USA) Therapeutic Solid tumors Phase I Oncology 1 studies found, 0 recruiting NCI: C80045

 [r]
361 enokizumab 9262 104
(2010)		 66
(2011)		 7F3com-2H2,
MEDI-528		 IG Humanized IgG1 - kappa

9262 IL9 (interleukin 9, IL-9, T cell growth factor p40) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Asthma Phase II Immunology 5 studies found, 0 recruiting [72]
40 epratuzumab 7920 82
(1999)		 44
(2000)		 90Y-DOTA-hLL2,
90Y-epratuzumab tetraxetan,
90Y-hLL2,
AMG-412,
hLL2,
IMMU-hLL2		 LYMPHOCIDE™ IG Humanized IgG1 - nd conjugated with chelator tetraxetan (DOTA)

radiolabelled with Yttrium-90, Y-90		 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] Mus musculus LL2 (IgG2a) Immunomedics Inc. (Morris Plains NJ USA) / UCB (Brussels Belgium) Therapeutic Systemic lupus erythematosus (SLE) Phase III Immunology 39 studies found, 8 recruiting [a] [b] [e] (31) [92]
Immunomedics Inc. (Morris Plains NJ USA) Therapeutic B cell lymphoma Phase II Oncology
Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I/II Oncology
280 erlizumab 8076 84
(2000)		 46
(2001)		 rhuMAb IG Humanized IgG1 - nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Unknown Unknown Unknown 216 studies found, 62 recruiting
240 etaracizumab 8862 99
(2008)		 61
(2009)		 hLM60,
MEDI-522		 VITAXIN®
ABEGRIN™ 		IG Humanized IgG1 - nd

8862 ITGAV_ITGB3 (integrin alphaV_beta3, integrin αVβ3, CD51_GPIIIa, vitronectin receptor, VNR, CD51_CD61) [Homo sapiens] Mus musculus LM609 MedImmune Inc. (Gaithersburg MD USA) Therapeutic Melanoma, metastatic Phase II Oncology 10 studies found, 0 recruiting [a]
Therapeutic Sarcoma Phase II Oncology
362 etrolizumab 9290 104
(2010)		 66
(2011)		 Anti-Beta7,
PRO145223,
RG7413,
rhuMAb Beta7		 IG Humanized IgG1 - kappa

9290 ITGA4_ITGB7 (integrin alpha4_beta7, integrin α4β7, lymphocyte Peyer s patch adhesion molecule 1, LPAM-1) [Homo sapiens] ;
ITGAE_ITGB7 (integrin alphaE_beta7, integrin αEβ7, human mucosal lymphocyte antigen 1, HML-1) [Homo sapiens] 		F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic Ulcerative colitis (UC) Phase I Immunology 3 studies found, 2 recruiting
292 farletuzumab 9067 100
(2008)		 62
(2009)		 M3,
MORAb-003		 IG Humanized IgG1 - kappa

9067 FOLR1 (folate receptor 1, folate receptor FR alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18) [Homo sapiens] Morphotek Inc. (Exton PA USA) Therapeutic Ovarian cancers Phase III EC Orphan drug April 01, 2008 Oncology 531 studies found, 107 recruiting
86 felvizumab 7623 77
(1997)		 39
(1998)		 SB 209763 IG Humanized IgG1 - kappa

glycoprotein F RSV [Respiratory syncytial virus] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) Therapeutic Respiratory Syncytial Virus (RSV) disease
(Treatment)
(Prophylaxis in high risk infants)		 Phase III Infectiology, Pulmonary, Respiratory diseases 0 studies found, 0 recruiting [e]
379 ficlatuzumab 9465 105
(2011)		 67
(2012)		 AV-299 ,
SCH 900105		 IG Humanized IgG1 - kappa

9465 HGF (hepatocyte growth factor, scatter factor, SF, hepatopoeitin A) [Homo sapiens] Mus musculus AVEO Pharmaceuticals (Cambridge MA US) Solid tumors Phase I Oncology 4 studies found, 0 recruiting
Non-small cell lung cancers (NSCLC) Phase II Oncology
Neoplasms Phase I Oncology
Lung cancers Phase I Oncology
43 fontolizumab 8264 87
(2002)		 49
(2003)		 IG Humanized IgG1 - nd

IFNG (interferon gamma, IFN gamma) [Homo sapiens] Mus musculus Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Crohn's disease (CD) Phase I/II Immunology 1 studies found, 0 recruiting
44 gemtuzumab 8024 83
(2000)		 45
(2001)		 CMA-676,
gemtuzumab ozogamicin		 MYLOTARG® IG Humanized IgG4 - kappa conjugated with calicheamicin

 CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) [Homo sapiens] Mus musculus P67.6 Pfizer (New York NY USA) Therapeutic Acute myeloid leukemia (AML) (CD33 positive) Withdrawn FDA withdrawal (by Pfizer, on concerns about the product's safety and absence of clinical benefit in trials) June 01, 2010, FDA approval May 17, 2000 Hematology, Oncology 65 studies found, 14 recruiting ATC: L01XC05

 [f] [j] (17) (33)
102 gevokizumab 9310 104
(2010)		 66
(2011)		 XOMA 052 IG Humanized IgG2 - kappa

9310 IL1B (interleukin 1 beta, IL-1B) [Homo sapiens] Mus musculus Xoma (Berkeley CA USA) Therapeutic Type 2 diabetes (T2 DM) Phase II Immunology 12 studies found, 5 recruiting [p] [71]
Therapeutic Type 1 diabetes Phase II Immunology
Therapeutic Cardiovascular disease Phase II Cardiovascular diseases
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
241 ibalizumab 8818 97
(2007)		 59
(2008)		 Hu5A8,
TNX-355		 IG Humanized IgG4 - kappa

8818 3o2d CD4 (p55) [D2] domain [Homo sapiens] Mus musculus 5A8 Taimed Biologics Inc. (Ivine CA USA) Therapeutic HIV-1 infection, AIDS Phase II Infectiology 4 studies found, 0 recruiting [l] (106)
420 imgatuzumab 9598 107
(2011)		 69
(2013)		 GA201,
RG7160,
RO5083945		 IG Humanized IgG1 - kappa

9598 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Rattus sp. ICR62 F. Hoffmann-La Roche Ltd. (Basel Switzerland) Solid tumors Phase II Oncology 6 studies found, 0 recruiting
259 inotuzumab ozogamicin 8574 92
(2004)		 54
(2005)		 CMC-544 IG Humanized IgG4 - kappa conjugated with calicheamicin

 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] Mus musculus G544 Pfizer (New York NY USA) / Wyeth Pharmaceuticals (Madison NJ USA) Non-Hodgkin's lymphoma (NHL) Phase III Oncology 17 studies found, 9 recruiting
Diffuse large B cell lymphoma (DLBCL) Phase II Oncology
351 itolizumab 9321 103
(2010)		 65
(2011)		 T1h IG Humanized IgG1 - kappa

9321 CD6 (Tp120) [Homo sapiens] Biocon (Bangalore India) Therapeutic Rheumatoid arthritis (RA) Phase II Immunology 0 studies found, 0 recruiting
Therapeutic Psoriasis Phase II Immunology
380 ixekizumab 9467 105
(2011)		 67
(2012)		 LY2439821 IG Humanized IgG4 - kappa

9467 IL17A (interleukin 17A, IL-17A) [Homo sapiens] Eli Lilly (Indianapolis IN USA) Rheumatoid arthritis (RA) Phase II Immunology 10 studies found, 6 recruiting
Psoriasis Phase II Immunology
62 labetuzumab 8127 85
(2001)		 47
(2002)		 hMN14 CEACIDE™ IG Humanized IgG - nd

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Colorectal cancers Phase I/II Oncology 7 studies found, 3 recruiting NCI: C2043

 [b]
421 lampalizumab 9578 107
(2011)		 69
(2013)		 AFD, Anti-fD,
Anti-FACTOR D,
FCFD4514S,
RG7417		 IG Humanized Fab - G1 - kappa

9578 CFD (Complement Factor D, adipsin, C3 convertase activator, properdin factor D) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Age-related macular degeneration (AMD), neovascular (wet) Phase II Ophthalmology 9 studies found, 3 recruiting
325 lebrikizumab 9165 101
(2009)		 63
(2010)		 MILR1444A,
PRO301444		 IG Humanized IgG4 - kappa

9165 IL13 (interleukin 13, IL-13) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Allergic asthma Immunology 6 studies found, 2 recruiting
422 ligelizumab 9653 107
(2011)		 69
(2013)		 CL-2C IG Humanized IgG1 - kappa

9653 IGHE (immunoglobulin constant epsilon region of the heavy chain of IgE CH3) 1.3-9 (12aa) 108-121 (12aa) epitope [Homo sapiens] Novartis (Basel Switzerland) Allergic diseases Immunology 0 studies found, 0 recruiting
53 lintuzumab 7580 76
(1996)		 38
(1997)		 HuM195,
SGN-33		 ZAMYL™
Smart™ M195 		IG Humanized IgG - nd

CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / Seattle genetics, Inc. (Bothell WA USA) Therapeutic Acute myeloid leukemia (AML) Discontinued Sp2/0 mouse myeloma cells (ATCC CRL 1581) Hematology, Oncology 17 studies found, 2 recruiting [b] (58) [32]
461 lodelcizumab 9733 108
(2012)		 LGT209,
NVP-LGT209		 IG Humanized IgG1 - kappa

9733 PCSK9 (proprotein convertase subtilisin/kexin type 9) [Homo sapiens] Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic LDL hypercholesterolemy
(Treatment)
Phase II Cardiovascular diseases 0 studies found, 0 recruiting
58 lorvotuzumab mertansine 9299 103
(2010)		 65
(2011)		 BB-10901,
huN901-DM1,
IMGN901		 IG Humanized IgG1 - kappa conjugated with maytansinoid DM1

 9299 NCAM1 (neural cell adhesion molecule 1, NCAM-1, NCAM, CD56) [Homo sapiens] Mus musculus ImmunoGen Inc. (Cambridge MA USA) Therapeutic Small cell lung cancers (SCLC) CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Oncology 5 studies found, 1 recruiting [c] [36]
39 matuzumab 8103 88
(2003)		 50
(2003)		 EMD-72000,
EMD72000		 IG Humanized IgG1 - nd

3c09 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Mus musculus 425 Merck Serono International S.A. (Geneva Switzerland) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan) Therapeutic Lung cancers Phase II Oncology 5 studies found, 0 recruiting [c] [k] [4]
Therapeutic Gastric cancers Phase II Oncology
87 mepolizumab 7876 81
(1999)		 43
(2000)		 SB-240563 Bosatria® IG Humanized

IL5 (interleukin 5, IL-5) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Atopic dermatitis Phase II Immunology 20 studies found, 8 recruiting ATC: L04AC06

 [a]
Therapeutic Hypereosinophilic syndrome (HES) Phase III Hematology
Therapeutic Asthma Phase II Immunology
135 milatuzumab 8922 98
(2007)		 60
(2008)		 hLL1,
MEDI-115		 IG Humanized IgG1 - nd

8922 CD74 (major histocompatibility class II invariant chain, MH2) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Multiple myeloma (MM) Hematology, Immunology, Oncology 8 studies found, 7 recruiting
366 mogamulizumab 9374 104
(2010)		 66
(2011)		 AMG-761,
KM8761,
KW-0761		 POTELIGEO® IG Humanized IgG1 - kappa

9374 CCR4 (chemokine C-C motif receptor 4, chemokine CC receptor 4, CCR-4, CKR4, k5-5, CD194) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Asthma Phase I Immunology 10 studies found, 3 recruiting NCI: C62510

 (51) (90) [73]
Kyowa Hakko Kirin (Tokyo Japan) Therapeutic Peripheral T/NK cell lymphoma Phase II Hematology, Oncology
Therapeutic Adult T cell leukemia / lymphoma Phase M MHLW approval March 30, 2012 Hematology, Oncology
Therapeutic Peripheral T cell lymphoma and cutaneous T cell lymphoma Phase I/II Oncology
73 motavizumab 8693 95
(2006)		 57
(2007)		 MEDI-524 NUMAX® IG Humanized IgG1 - kappa

8693 3ixt
3qwo		 glycoprotein F RSV [Respiratory syncytial virus] affinity matured from palivizumab (#79) Mus musculus MedImmune Inc. (Gaithersburg MD USA) Therapeutic Respiratory Syncytial Virus (RSV) disease
(Treatment)
(Prophylaxis in high risk infants)		 Phase II Infectiology, Pulmonary, Respiratory diseases 12 studies found, 0 recruiting [p] (94)
75 natalizumab 7716 79
(1998)		 41
(1999)		 AN100226 TYSABRI®
ANTEGREN® (formerly) 		IG Humanized IgG4 - nd

ITGA4 (integrin alpha4 subunit, CD49d) [Homo sapiens] Mus musculus AN100226m, MAb 21.6 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Elan Pharmaceuticals International Ltd. (Dublin Ireland) Therapeutic Colitis Phase II Immunology 65 studies found, 21 recruiting FDA: (BLA) 125104

ATC: L04AA23

Drugnum: 869

 [a] [b] [c] [e] [j] [k] (3) (4) [7]
Therapeutic Crohn's disease (CD) Phase M FDA approval January 14, 2008 NSO mouse myeloma cells Immunology
Therapeutic Multiple sclerosis (MS) Phase M FDA SBLA reintroduced June 05, 2006, Market suspension (three patients developed progressive multifocal leukoencephalopathy (PML)) February 28, 2005, FDA approval November 23, 2004 NSO mouse myeloma cells Immunology
Therapeutic Inflammatory conditions, acute and chronic COS cells transient expression Immunology
76 nimotuzumab 8545 94
(2005)		 56
(2006)		 hR3,
Theraloc		 THERACIM® (India, China, Cuba, Argentina, Columbia) IG Humanized IgG1 - kappa

3gkw EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Mus musculus YM BioSciences Inc. (Mississauga Canada) Therapeutic Pancreatic cancers, metastatic Phase II Oncology 38 studies found, 22 recruiting NCI: C2733

 [n]
Therapeutic Pancreatic cancers Phase M EMA Orphan drug June 03, 2008 NSO mouse myeloma cells Oncology
Therapeutic Lung cancers Phase II Oncology
Therapeutic Gastric cancers Phase II Oncology
Therapeutic Glioma cancers Phase M EMA withdrawal December 04, 2008, EMA Orphan drug September 02, 2004 NSO mouse myeloma cells Oncology
Therapeutic Head and Neck cancers Phase M NSO mouse myeloma cells Oncology
238 obinutuzumab 9043 99
(2008)		 65
(2011)		 GA101,
RO5072759		 IG Humanized IgG1 - kappa

9043 3pp3
3pp4		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus B-ly1 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase III Oncology 14 studies found, 9 recruiting [p] (40)
425 ocaratuzumab 9590 107
(2011)		 69
(2013)		 AME-133v,
LY2469298		 IG Humanized IgG1 - kappa

9590 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mentrik Biotech (Dallas TX USA) Non-Hodgkin's lymphoma (NHL) Phase I/II Oncology 3 studies found, 1 recruiting
227 ocrelizumab 8636 94
(2005)		 56
(2006)		 2H7 IG Humanized IgG1 - nd

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) Therapeutic Lupus nephritis Phase III Immunology 26 studies found, 10 recruiting NCI: C66250
Therapeutic Multiple sclerosis (MS) (relapsing remitting) Phase II Immunology
Therapeutic Systemic lupus erythematosus (SLE) Phase III Immunology
Therapeutic Rheumatoid arthritis (RA) Phase III Immunology
353 olokizumab 9333 103
(2010)		 65
(2011)		 CDP 6038 IG Humanized IgG4 - kappa

9333 IL6 (interleukin 6, IL-6) [Homo sapiens] UCB (Brussels Belgium) Therapeutic Autoimmune diseases Phase I Immunology 8 studies found, 0 recruiting
77 omalizumab 8039 84
(2000)		 46
(2001)		 IGE25,
olizumab,
pSVIE26,
rhuMab-E25		 XOLAIR® IG Humanized IgG1 - kappa

8039 IgE Fc [Homo sapiens] Mus musculus MaE11 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) Therapeutic Asthma, severe persistent (allergic asthma) Phase M FDA approval (for subcutaneous use) June 20, 2003 CHO (Chinese Hamster Ovary) cells Immunology 111 studies found, 26 recruiting FDA: (BLA) 103976

REMS

NCI: C29299

 [a] [b] [l]
368 onartuzumab 9368 104
(2010)		 66
(2011)		 MetMAb,
OA-5D5,
OA5D5,
PRO 143966		 IG Humanized Fab/Fc - G1 - kappa

9368 MET (met proto-oncogene, hepatocyte growth factor HGF receptor, HGFR, scatter factor SF receptor, HGF/SF receptor, tyrosine protein kinase c-met, papillary renal cell carcinoma 2, RCCP2) [Homo sapiens] Mus musculus 5D5 Genentech Inc. (S. San Francisco CA USA) Therapeutic Solid tumors Phase I Oncology 10 studies found, 8 recruiting
237 oportuzumab monatox 9045 100
(2008)		 62
(2009)		 VB4-845 PROXINIUM™
VICINIUM™ 		IG Humanized scFv - nd - nd conjugated with Pseudomonas aeruginosa exotoxin A

 9045 EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Homo sapiens Viventia Biotechnologies Inc. (Mississauga ON Canada) Therapeutic Bladder cancers Phase II FDA Orphan drug (US) February 01, 2005 Oncology 3 studies found, 0 recruiting (29)
Therapeutic Head and Neck cancers Phase II/III FDA Orphan drug (US) February 01, 2005 Oncology
235 otelixizumab 8864 98
(2007)		 60
(2008)		 ChAglyCD,
TRX4		 IG Hybrid
Chimeric
Humanized		 IgG1 - lambda

8864 CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. YTH12.5 GlaxoSmithKline (Brentford UK) Therapeutic Psoriasis Phase I Immunology 8 studies found, 1 recruiting
TolerRx (Cambridge CA USA) Therapeutic Type 1 diabetes Phase III Immunology
454 ozanezumab 9703 108
(2012)		 GSK-1223249 IG Humanized IgG1 - nd

9703 RTN4 (reticulon 4, neurite outgrowth inhibitor, NOGO) (NOGO-A) [Homo sapiens] GlaxoSmithKline (Brentford UK) Therapeutic amyotrophic lateral sclerosis
(Treatment)
Phase I CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Immunology 4 studies found, 1 recruiting
Therapeutic Multiple sclerosis (MS)
(Treatment)
Phase I CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Immunology
382 ozoralizumab 9369 105
(2011)		 67
(2012)		 ATN-103 IG Humanized VH - VH' - VH

9369 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] ;
bispecific [Homo sapiens] ;
ALB (albumin, human serum albumin, HSA) [Homo sapiens] 		Lama glama Ablynx (Ghent/Zwijnaarde Belgium) Rheumatoid arthritis (RA) Phase II Immunology 4 studies found, 0 recruiting (60) (126)
Pfizer (New York NY USA) (USA/Japan) Rheumatoid arthritis (RA) Discontinued Immunology
79 palivizumab 7753 79
(1998)		 41
(1999)		 MEDI-493 SYNAGIS® IG Humanized IgG1 - kappa

glycoprotein F RSV [Respiratory syncytial virus] Mus musculus Abbott Laboratories (Abbott Park IL USA) (EU) / MedImmune Inc. (Gaithersburg MD USA) (US) Therapeutic Respiratory Syncytial Virus (RSV) disease
(Treatment)
(Prophylaxis in high risk infants)		 Phase M AMM Market authorization (Abbott) August 01, 1999, FDA approval June 19, 1998 NSO mouse myeloma cells Infectiology, Pulmonary, Respiratory diseases 23 studies found, 5 recruiting FDA: (BLA) 103770

NCI: C2625

Drugnum: 447

 [a] [b] [d] [j] [49]
427 parsatuzumab 9647 107
(2011)		 69
(2013)		 RG7414 IG Humanized IgG1 - kappa

9647 EGFL7 (epidermal growth factor (EGF) like repeat superfamily member 7, EGF-like-domains protein 7) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Solid tumors Phase II Oncology 0 studies found, 0 recruiting
88 pascolizumab 8227 87
(2002)		 49
(2003)		 SB-240683 IG Humanized

IL4 (interleukin 4, IL-4) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Asthma Phase II Immunology 2 studies found, 1 recruiting [a]
Therapeutic Allergy Phase II Immunology
383 pateclizumab 9428 105
(2011)		 67
(2012)		 MLTA3698A,
PRO283698,
RG7416		 IG Humanized IgG1 - kappa

9428 LTA (lymphotoxin alpha, TNF superfamily member 1, TNFSF1, LT) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Disease-Modifying Anti-Rheumatic Drug (DMARD) Phase II Immunology 2 studies found, 0 recruiting [t]
Rheumatoid arthritis (RA) Phase II Immunology
428 perakizumab 9648 107
(2011)		 69
(2013)		 RG4934,
RO5310074		 IG Humanized IgG1 - kappa

9648 IL17A (interleukin 17A, IL-17A) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Psoriatic arthritis (PSA) Immunology 1 studies found, 0 recruiting
Rheumatoid arthritis (RA) Immunology
80 pertuzumab 8380 89
(2003)		 51
(2004)		 OMNITARG™,
rhuMAB 2C4		 PERJETA™ IG Humanized IgG1 - kappa

8380 1l7i
1s78		 ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Therapeutic Prostate cancers Phase II Oncology 41 studies found, 21 recruiting FDA: (BLA) 125409

NCI: C38692
Therapeutic Breast cancers Phase M FDA approval June 08, 2012 Oncology
81 pexelizumab 8153 85
(2001)		 47
(2002)		 5G1.1-SC IG Humanized scFv - nd - nd

C5 (complement 5) [Homo sapiens] Mus musculus Alexion Pharmaceuticals Inc. (New Haven CT USA) Therapeutic Myocardial infection Phase II Cardiology 3 studies found, 0 recruiting [a]
Therapeutic Cardiopulmonary bypass Phase III Cardiology
453 pidilizumab 9689 108
(2012)		 CT-011 IG Humanized IgG1 - kappa

9689 PDCD1 (programmed cell death 1, PD-1, PD1, CD279) [Homo sapiens] CureTech (Yavne Israel) Therapeutic follicular lymphoma
(Treatment)
Phase II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Oncology 12 studies found, 5 recruiting
Therapeutic Colorectal cancers, metastatic
(Treatment)
Phase II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Oncology
Therapeutic Pancreatic cancers
(Treatment)
Phase II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Oncology
Therapeutic Hodgkin lymphoma
(Treatment)
Phase II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Oncology
Therapeutic Prostate cancers
(Treatment)
Phase II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Oncology
Therapeutic Breast cancers
(Treatment)
Preclinical CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Oncology
Therapeutic Liver cancer
(Treatment)
Phase I/II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Oncology
Therapeutic Hepatitis C
(Treatment)
Phase I/II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Infectiology
Therapeutic Multiple myeloma (MM)
(Treatment)
Phase II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Hematology, Immunology, Oncology
Therapeutic Acute myeloid leukemia (AML)
(Treatment)
Phase II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Hematology, Oncology
457 pinatuzumab vedotin 9713 108
(2012)		 ACD22-VCMMAE,
DCDT2980S,
FCU2803,
RO5541072-000		 IG Humanized IgG1 - nd

9713 CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic B cell lymphoma
(Treatment)
Phase I Oncology 2 studies found, 2 recruiting
Therapeutic Chronic lymphocytic leukemia (CLL)
(Treatment)
Phase I Hematology, Oncology
458 polatuzumab vedotin 9714 108
(2012)		 ACD79B-VCMMAE,
DCDS4501A,
FCU2711,
RO5541077-000		 IG Humanized IgG1 - nd

9714 CD79B [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic Non-Hodgkin's lymphoma (NHL)
(Treatment)
Phase I Oncology 2 studies found, 2 recruiting
Therapeutic Chronic lymphocytic leukemia (CLL)
(Treatment)
Phase I Hematology, Oncology
369 ponezumab 9322 104
(2010)		 66
(2011)		 clone 9TL,
PF-04360365,
RN-1219		 IG Humanized IgG2 - kappa

9322 3u0t amyloid beta (Abeta) peptide Aβ40 [Homo sapiens] Homo sapiens 9TL Pfizer (New York NY USA) Therapeutic Alzheimer's disease Phase II Neurology 7 studies found, 0 recruiting
406 quilizumab 9541 106
(2011)		 47H4,
Anti-M1 prime,
MEMP1972A,
RG-7449		 IG Humanized IgG1 - kappa

9541 IGHE connecting region (CO) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) / Roche (Basel Suisse) Asthma Phase II Immunology 3 studies found, 1 recruiting
84 ranibizumab 8313 90
(2004)		 52
(2004)		 Fab-12 variant Y0317,
RhuFab		 LUCENTIS® IG Humanized Fab - G1 - kappa

8313 1cz8 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Age-related macular degeneration (AMD), neovascular (wet) Phase M FDA approval June 30, 2006 E.coli (Escherichia coli) Ophthalmology 316 studies found, 104 recruiting FDA: (BLA) 125156

Drugnum: 904
279 reslizumab 8106 85
(2001)		 47
(2002)		 CDP-835,
CDP835,
JES1-39D10,
JES139D10,
Sch 55700,
SCH55700		 CINQUIL™ IG Humanized IgG4 - nd

IL5 (interleukin 5, IL-5) [Homo sapiens] Rattus sp. 39D10 (IgG2a - kappa) Celltech, UCB (Brussels Belgium) / Schering-Plough (Kenilworth NJ USA) / Teva Pharmaceutical Industries Ltd (Cephalon)0 (Frazer PA USA) Therapeutic Adult eosinophilic asthma Phase III Immunology 10 studies found, 2 recruiting [a] [c] (114) [30]
404 romosozumab 9533 106
(2011)		 68
(2012)		 785A070802,
AMG 785,
AMG-785,
CDP-7851,
CDP7851,
sclerostin Ab		 IG Humanized IgG2 - kappa

9533 SOST (sclerostin) [Homo sapiens] Amgen (Thousand Oaks CA USA) Low bone mineral density Phase II Immunology, Osteology 11 studies found, 4 recruiting [87]
Postmenopausal women osteoporosis Phase II Osteology
327 rontalizumab 9114 101
(2009)		 63
(2010)		 RhuMAB IFNalpha IG Humanized IgG1 - kappa

9114 IFNA1 (interferon alpha1, IFN alpha, IFN alpha 1/13, IFN 13) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Systemic lupus erythematosus (SLE)
(Treatment)
Phase II Immunology 4 studies found, 0 recruiting
304 rovelizumab 7869 81
(1999)		 43
(2000)		 Hu23F2G LEUKARREST™ IG Humanized IgG4 - nd

ITGAL (integrin alpha L subunit, lymphocyte function associated antigen 1, CD11a) [Homo sapiens] ;
ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] ;
bispecific [Homo sapiens] 		Eli Lilly (Indianapolis IN USA) Therapeutic Multiple sclerosis (MS) Phase II Immunology 0 studies found, 0 recruiting [b]
Therapeutic Myocardial infection Phase II Cardiology
Therapeutic Ischemic stroke Phase III Hematology
17 ruplizumab 8014 83
(2000)		 45
(2001)		 BG-9588,
hu5c8		 Antova™ IG Humanized IgG1 - kappa

CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Systemic lupus erythematosus (SLE) Phase II Immunology 2 studies found, 0 recruiting [a]
Therapeutic Allograft rejection Phase I/II Immunology
356 samalizumab 9307 103
(2010)		 65
(2011)		 ALXN6000,
Anti-CD200,
hB7V3V2 G2G4		 IG Humanized IgG2 / G4 - kappa

9307 CD200 (OX-2) [Homo sapiens] Alexion Pharmaceuticals Inc. (New Haven CT USA) Therapeutic Multiple myeloma (MM) Preclinical Hematology, Immunology, Oncology 1 studies found, 0 recruiting [68]
Therapeutic Blood cancers Preclinical Immunology, Oncology
285 sibrotuzumab 7866 81
(1999)		 43
(2000)		 BIBH1 IG Humanized

FAP (fibroblast activation protein, alpha) [Homo sapiens] Unknown Unknown Unknown 2 studies found, 0 recruiting
430 simtuzumab 9626 107
(2011)		 69
(2013)		 AB0024,
GS-6624		 IG Humanized IgG4 - kappa

9626 LOXL2 (lysyl oxidase-like 2) [Homo sapiens] Gilead (Foster City CA USA) Idiopathic pulmonary fibrosis Phase I Pulmonary, Respiratory diseases 14 studies found, 10 recruiting
Solid tumors Phase I Oncology
Myelofibrosis Phase II Hematology
Pancreatic cancers Oncology
71 siplizumab 8251 87
(2002)		 49
(2003)		 MEDI-507 ALLOMUNE™ IG Humanized IgG1 - kappa

CD2 (lymphocyte function-antigen 2, LFA-2) [Homo sapiens] Rattus sp. BTI-322/LO-CD2a (IgG2b – kappa) BioTransplant (Charlestown MA USA) / MedImmune Inc. (Gaithersburg MD USA) Therapeutic Graft-versus-host disease (GvHD) Phase II Immunology 15 studies found, 1 recruiting [a] [b] (110)
Therapeutic Psoriasis Phase II Immunology
Therapeutic Acute kidney transplant rejection Phase I/II Immunology
298 solanezumab 9097 100
(2008)		 62
(2009)		 LY2062430 IG Humanized IgG1 - kappa

9097 amyloid beta (Abeta) peptide soluble monomer [Homo sapiens] Mus musculus m266 Eli Lilly (Indianapolis IN USA) Therapeutic Alzheimer's disease Phase III Neurology 7 studies found, 1 recruiting (85)
251 sontuzumab 8438 94
(2005)		 56
(2006)		 AS1402,
huHMFG-1		 IG Humanized IgG1 - nd

MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus Antisoma (London UK) Therapeutic Breast cancers Phase I Oncology 3 studies found, 0 recruiting
330 suvizumab 9185 102
(2009)		 64
(2010)		 KD-247 IG Humanized IgG1 - kappa

9185 HIV-1 (human immunodeficiency virus) IIIB strain gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus C25 Kaketsuken (the Chemo-Sero-Therapeutic Research Institute) (Kumamoto Japan) Therapeutic HIV-1 infection, AIDS
(Treatment)
Phase I Infectiology 1 studies found, 0 recruiting [63]
103 tadocizumab 8651 94
(2005)		 56
(2006)		 C4G1,
YM-337		 IG Humanized Fab - G1 - kappa

8651 ITGA2B_ITGB3 (integrin alpha2b_beta3, integrin αIIbβ3, GPIIbIIIa, fibrinogen receptor, CD41_CD61) platelet [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / Yamanouchi USA (White Plains NY USA) Therapeutic Platelet aggregation Phase II Hematology 0 studies found, 0 recruiting [b]
271 talizumab 8370 89
(2003)		 51
(2004)		 C21/AL-90,
HU-901,
Hu901,
TNX-901		 IG Humanized IgG1 - nd

IgE Fc [Homo sapiens] Mus musculus MRC Technology (London UK) / Novartis (Basel Switzerland) / Tanox Inc. (Houston TX USA) Peanut allergy (severe) Phase II Immunology 0 studies found, 0 recruiting [b] [k] [l]
Unknown Unknown Unknown
230 tanezumab 8941 99
(2008)		 61
(2009)		 RN624 IG Humanized IgG2 - nd

8941 NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF) [Homo sapiens] Mus musculus Pfizer (New York NY USA) Therapeutic Pain chronic Phase II Neurology 30 studies found, 0 recruiting
Therapeutic Pain, severe acute Phase II Neurology
Osteoarthritis (OA) Phase III Immunology
261 tefibazumab 8500 92
(2004)		 54
(2005)		 Aurexis AUREXIS® IG Humanized IgG1 - kappa

fibrin-binding surface epitope clumping factor A (ClfA) [Staphylococcus aureus] Inhibitex Inc. (Alpharetta GA USA) Therapeutic Staphylococcal infections
(Treatment)
Phase II Infectiology 2 studies found, 0 recruiting (123)
92 teplizumab 8869 97
(2007)		 59
(2008)		 hOKT3-gamma-1 (Ala-Ala),
humanized OKT3,
MGA031		 IG Humanized IgG1 - kappa

8869 CD3E (CD3 epsilon) [Homo sapiens] Mus musculus OKT3 MacroGenics Inc. (Rockville MD USA) Therapeutic Type 1 diabetes Phase I/II CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells, COS-1 cells transient expression and larger scale preparation in roller bottles Immunology 12 studies found, 1 recruiting [c] [37]
234 tigatuzumab 8979 98
(2007)		 60
(2008)		 CS-1008,
TRA-8		 IG Humanized IgG1 - nd

8979 TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262) [Homo sapiens] Mus musculus Daiichi Sankyo Inc. (Parsippany NJ USA) Unknown Unknown 12 studies found, 1 recruiting
450 tildrakizumab 9672 108
(2012)		 MK-3222,
SCH900222		 IG Humanized IgG1 - kappa

9672 IL23 (interleukin 23, IL-23) subunit alpha [Homo sapiens] Merck & Co., Inc. (Whitehouse Station NJ USA) Therapeutic Psoriasis
(Treatment)
Phase II CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Immunology 3 studies found, 2 recruiting
96 tocilizumab 8394 90
(2004)		 52
(2004)		 atlizumab,
MRA,
rhPM-1		 ACTEMRA™
RoACTEMRA® (EU) 		IG Humanized IgG1 - kappa

8394 IL6R (interleukin 6 receptor, IL-6R, CD126) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Tokyo Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) Therapeutic Multiple myeloma (MM) CHO (Chinese Hamster Ovary) DHFR cells Hematology, Immunology, Oncology 292 studies found, 123 recruiting FDA: (BLA) 125276

REMS

EMA: H-C-955

ATC: L04AC07

 [c] (5) [38] [84] [85]
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval January 08, 2010, EMA approval January 16, 2009, Approval (by Japan) April 17, 2008 CHO (Chinese Hamster Ovary) DHFR cells Immunology
Diagnostic, Therapeutic Systemic juvenile idiopathic athritis (SJIA) Phase M FDA approval (sBLA) April 15, 2011 Immunology
Therapeutic Lymphoproliferative disorder giant lymph node hyperplasia (Castleman's disease) Phase III Approval (by Japan) June 01, 2005, NDA approval April 01, 2005 CHO (Chinese Hamster Ovary) DHFR cells Oncology
60 toralizumab 8232 87
(2002)		 49
(2003)		 E6040,
IDEC-131		 IG Humanized

CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Eisai Co. Ltd. (Tokyo Japan) Therapeutic Multiple sclerosis (MS) Phase II Immunology 0 studies found, 0 recruiting [a] [b]
Therapeutic Systemic lupus erythematosus (SLE) Phase I Immunology
97 trastuzumab 7637 78
(1997)		 40
(1998)		 4D5V8,
Herceptin		 HERCEPTIN® IG Humanized IgG1 - kappa

7637 1n8z ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] Mus musculus 4D5 F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Genentech Inc. (S. San Francisco CA USA) (US) Therapeutic Breast cancers overexpressing ERBB2, metastatic Phase M AMM Market authorization (Roche) August 01, 2000, FDA approval September 01, 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Oncology 554 studies found, 174 recruiting FDA: (BLA) 103792

ATC: L01XC03

NCI: C1647

Drugnum: 485

 [a] [b] [d] [e] [j] [48]
Genentech Inc. (S. San Francisco CA USA) Therapeutic Gastric cancers Phase M FDA approval October 20, 2010 Oncology
357 trastuzumab emtansine 9295 103
(2010)		 65
(2011)		 PRO132365,
RG3502,
T-DM1,
trastuzumab-MCC-DM1		 KADCYLA™ IG Humanized IgG1 - kappa conjugated with maytansinoid DM1

 9295 ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) Breast cancers overexpressing ERBB2, metastatic Phase III FDA approval February 22, 2013 Oncology 23 studies found, 12 recruiting FDA: (BLA) 125427

 (125)
371 tregalizumab 9413 104
(2010)		 66
(2011)		 BT-061,
hB-F5,
hBF5(H37L_L4M)		 IG Humanized IgG1 - kappa

9413 CD4 (p55) [Homo sapiens] Biotest AG (Dreieich Germany) Therapeutic Rheumatoid arthritis (RA) Phase II Immunology 2 studies found, 1 recruiting [s]
Therapeutic Psoriasis Phase II Immunology
254 tucotuzumab celmoleukin 8652 94
(2005)		 56
(2006)		 EMD 273066,
huKS-IL2,
KSA-Interleukin-2		 IG Humanized IgG1 - nd conjugated with interleukin 2

 EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Merck Serono International S.A. (Geneva Switzerland) Therapeutic Small cell lung cancers (SCLC) Phase II Oncology 3 studies found, 0 recruiting
Therapeutic Ovarian cancers Phase II Oncology
265 urtoxazumab 8276 90
(2004)		 52
(2004)		 HuVTm1.1,
TMA-15		 IG Humanized IgG1 - kappa

Shiga-like toxin 2 B subunit (SLT2, Stx2, SLT-II) [Escherichia coli] Teijin Ltd. (Tokyo Japan) Staphylococcal sepsis in infants with low birth weight
(Treatment)
Phase II Infectiology 0 studies found, 0 recruiting (124)
386 vatelizumab 9439 105
(2011)		 67
(2012)		 GBR500 IG Humanized IgG4 - kappa

9439 ITGA2 (integrin alpha2 subunit, GPIa, subunit of the alpha-2beta1 integrin, VLA-2, collagen receptor, CD49b) [Homo sapiens] Glenmark Pharmaceuticals SA (Neuchâtel Switzerland) / Sanofi-Aventis (Paris France) Chronic Obstructive Pulmonary Disease (COPD) Phase I Pulmonary, Respiratory diseases 0 studies found, 0 recruiting
Inflammatory bowel disease (IBD) Phase I Immunology
Multiple sclerosis (MS) Phase I Immunology
300 vedolizumab 9093 100
(2008)		 62
(2009)		 LDP-02,
LDP02,
MLN-02,
MLN0002,
MLN02		 IG Humanized IgG1 - kappa

9093 ITGA4_ITGB7 (integrin alpha4_beta7, integrin α4β7, lymphocyte Peyer s patch adhesion molecule 1, LPAM-1) [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) / MRC Technology (London UK) Therapeutic Ulcerative colitis (UC) Phase III Immunology 7 studies found, 0 recruiting [a] [b] [k]
Therapeutic Crohn's disease (CD) Phase III Immunology
21 veltuzumab 8932 98
(2007)		 60
(2008)		 hA20,
IMMU-106		 IG Humanized IgG1 - nd

8932 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I Oncology 12 studies found, 7 recruiting
100 visilizumab 8054 84
(2000)		 46
(2001)		 HuM291 NUVION®
SMART™ anti-CD3 		IG Humanized IgG2 - nd

CD3E (CD3 epsilon) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Intravenous steroid-refractory ulcerative colitis (IVSR-UC) Phase I/II Immunology 70 studies found, 20 recruiting NCI: C2687

 [a] [b]
Therapeutic Psoriasis Phase I/II Immunology
Therapeutic Autoimmune diseases Phase I Immunology
Therapeutic Kidney transplantation Phase II Immunology
Therapeutic Allograft rejection Phase I/II Immunology
431 vorsetuzumab 9611 107
(2011)		 69
(2013)		 h1F6,
SGN-70		 IG Humanized IgG1 - kappa

9611 CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L) [Homo sapiens] Seattle genetics, Inc. (Bothell WA USA) Cancers Oncology 0 studies found, 0 recruiting
Autoimmune diseases Phase I Immunology
432 vorsetuzumab mafodotin 9610 107
(2011)		 SGN-75 IG Humanized IgG1 - kappa conjugated with monomethyl auristatin F (MMAF), non-cleavable maleimidocaproyl (mc) linker

 9610 CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L) [Homo sapiens] Seattle genetics, Inc. (Bothell WA USA) CD70-positive hematologic malignancies Phase I Hematology, Immunology 2 studies found, 1 recruiting
Renal cell carcinoma (RCC) Phase I Oncology
Non-Hodgkin's lymphoma (NHL) Phase I Oncology
229 yttrium (90 Y) clivatuzumab tetraxetan 9226 102
(2009)		 64
(2010)		 IMMU-107 IG Humanized IgG1 - kappa conjugated with chelator tetraxetan (DOTA)

radiolabelled with Yttrium-90, Y-90		 9226 MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Pancreatic cancers (metastatic) Phase II Oncology 1 studies found, 0 recruiting (31) (61)
255 yttrium (90Y) tacatuzumab tetraxetan 8484 91
(2004)		 55
(2006)		 hAFP-31 AFP-Cide™ IG Humanized IgG1 - kappa conjugated with chelator tetraxetan (DOTA)

radiolabelled with Yttrium-90, Y-90		 AFP (alpha-fetoprotein) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Therapeutic Cancers Oncology 0 studies found, 0 recruiting (31)
2 15,
4F2		 IG Humanized IgG1 - nd

SFRP1 (selected frizzled-related protein 1, fusion regulatory protein 1, FRP-1) [Homo sapiens] ;
SLC3A2 (solute carrier family 3 -activators of dibasic and neutral amino acid transport- member 2, 4F2 antigen heavy chain, 4F2HC, CD98 heavy chain, CD98hc, CD98) [Homo sapiens] 		Mus musculus Merck KgaA (Darmstadt Germany) / MRC Technology (London UK) Therapeutic Cancers Oncology
3 1B4 IG Humanized IgG4 - nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Merck & Co., Inc. (Whitehouse Station NJ USA) / NIH (Bethesda MD USA) Acute inflammatory disease CV1P cells Immunology [c] [2]
4 3α4D10 IG Humanized IgG1 - nd

toxin (epitope ARGFAK) [Clostridium perfringens] Mus musculus Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Gas gangrene YB2/0 rat myeloma cells Infectiology [c] [3]
220 520C9XH22,
MDX-H210,
Murine 520C9 (anti-ERBB2)/ Humanized H22 (anti-FcγRI)		 IG Humanized F(ab')2 - G1 - nd

FCGR1 (immunoglobulin G Fc receptor high affinity I, Fc gamma RI, CD64, encoded by human FCGR1A, FCGR1B, FCGR1C) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] ;
bispecific [Homo sapiens] 		Mus musculus 22 (anti-FcγRI), 520C9 (anti-ERBB2) Medarex (Princeton NJ USA) Therapeutic All ERBB2-positive malignancies Phase I/II Oncology [e] (36) (45) (46) (47) (48) (74) [33]
Therapeutic Prostate cancers Phase II Oncology
5 5c8 IG Humanized

15c8
1i9r
25c8
35c8		 CD40LG (CD40 ligand, CD40L, tumor necrosis factor ligand superfamily member 5, TNFSF5, tumor necrosis factor related activation protein, TRAP, CD154) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / MRC Technology (London UK) Unknown Autoimmune diseases Immunology [k]
Unknown Inflammation Immunology
6 60,3 IG Humanized IgG1 - nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Bristol-Myers Squibb (Princeton NJ USA) Myocardial infection Ag8.653 mouse myeloma cells Cardiology [c] (2) [5]
33 7F11C7,
CTM01-humanized,
hCTM01		 IG Humanized IgG4 - kappa

1ad9 MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus CTM01, mCTM01 Celltech, UCB (Brussels Belgium) Breast cancers Oncology [c] (6) (7) (77) [18]
Ovarian cancers NSO mouse myeloma cells, Transient in CHO (Chinese Hamster Ovary) L761h cells Oncology
34 ABC-48,
CY-174		 IG Humanized

SELP (P-selectin, CD62) [Homo sapiens] Mus musculus Cytel Corporation (San Diego CA USA) / MRC Technology (London UK) Inflammation Preclinical Immunology [k]
35 ABC-88,
CY-178		 IG Humanized

SELE (E-selectin, CD62E) [Homo sapiens] Mus musculus Cytel Corporation (San Diego CA USA) / MRC Technology (London UK) Inflammation Immunology [k]
9 AD-159 IG Humanized

HIV-1 (human immunodeficiency virus) gp120 [Human immunodeficiency virus 1] Mus musculus Tanox Inc. (Houston TX USA) HIV-1 infection, AIDS Phase I/II Infectiology [a]
10 AD-439 IG Humanized

HIV-1 (human immunodeficiency virus) gp120 V3 loop [Human immunodeficiency virus 1] Mus musculus Tanox Inc. (Houston TX USA) HIV-1 infection, AIDS Phase II Infectiology [a] [e]
257 AS1409,
BC1-IL12,
huBC1-huIL12		 IG Humanized conjugated with interleukin 12

 fibronectin extra domain B (ED-B) [Homo sapiens] Antisoma (London UK) Melanoma Phase I Oncology
Renal cancers Phase I Oncology
19 AT13/5 IG Humanized IgG1 - nd

CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10) [Homo sapiens] Mus musculus Tenovus Research (Cardiff UK) / Wellcome (London UK) Therapeutic Multiple myeloma (MM) CHO (Chinese Hamster Ovary) cells, NSO mouse myeloma cells Hematology, Immunology, Oncology [c] [8]
20 AUK12-20 IG Humanized IgG1 - nd

IL6R (interleukin 6 receptor, IL-6R, CD126) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Tokyo Japan) / MRC Technology (London UK) / Osaka University Medical School (Osaka Japan) IL6 dependent tumors COS cells transient expression Immunology [c] [k] (5) [9]
16 Anti-TAC 90 Υ-HAT IG Humanized

Mus musculus National Cancer Institute (Bethesda MD USA) Lymphoma Phase II NCI trial Oncology
30 BAY 103356,
BAY W 3356,
CDP571		 Humicade™ IG Humanized IgG4 - kappa

TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus CB0010 Celltech, UCB (Brussels Belgium) Rheumatoid arthritis (RA) Phase II Immunology [a] [89]
Crohn's disease (CD) Phase II Immunology
23 BC-1 IG Humanized

fibronectin extra domain B (ED-B) [Homo sapiens] Mus musculus Antisoma (London UK) / MRC Technology (London UK) Angiogenesis Preclinical Oncology [k] [51]
25 BMA 031 IG Humanized IgG1 - nd

T cell receptor (TR, TR alpha_beta) [Homo sapiens] Mus musculus Behringwerke Aktiengesellschaft (Marburg Germany) / Genzyme Corp. (Cambridge MA USA) Graft-versus-host disease (GvHD) Sp2/0 mouse myeloma cells Immunology [c] [13]
Transplantation Sp2/0 mouse myeloma cells Immunology
Autoimmunity Sp2/0 mouse myeloma cells Immunology
27 BW431/26 IG Humanized IgG3 - nd

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus Behringwerke Aktiengesellschaft (Marburg Germany) / MRC Laboratory of Molecular Biology (Cambridge UK) Colorectal cancers BHK cells (ATCC CCL 10) Oncology [c] [15]
Lung cancers BHK cells (ATCC CCL 10) Oncology
Breast cancers BHK cells (ATCC CCL 10) Oncology
26 BrE-3 IG Humanized IgG1 - nd

MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) [Homo sapiens] Mus musculus Cancer Research Fund of Contra Costa (Walnut Creek CA USA) / NIH (Bethesda MD USA) Breast cancers Sp2/0-Ag14 mouse myeloma cells Oncology [c] [16]
239 CAR RN 894777-94-7 IG Humanized scFv - Fc

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Unknown Unknown Unknown
29 CC49 IG Humanized IgG1 - nd

1za6 tumour associated glycoprotein 72 (TAG-72, TAG, HMW mucin-like glycoprotein, CA 72-4) [Homo sapiens] Mus musculus NIH (Bethesda MD USA) Diagnostic Cancers Oncology [c] [e] [17]
31 CDP850 IG Humanized

SELE (E-selectin, CD62E) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Psoriasis Phase I Immunology [a]
32 CE25/B7 IG Humanized

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus MRC Technology (London UK) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Cancers Oncology [k]
28 Campath-9H IG Humanized IgG1 - kappa

CD4 (p55) [Homo sapiens] Rattus sp. YNB46.1.8SG2B1.19 Pathology Dept., University of Cambridge (Cambridge UK) Establishment of immunological tolerance state CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells Immunology [c] [20] [101]
41 Fd138-80 IG Humanized IgG1 - nd

HSV (herpes simplex virus) gD glycoprotein [Human herpesvirus 1] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / University of Alabama (Tuscaloosa AL USA) Neutralisation activity of HSV-1 Sp2/0 mouse myeloma cells Immunology [c] [24]
42 Fd79 IG Humanized IgG1 - nd

HSV (herpes simplex virus) gB glycoprotein [Human herpesvirus 1] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / University of Alabama (Tuscaloosa AL USA) Neutralisation activity of HSV-1 Sp2/0 mouse myeloma cells Immunology [c] [24]
45 H17E2 IG Humanized IgG1 - nd

ALPP (alkaline phosphatase, placental, EC 3.1.3.1) [Homo sapiens] Mus musculus Unilever (London UK) Testicular cancers NSO mouse myeloma cells Oncology [c] [25]
Ovarian cancers NSO mouse myeloma cells Oncology
46 H52,
Huh52		 IG Humanized IgG1 - nd

1fgv
2fgw		 ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Potential to ameliorate deleterious immunological and inflammatory processes E.coli (Escherichia coli) Immunology [c] [26]
49 HMFG1 IG Humanized IgG1 - nd

MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227) (epitope PDTR) [Homo sapiens] Mus musculus The Netherlands CRC Labs (Nottingham UK) / Unilever (London UK) Neoplasms of epithelial origin, particularly carcinomas of breast, ovary, cervix, bronchus, and gastrointestinal tract NSO mouse myeloma cells Oncology [c] (7) [29]
59 ICM3 IG Humanized

ICAM3 (intercellular adhesion molecule 3, ICAM-3, CD50) [Homo sapiens] Mus musculus ICOS Corporation (Bothell WA USA) Psoriasis Phase I/II Immunology [a] (111)
106 KB001 IG Humanized Fab' - nd - nd

PcrV located at the tip of the syringe-like TTSS (Type Three Secretion System) [Pseudomonas aeruginosa] ;
PcrV located at the tip of the syringe-like TTSS (Type Three Secretion System) [Gram negative bacteria] 		Mus musculus KaloBios Pharmaceuticals Inc. (Palo Alto CA USA) Pseudomonas aeruginosa infections Phase I/II Infectiology [p] (43)
63 LDP-01,
MLNM2201		 IG Humanized IgG - nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Millennium Pharmaceuticals Inc. (Cambridge MA USA) Stroke Phase I/II Cardiology [a] [b]
Allograft rejection (in kidney transplantation) Immunology
67 M4 IG Humanized IgG1 - nd

tumour associated glycoprotein 72 (TAG-72, TAG, HMW mucin-like glycoprotein, CA 72-4) (epitope sialosyl-Tn) [Homo sapiens] Mus musculus University of Saskatchewan (Saskatchewan Canada) Gastric cancers Sp2/0-Ag14 mouse myeloma cells Oncology [c] [12]
Colorectal cancers Sp2/0-Ag14 mouse myeloma cells Oncology
Ovarian cancers Sp2/0-Ag14 mouse myeloma cells Oncology
221 MDX-220 Humanized

tumour associated glycoprotein 72 (TAG-72, TAG, HMW mucin-like glycoprotein, CA 72-4) [Homo sapiens] Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Acute myeloid leukemia (AML) Phase I Hematology, Oncology (36) (45) (74)
222 MDX-447 Humanized

FCGR1 (immunoglobulin G Fc receptor high affinity I, Fc gamma RI, CD64, encoded by human FCGR1A, FCGR1B, FCGR1C) [Homo sapiens] ;
EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] ;
bispecific [Homo sapiens] 		Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Cancers Phase II Oncology (36) (45) (74)
69 MDX-CD4 IG Humanized IgG - nd

CD4 (p55) [Homo sapiens] Mus musculus Eisai Co. Ltd. (Tokyo Japan) / Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Rheumatoid arthritis (RA) Phase I Immunology [a] (74)
68 MaE11 IG Humanized IgG1 - nd

IgE Fc [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) IgE mediated allergies Adenovirus transformed human embryonic 293 kidney cells Immunology [c] [34]
72 MikB1 IG Humanized IgG1 - nd

IL2RB (interleukin 2 receptor beta subunit, IL-2RB, p70, CD122) [Homo sapiens] Mus musculus F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Kyoto-Katsura Hospital (Kyoto Japan) / National Cancer Institute (Bethesda MD USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Graft-versus-host disease (GvHD) Sp2/0 mouse myeloma cells Immunology [c] [35]
Autoimmune diseases Sp2/0 mouse myeloma cells Immunology
Allograft rejection
(Prevention)
(in conjunction with humanized anti-Tac)		 Sp2/0 mouse myeloma cells Immunology
441 PRO 140 IG Humanized IgG4 - nd

CCR5 (chemokine (C-C) receptor 5, CD195) [Homo sapiens] Mus musculus PA14 Progenics Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic HIV-1 infection, AIDS
(Treatment)
Phase I Infectiology (104) (105)
85 RSV19 IG Humanized IgG1 - nd

glycoprotein F RSV [Respiratory syncytial virus] Mus musculus AFRC Inst. Animal Health (UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Respiratory Syncytial Virus (RSV) disease YB2/0 rat myeloma cells (from ATCC) Infectiology, Pulmonary, Respiratory diseases [c] [39] [95] [96]
390 SGN-70 IG Humanized IgG1 - nd

CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L) [Homo sapiens] Seattle genetics, Inc. (Bothell WA USA) Psoriasis Phase I Immunology
Autoimmune diseases Phase I Immunology
91 SK2 IG Humanized IgG1 - nd

IL6 (interleukin 6, IL-6) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Tokyo Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) Cardiac myxoma CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression Cardiology [c] [40]
Increased levels of IL6 in sepsis CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression Immunology
Rheumatoid arthritis (RA) CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression Immunology
HIV-1 infection, AIDS CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression Infectiology
93 TES-C21 IG Humanized IgG1 - nd

IgE Fc free and bound to B cells [Homo sapiens] Mus musculus Ciba-Geigy AG (Basel Switzerland) / MRC Laboratory of Molecular Biology (Cambridge UK) Immediate-type hypersensitivities COS cells transient expression, NSO mouse myeloma cells Immunology [c] [41]
104 YFC51.1 IG Humanized IgG1 - nd
IgG4 - nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Rattus sp. Cambridge University (Cambridge UK) / Wellcome (London UK) Influx of leukocytes in Sepsis or reperfusion injury, adult respiratory distress syndrome and graft rejection
(Prevention)
COS cells transient expression, NSO mouse myeloma cells Immunology [c] (2) [43]
105 YTH12.5 IG Humanized IgG1 - nd

CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. Cambridge University (Cambridge UK) T cell lymphoma CHO (Chinese Hamster Ovary) DHFR cells Immunology [c] [44]
Organ rejection CHO (Chinese Hamster Ovary) DHFR cells Immunology
Autoimmunity CHO (Chinese Hamster Ovary) DHFR cells Immunology
13 anti-B4 IG Humanized IgG1 - nd

CD19 (B lymphocyte surface antigen B4, Leu-12) [Homo sapiens] Mus musculus ImmunoGen Inc. (Cambridge MA USA) / University Bath (Bath UK) B cell malignancies COS cells transient expression Hematology, Oncology [c] [45]
14 anti-CD18 IG Humanized F(ab')2 - nd - nd

ITGB2 (integrin beta2 subunit, LFA-1, MAC-1, CD18) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Acute myocardial infarction Phase II Cardiology [a] [b]
15 anti-IL4 IG Humanized

IL4 (interleukin 4, IL-4) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Asthma Phase I Immunology [b]
436 hE16,
MGAWN1		 IG Humanized IgG1 - nd

WNV (West Nile Virus) domain III [West Nile virus] Mus musculus E16 MacroGenics Inc. (Rockville MD USA) West Nile Virus Infection Infectiology
50 hT84.66,
T84.66 M5A		 IG Humanized

1J05 CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e) [Homo sapiens] Mus musculus Beckman Research Institute (Duarte CA USA) Colorectal cancers, metastatic Oncology [p] [58]
54 humanized B1-8 IG Humanized IgE - nd

hapten NP-cap (4-hydroxy-3-nitrophenacetyl caproic acid) [Homo sapiens] ;
NIP-cap (3-iodo-4-hydroxy-5-nitrophenyl-acetyl caproic acid) [Homo sapiens] 		Mus musculus B1-8 MRC Laboratory of Molecular Biology (Cambridge UK) Unknown Proof of concept Stably transformed J558L cells Unknown [c] [10]
55 humanized D1.3 IG Humanized IgG1 - nd
IgG2 - nd

chicken lysosyme [Gallus gallus] Mus musculus D1.3 MRC Laboratory of Molecular Biology (Cambridge UK) Unknown Proof of concept J558L mouse myeloma cells, NSO mouse myeloma cells Unknown [c] [21] [22]
56 humanized DX48 IG Humanized IgG1 - nd

digoxin [Digitalis lanata] Rattus sp. DX48 Wellcome (London UK) Unknown Proof of concept Unknown [c] [23]
57 humanized K20 IG Humanized IgG1 - nd

ITGB1 (integrin beta1 subunit, GPIIa, CD29) [Homo sapiens] Mus musculus MuK20 INSERM (Montpellier France) / LIGM (Montpellier France) Unknown Immunosuppression Proof of concept Insect cells, NSO mouse myeloma cells Immunology [c] [31]
47 humanized-HCMV16 IG Humanized IgG1 - kappa

HCMV (human cytomegalovirus) gH envelope glycoprotein [Human herpesvirus 5] Mus musculus HCMV16 (51C1) Royal Free Hospital School of Medicine (London UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Human cytomegalovirus (HCMV)
(Prevention and treatment)
(infections in immunocompromised patients (Passive immunisation either alone or in combination with antiviral agents))		 NSO mouse myeloma cells, YB2/0 rat myeloma cells Immunology [c] [27]
48 humanized-HCMV37 IG Humanized IgG1 - kappa

HCMV (human cytomegalovirus) gB envelope glycoprotein [Human herpesvirus 5] Mus musculus HCMV37 Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Human cytomegalovirus (HCMV) (Herpes infections in immunocompromised individuals) YB2/0 rat myeloma cells Immunology [c] [86]
74 mu-39.1 IG Humanized

HIV-1 (human immunodeficiency virus) [Human immunodeficiency virus 1] Mus musculus Kaketsuken (the Chemo-Sero-Therapeutic Research Institute) (Kumamoto Japan) / MRC Technology (London UK) HIV-1 infection, AIDS Infectiology [k]
98 IG Humanized IgG1 - kappa conjugated with calicheamicin

radiolabelled with Indium-111, In-111		 ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) extracellular domain [Homo sapiens] Mus musculus 4D5 Genentech Inc. (S. San Francisco CA USA) Breast cancers (overexpressing ERBB2) Adenovirus transformed human embryonic 293 kidney cells Oncology [c] (31) [47]
Ovarian cancers (overexpressing ERBB2) Adenovirus transformed human embryonic 293 kidney cells Oncology

up

Human

Number of results: 149

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA, RPI, CPCA chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Development Technology Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain Clinical trials FDA / EMA / NCI number or ATC code Citations/ Notes/ References Biosimilars
212 abatacept 8495 91
(2004)		 53
(2005)		 BMS-188667,
CTLA4-Ig		 ORENCIA® FPIA Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)-IGHG1 Fc

CD80 (B7-1, CD28LG1) [Homo sapiens] ;
CD86 (B7-2, CD28LG2) [Homo sapiens] 		Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval December 23, 2005 CHO (Chinese Hamster Ovary) cells Immunology 133 studies found, 43 recruiting FDA: (BLA) 125118

ATC: L04AA24

Drugnum: 888

 [j] [n] (16) (30)
Therapeutic Psoriasis Phase I CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Juvenile Idiopathic Arthitis Phase M sBLA August 01, 2008 Immunology
Therapeutic Graft-versus-host disease (GvHD) (solid organ transplant) Phase I CHO (Chinese Hamster Ovary) cells Immunology
410 actoxumab 9568 107
(2011)		 69
(2013)		 CDA 1,
CDA-1,
HuMAb EGFR,
MBL-CDA1,
MDX-066,
MK-3415A (combination of actoxumab and bezlotoxumab)		 IG Homo sapiens IgG1 - kappa

9568 toxin A [[Clostridium] difficile] Merck & Co., Inc. (Whitehouse Station NJ USA) Clostridium difficile infectious diarrhea Infectiology 88 studies found, 34 recruiting
165 adalimumab 7860 82
(1999)		 44
(2000)		 D2E7 HUMIRA® (EU/US)
TRUDEXA® (EU) 		IG Homo sapiens IgG1 - kappa

7860 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Abbott Laboratories (Abbott Park IL USA) Therapeutic Juvenile Idiopathic Arthitis Phase M FDA approval February 21, 2008 Immunology 304 studies found, 116 recruiting FDA: (BLA) 125057

REMS

EMA: H-C-481

ATC: L04AB04

Drugnum: 814

 [a] [j] (12)
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval August 28, 2006 Immunology
Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval January 18, 2008 Immunology
Abbott Laboratories (Abbott Park IL USA) (EU/US) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval December 31, 2002 CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval October 03, 2005 CHO (Chinese Hamster Ovary) cells Immunology
Abbott Laboratories (Abbott Park IL USA) Therapeutic Crohn's disease (CD) (if inadequate response to conventional therapy) Phase M FDA approval February 27, 2010 Immunology
164 adecatumumab 8449 90
(2004)		 52
(2004)		 MT201 IG Homo sapiens IgG1 - nd

EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Homo sapiens Micromet AG (Munich Germany) Therapeutic Prostate cancers Phase II Oncology 1 studies found, 0 recruiting [p]
Therapeutic Breast cancers Phase II Oncology
214 aflibercept 8739 95
(2006)		 57
(2007)		 VEGF Trap,
VEGF Trap R1/R2,
VEGF-trapR1,
VEGF-TRAPR1R2		 ZALTRAP™
EYLEA® 		FPIA Homo sapiens FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1 VEGFR, FLT, RFT, vascular permeability factor receptor) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, FLK1, CD309) - IGHG1 Fc

8739 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic Age-related macular degeneration (AMD), neovascular (wet) Phase M FDA approval (EYLEA®) July 18, 2011 Ophthalmology 94 studies found, 40 recruiting FDA: (BLA) 125387 (Eylea®)


FDA: (BLA) 125418 (Zaltrap™)

 [p] (30)
Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) / Sanofi-Aventis (Paris France) Colorectal cancers, metastatic Phase M FDA approval (ZALTRAP®) August 03, 2012 Oncology
Therapeutic Ovarian cancers Phase II Oncology
397 albiglutide 8829 97
(2007)		 59
(2008)		 GSK 716155,
Syncria		 CPCA Homo sapiens GCG 98-127 [glucagon-like peptide 1 (7-36)] - GCG 98-127 [glucagon-like peptide 1 (7-36)]- ALB (albumin 25-609)

GLP1R (glucagon-like peptide 1 receptor) [Homo sapiens] GlaxoSmithKline (Brentford UK) Type 2 diabetes (T2 DM) Phase III Immunology 25 studies found, 2 recruiting (64) (65) (66) (67) (69)
396 albinterferon alfa-2b 8827 97
(2007)		 59
(2008)		 Joulferon ZALBIN™ CPCA Homo sapiens ALB (albumin 25-609) - IFNA2 (interferon alpha 2, IFN-Alpha, IFNA, 24-188)

Human Genome Sciences Inc. (HGSI) (Rockville MD USA) / Novartis (Basel Switzerland) Hepatitis C Discontinued Infectiology 7 studies found, 0 recruiting (75)
215 alefacept 8059 84
(2000)		 46
(2001)		 CD58-Fc,
LFA3-Fc		 AMEVIVE® FPIA Homo sapiens CD58 (LFA3, lymphocyte function associated antigen 3)-IGHG1 Fc

CD2 (lymphocyte function-antigen 2, LFA-2) [Homo sapiens] Homo sapiens Biogen Canada Inc. (Mississauga ON Canada) Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval January 31, 2003 CHO (Chinese Hamster Ovary) cells Immunology 42 studies found, 3 recruiting FDA: (BLA) 125036

ATC: L04AA15

Drugnum: 820

 [j] [n] (30)
412 alirocumab 9620 107
(2011)		 69
(2013)		 REGN727,
SAR-236553,
SAR236553		 IG Homo sapiens IgG1 - kappa

9620 PCSK9 (proprotein convertase subtilisin/kexin type 9) [Homo sapiens] Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) LDL hypercholesterolemy Cardiovascular diseases 26 studies found, 13 recruiting
Atherosclerosis Cardiovascular diseases
289 alvircept sudotox 7105 69
(1993)		 34
(1994)		 sCD4-PE40 RPI Homo sapiens CD4- Pseudomonas aeruginosa exotoxin A conjugated with Pseudomonas aeruginosa exotoxin A

 HIV-1 (human immunodeficiency virus) gp120 [Human immunodeficiency virus 1] pT4B National Institute of Allergy and Infectious Diseases (NIAID) (Bethesda USA) Therapeutic HIV-1 infection, AIDS Discontinued Infectiology 2 studies found, 0 recruiting
395 asfotase alfa 9269 104
(2010)		 66
(2011)		 ENB-0040 CPCA Homo sapiens ALPL (alkaline phosphatase, TNSALP, tissue non-specific alkaline phosphatase, 18-502) - IGHG1 Fc

Alexion Pharmaceuticals Inc. (New Haven CT USA) / Enobia pharma (Cambridge MA USA) Hypophosphatasia in juvenils (HPP) Phase II Osteology 8 studies found, 1 recruiting (70)
213 atacicept 8669 95
(2006)		 57
(2007)		 TACI-Fc,
TACI-Ig		 FPIA Homo sapiens TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor, CD267)-IGHG1 Fc

8669 TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, a proliferation-including ligand, APRIL, CD256) [Homo sapiens] ;
TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] 		Homo sapiens Merck Serono International S.A. (Geneva Switzerland) / ZymoGenetics Inc. (Seattle WA USA) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase I Oncology 10 studies found, 0 recruiting [p] (30)
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Systemic lupus erythematosus (SLE) Phase II Immunology
Therapeutic Multiple myeloma (MM) Phase I Hematology, Immunology, Oncology
358 atinumab 9336 104
(2010)		 66
(2011)		 6A3-IgG4,
ATI355		 IG Homo sapiens IgG4 - kappa

9336 RTN4 (reticulon 4, neurite outgrowth inhibitor, NOGO) [Homo sapiens] Novartis (Basel Switzerland) Therapeutic Spinal cord injury, acute Phase I Myelopathy 1 studies found, 0 recruiting
308 atorolimumab 7647 80
(1998)		 42
(1999)		 P3x22914G4 IG Homo sapiens IgG3 - nd

RHD (Rhesus blood group D antigen, RhD, CD240D) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
245 baminercept 8944 98
(2007)		 60
(2008)		 BG9924,
TT-47		 FPIA Homo sapiens LTBR ( lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily member 3, TNFCR)-IGHG1 Fc

8944 LTA (lymphotoxin alpha, TNF superfamily member 1, TNFSF1, LT) [Homo sapiens] ;
LTB (lymphotoxin beta, TNF superfamily member 3, TNFSF3, p33) [Homo sapiens] ;
TNFSF14 (tumor necrosis factor (TNF) superfamily member 14, LIGHT, HVEM-L, CD258) [Homo sapiens] 		Homo sapiens Biogen IDEC Pharmaceuticals (Cambridge MA USA) Therapeutic Rheumatoid arthritis (RA) Immunology 8 studies found, 2 recruiting (30)
247 belatacept 8627 93
(2005)		 59
(2008)		 BMS-224818,
LEA29Y		 NULOJIX® FPIA Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)-IGHG1 Fc

CD80 (B7-1, CD28LG1) [Homo sapiens] ;
CD86 (B7-2, CD28LG2) [Homo sapiens] ;
bispecific [Homo sapiens] 		Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Rheumatoid arthritis (RA) FDA approval June 15, 2011 Immunology 113 studies found, 33 recruiting FDA: (BLA) 125288

ATC: L04AA28

 (30)
266 belimumab 8381 89
(2003)		 51
(2004)		 hBlySmAb-1.1,
LymphoStat-B		 BENLYSTA® IG Homo sapiens IgG1 - lambda

TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] GlaxoSmithKline (Brentford UK) / Human Genome Sciences Inc. (HGSI) (Rockville MD USA) Therapeutic Systemic lupus erythematosus (SLE) Phase M FDA approval March 10, 2011 Immunology 34 studies found, 18 recruiting FDA: (BLA) 125370

ATC: L04AA26

 (82)
170 bertilimumab 8332 88
(2003)		 50
(2003)		 CAT-213,
iCo-008		 IG Homo sapiens IgG4 - kappa

CCL11 (chemokine -C-C motif- ligand 11, chemokine CC 11, eotaxin1) [Homo sapiens] Homo sapiens iCo Therapeutics Inc. (Vancouver BC Canada) Therapeutic Allergies, severe ocular Phase I Immunology 1 studies found, 1 recruiting (42)
411 bezlotoxumab 9608 107
(2011)		 69
(2013)		 CDB 1,
CDB-1,
MDX-1388,
MK-3415A (combination of actoxumab and bezlotoxumab)		 IG Homo sapiens IgG1 - kappa

9608 toxin B [[Clostridium] difficile] Merck & Co., Inc. (Whitehouse Station NJ USA) Clostridium difficile infectious diarrhea Infectiology 25 studies found, 2 recruiting
278 bifarcept 8109 86
(2002)		 48
(2002)		 RPI Homo sapiens IFNAR2 (interferon alpha/beta receptor 2, IFNABR)

bispecific [Homo sapiens] ;
IFNA1 (interferon alpha1, IFN alpha, IFN alpha 1/13, IFN 13) [Homo sapiens] ;
IFNB1 (interferon beta 1, IFNB) [Homo sapiens] 		Unknown Unknown Unknown 0 studies found, 0 recruiting
456 bimagrumab 9711 108
(2012)		 BYM338 IG Homo sapiens IgG1 - lambda

9711 ACVR2B (activin A receptor type IIB, ActR-IIB) [Homo sapiens] Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Sporadic inclusion body myositis
(Prevention and treatment)
Phase II Immunology 4 studies found, 3 recruiting
Therapeutic Cachexia
(Prevention and treatment)
Phase II Immunology
413 blisibimod 9583 107
(2011)		 A-623 CPCA Homo sapiens Fusion - [TNFSF13B-binding peptide]2 - IGHG1 Fc

9583 TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] Anthera pharmaceuticals (Hayward CA USA) Systemic lupus erythematosus (SLE) Immunology 5 studies found, 3 recruiting
162 briakinumab 9153 101
(2009)		 63
(2010)		 ABT-874 IG Homo sapiens IgG1 - lambda

9153 IL12B (interleukin 12 beta, IL-12B, IL12 p40, CMLF2, NKSF2) [Homo sapiens] Homo sapiens Abbott Laboratories (Abbott Park IL USA) Therapeutic Multiple sclerosis (MS) Phase I Immunology 10 studies found, 0 recruiting ATC: L04AC09

 [p]
Therapeutic Psoriasis Phase II Immunology
Therapeutic Crohn's disease (CD) Phase I Immunology
246 briobacept 8963 98
(2007)		 60
(2008)		 BR3-Fc,
SS-79		 FPIA Homo sapiens TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BR3, B cell activating factor receptor, CD268)-IGHG1 Fc

8963 TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) Therapeutic Rheumatoid arthritis (RA) Phase I Immunology 0 studies found, 0 recruiting (30)
376 brodalumab 9475 105
(2011)		 67
(2012)		 AMG827 IG Homo sapiens IgG2 - kappa

9475 IL17RA (interleukin 17 receptor A, CD217) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Psoriasis Phase II Immunology 14 studies found, 4 recruiting (63)
Crohn's disease (CD) Discontinued Immunology
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Asthma Phase II Immunology
244 canakinumab 8836 97
(2007)		 59
(2008)		 ACZ885 ILARIS® IG Homo sapiens IgG1 - kappa

8836 IL1B (interleukin 1 beta, IL-1B) [Homo sapiens] Homo sapiens Novartis (Basel Switzerland) Therapeutic Rheumatoid arthritis (RA) Immunology 59 studies found, 17 recruiting FDA: (BLA) 125319

ATC: L04AC08
Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Cryopyrin-Associated Periodic Syndromes (CAPS) (including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 4 and older) Phase M FDA approval June 17, 2009 Hereditary inflammatory diseases, Immunology
359 carlumab 9372 104
(2010)		 66
(2011)		 CNTO 888 IG Homo sapiens IgG1 - kappa

9372 CCL2 (chemokine C-C motif ligand 2, chemokine CC 2, monocyte chemoattractant protein-1, MCP-1, monocyte chemotactic and activating factor, MCAF, small inducible cytokine A2, SCYA2, HC11) [Homo sapiens] Centocor Inc. (Horsham PA USA) Therapeutic Pulmonary Fibrosis Phase I Pulmonary, Respiratory diseases 5 studies found, 1 recruiting NCI: C71010
290 cixutumumab 9099 100
(2008)		 62
(2009)		 IMC-A12,
LY3012217		 IG Homo sapiens IgG1 - lambda

9099 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens ImClone Systems Inc. (Somerville NJ USA) Therapeutic Hepatocellular carcinoma (HCC) Phase II Oncology 46 studies found, 7 recruiting
Therapeutic Non-small cell lung cancers (NSCLC) Phase II Oncology
414 clazakizumab 9599 107
(2011)		 69
(2013)		 ALD-518,
BMS-945429		 IG Homo sapiens IgG1 - kappa

9599 IL6 (interleukin 6, IL-6) [Homo sapiens] Bristol-Myers Squibb (Princeton NJ USA) Rheumatoid arthritis (RA) Immunology 7 studies found, 3 recruiting
Lung cancers Oncology
Crohn's disease (CD) Phase II Immunology
224 conatumumab 9029 99
(2008)		 61
(2009)		 AMG 655,
TRAIL-R2mAb,
XG1-048 v w		 IG Homo sapiens IgG1 - kappa

9029 TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Therapeutic Non-small cell lung cancers (NSCLC) Discontinued Oncology 10 studies found, 1 recruiting (62)
377 conbercept 9487 105
(2011)		 67
(2012)		 FP3 protein,
KH902,
KH903		 FPIA Homo sapiens FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1 VEGFR, FLT, RFT, vascular permeability factor receptor) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, FLK1, CD309) - IGHG1 Fc

9487 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Chengdu Kanghong Biotech Co.,Ltd. (China) Therapeutic Diabetic Macular Edema Phase I/II Immunology 4 studies found, 1 recruiting
Solid tumors Phase I Oncology
Age-related macular degeneration (AMD), neovascular (wet) Phase II Ophthalmology
388 dalantercept 9427 105
(2011)		 67
(2012)		 ACE-041 FPIA Homo sapiens ACVRL1 (activin A receptor type II-like 1, activin receptorlike kinase 1, ALK1, ALK-1, serine/threonine-protein kinase receptor R3, SKR3, transforming growth factor-beta superfamily receptor type I, TGF-B superfamily receptor type I, TSR-I, HHT2, ORW2) - IGHG1 Fc

9427 GDF2 (growth differentiation factor 2, BMP9, BMP-9) [Homo sapiens] ;
BMP10 (bone morphogenetic protein 10) [Homo sapiens] 		Acceleron Pharma, Inc (Cambridge UK) Solid tumors Phase I Oncology 5 studies found, 4 recruiting
Multiple myeloma (MM) Phase I Hematology, Immunology, Oncology
301 daratumumab 9128 101
(2009)		 63
(2010)		 HuMax-CD38 IG Homo sapiens IgG1 - kappa

9128 CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10) [Homo sapiens] Genmab A/S (Copenhagen Denmark) Therapeutic Multiple myeloma (MM) Phase I/II Hematology, Immunology, Oncology 4 studies found, 4 recruiting NCI: C74007
249 denosumab 8653 94
(2005)		 56
(2006)		 AMG162 XGEVA™
PROLIA® 		IG Homo sapiens IgG2 - nd

TNFSF11 (tumor necrosis factor (TNF) superfamily member 11, osteoclast differentiation factor, ODF, OPGL, RANKL, TRANCE, CD254) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Therapeutic skeletal-related events in patients with bone metastases from solid tumors
(Prevention and treatment)
Phase III FDA approval June 13, 2013 Osteology 61 studies found, 20 recruiting FDA: (BLA) 125320

REMS

ATC: M05BX04

NCI: C61313

 (52) (127)
Therapeutic Postmenopausal women osteoporosis Phase III FDA approval June 01, 2010 Osteology
348 drozitumab 9255 103
(2010)		 65
(2011)		 anti-DR5,
PRO95780,
rhuMAb DR5		 IG Homo sapiens IgG1 - lambda

9255 TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Colorectal cancers Phase I Oncology 7 studies found, 0 recruiting
394 dulaglutide 9164 103
(2010)		 65
(2011)		 GLP-1Fc,
LY2189265		 CPCA Homo sapiens GCG 98-128 [glucagon-like peptide 1 (7-37)] - IGHG4 Fc

GLP1R (glucagon-like peptide 1 receptor) [Homo sapiens] Eli Lilly (Indianapolis IN USA) Type 2 diabetes (T2 DM) Phase III Immunology 30 studies found, 9 recruiting (64) (67) (68) (69)
416 duligotumab 9646 107
(2011)		 MEHD7945A,
RG-7597,
RG7597		 IG Homo sapiens IgG1 - kappa

9646 ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3) [Homo sapiens] F. Hoffmann-La Roche Ltd. (Basel Switzerland) Cancers Phase II Oncology 3 studies found, 2 recruiting
449 dupilumab 9669 108
(2012)		 CD124,
REGN668,
SAR231893		 IG Homo sapiens IgG4 - nd

9669 IL4 (interleukin 4, IL-4) subunit alpha [Homo sapiens] Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic Atopic dermatitis
(Treatment)
Phase I Immunology 13 studies found, 1 recruiting
Therapeutic Asthma
(Treatment)
Phase II Immunology
Therapeutic Allergy
(Treatment)
Phase I Immunology
451 dusigitumab 9679 108
(2012)		 MEDI-573 IG Homo sapiens IgG2 - nd

9679 IGF2 (insulin-like growth factor 2) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Breast cancers
(Treatment)
Phase II Oncology 4 studies found, 2 recruiting
173 efungumab 8658 95
(2006)		 57
(2007)		 HSP90mab MYCOGRAB® IG Homo sapiens scFv - heavy - kappa

8658 heat shock protein 90 homolog [Candida albicans] Homo sapiens NeuTec Pharma plc (Manchester UK) / Supplier: Onicon Chemical Co. Ltd. (HangZhou China) Candidiasis (yeast infection) EMA refusal of marketing March 20, 2007 Infectiology 3 studies found, 0 recruiting
417 enoticumab 9575 107
(2011)		 69
(2013)		 REGN-421,
REGN421,
SAR153192		 IG Homo sapiens IgG1 - kappa

9575 DLL4 (delta-like 4) [Homo sapiens] Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Cancers Phase I Oncology 1 studies found, 1 recruiting
216 etanercept 7783 81
(1999)		 43
(2000)		 TNFR-immunoadhesin,
TNFRSF1B-Fc		 ENBREL® FPIA Homo sapiens TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b) - IGHG1 Fc

7783 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Immunex Corporation Amgen (Thousand Oaks CA USA) Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval February 15, 2002 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Immunology 315 studies found, 79 recruiting FDA: (BLA) 103795

REMS

ATC: L04AB01

Drugnum: 737

 [f] [j] [n] (15) (30)
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval November 02, 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Immunology
448 evolocumab 9643 108
(2012)		 AMG145,
Anti-PCSK9,
NN7415		 IG Homo sapiens IgG2 - lambda

9643 PCSK9 (proprotein convertase subtilisin/kexin type 9) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Hypercholesterolemia
(Treatment)
Phase II Cardiovascular diseases 19 studies found, 9 recruiting
262 exbivirumab 8536 91
(2004)		 53
(2005)		 19.79.5,
HepeX-B™ (combination of exbivirumab and libivirumab)		 IG Homo sapiens IgG1 - lambda

HBV (hepatitis B virus) [Hepatitis B virus] Cubist Pharmaceuticals, Inc. (Lexington MA USA) / XTL Biopharmaceuticals (Herzliya Israel) Therapeutic Hepatitis B reinfection in liver transplant patients
(Prevention)
Phase II FDA Orphan drug August 04, 2003 Infectiology 0 studies found, 0 recruiting [93]
418 fasinumab 9589 107
(2011)		 69
(2013)		 REGN475,
SAR164877		 IG Homo sapiens IgG4 - kappa

9589 NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF) [Homo sapiens] Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Pain chronic Phase II Neurology 7 studies found, 0 recruiting
323 fezakinumab 9137 101
(2009)		 63
(2010)		 ILV-094 IG Homo sapiens IgG1 - lambda

9137 IL22 (interleukin 22, IL-22) [Homo sapiens] Wyeth Pharmaceuticals (Madison NJ USA) Therapeutic Inflammatory conditions, acute and chronic
(Treatment)
Immunology 4 studies found, 0 recruiting
293 figitumumab 9085 100
(2008)		 62
(2009)		 CP-751871 IG Homo sapiens IgG2 - kappa

9085 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens 2.13.2 Pfizer (New York NY USA) Therapeutic Solid tumors Phase I Oncology 7 studies found, 0 recruiting NCI: C52187
Therapeutic Non-small cell lung cancers (NSCLC) Phase I Oncology
403 flanvotumab 9520 106
(2011)		 68
(2012)		 20D7S,
IMC-20D7S,
IMC20D7S		 IG Homo sapiens IgG1 - kappa

9520 TYRP1 (tyrosinase-related protein 1, 5, 6-dihydroxyindole-2-carboxylic acid oxidase, DHICA oxidase, TRP1, melanoma antigen gp75) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Malignant melanoma Phase I Oncology 1 studies found, 0 recruiting
350 foralumab 9309 103
(2010)		 65
(2011)		 NI-0401 IG Homo sapiens IgG1 - kappa

9309 CD3E (CD3 epsilon) [Homo sapiens] NovImmmune (Geneva Switzerland) Therapeutic Multiple sclerosis (MS) Phase I Immunology 2 studies found, 0 recruiting [65]
Therapeutic Transplantation Phase I Immunology
Therapeutic Ulcerative colitis (UC) Phase I Immunology
Therapeutic Psoriasis Phase I Immunology
Therapeutic Atherosclerosis Phase I Cardiovascular diseases
Therapeutic Type 1 diabetes Phase I Immunology
Therapeutic Crohn's disease (CD) Phase I Immunology
90 foravirumab 9053 99
(2008)		 61
(2009)		 CR4098 IG Homo sapiens IgG1 - kappa

9053 glycoprotein G (RVG) antigenic site III [Rabies virus] Immune Ab phage display library Homo sapiens Crucell (CN Leiden Netherlands) Therapeutic Rabies post-exposure ( use in combination (Prophylaxis)) Phase II Immunology, Infectiology 0 studies found, 0 recruiting (27) [98]
174 fresolimumab 9158 101
(2009)		 63
(2010)		 GC-1008 IG Homo sapiens IgG4 - kappa

9158 TGFB1 (transforming growth factor beta1, TGF beta) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Genzyme Corp. (Cambridge MA USA) Therapeutic Idiopathic pulmonary fibrosis Phase I Pulmonary, Respiratory diseases 10 studies found, 3 recruiting
363 fulranumab 9373 104
(2010)		 66
(2011)		 4D4,
AMG-403,
JNJ-42160443		 IG Homo sapiens IgG2 - kappa

9373 NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF) [Homo sapiens] Amgen (Thousand Oaks CA USA) / Johnson & Johnson (Langhorne PA USA) Therapeutic Pain chronic Phase II Neurology 11 studies found, 2 recruiting
168 ganitumab 9323 103
(2010)		 65
(2011)		 AMG 479 IG Homo sapiens IgG1 - kappa

9323 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Cancers Phase I Oncology 25 studies found, 6 recruiting [p]
223 gantenerumab 8894 97
(2007)		 59
(2008)		 R1450 IG Homo sapiens IgG1 - nd

8894 amyloid beta (Abeta) peptides Aβ42 and Aβ40 [Homo sapiens] Homo sapiens F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic Alzheimer's disease Neurology 5 studies found, 4 recruiting
332 glembatumumab 9199 102
(2009)		 64
(2010)		 CDX-011,
CR011-vcMMAE,
glembatumumab vedotin		 IG Homo sapiens IgG2 - kappa conjugated with monomethyl auristatin E (MMAE)

 9199 GPNMB (glycoprotein transmembrane NMB, hematopoeitic growth factor inducible neurokinin-1 type, HGFIN) extracellular domain [Homo sapiens] Celldex Therapeutics, Inc. (Needham USA) Therapeutic Melanoma, metastatic Phase II Oncology 3 studies found, 0 recruiting (29)
Therapeutic Breast cancers Phase II Oncology
175 golimumab 8497 91
(2004)		 53
(2005)		 CNTO 148 SIMPONI™ IG Homo sapiens IgG1 - kappa

TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval April 24, 2009 Immunology 45 studies found, 18 recruiting FDA: (BLA) 125289

REMS

ATC: L04AB06
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval April 24, 2009 Immunology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval April 24, 2009 Immunology
365 icrucumab 9370 104
(2010)		 66
(2011)		 18F1,
IMC-18F1,
LY3012212		 IG Homo sapiens IgG1 - kappa

9370 FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor) [Homo sapiens] Eli Lilly (Indianapolis IN USA) / ImClone Systems Inc. (Somerville NJ USA) Therapeutic Rectal cancers Phase II Oncology 4 studies found, 3 recruiting
Therapeutic Colon cancers Phase II Oncology
402 inclacumab 9512 106
(2011)		 68
(2012)		 LC1004-002,
RO4905417		 IG Homo sapiens IgG4 - kappa

9512 SELP (P-selectin, CD62) [Homo sapiens] Roche (Basel Suisse) Peripheral Arterial Disease (PAD) Phase I Cardiology 3 studies found, 1 recruiting
Coronary heart disease Phase II Cardiology
Myocardial infection Phase II Cardiology
321 intetumumab 9134 101
(2009)		 63
(2010)		 CNTO 095,
CNTO-95		 IG Homo sapiens IgG1 - kappa

9134 ITGAV_ITGB3 (integrin alphaV_beta3, integrin αVβ3, CD51_GPIIIa, vitronectin receptor, VNR, CD51_CD61) [Homo sapiens] Johnson & Johnson (Langhorne PA USA) Therapeutic Solid tumors Oncology 3 studies found, 1 recruiting
180 ipilimumab 8568 94
(2005)		 56
(2006)		 MDX-010 YERVOY™ IG Homo sapiens IgG1 - kappa

CTLA4 (cytotoxic T lymphocyte-associated antigen 4, CD152) [Homo sapiens] Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) / Medarex (Princeton NJ USA) Therapeutic Melanoma, metastatic Phase II/III FDA approval March 25, 2011 Oncology 126 studies found, 69 recruiting FDA: (BLA) 125377

REMS

NCI: C2654

 (74)
250 iratumumab 8713 94
(2005)		 56
(2006)		 MDX-060 IG Homo sapiens IgG1 - kappa

TNFRSF8 (tumor necrosis factor receptor (TNFR) superfamily member 8, CD30) [Homo sapiens] Homo sapiens Medarex (Princeton NJ USA) Therapeutic Anaplastic large cell lymphoma (ALCL) Phase II Oncology 3 studies found, 0 recruiting (74)
Therapeutic Hodgkin's disease (HD) Phase II FDA Orphan drug October 01, 2004 Hematology, Oncology
288 lenercept 7310 72
(1994)		 35
(1995)		 TNFR55-Ig1,
TNFRSF1A-Fc		 FPIA Homo sapiens TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly member 1A, TNFAR, TNF-alpha, p55, CD120a) - IGHG1 Fc

TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] pTJ5 Cγ 1 Genentech Inc. (S. San Francisco CA USA) Therapeutic Severse sepsis and early septic shock Phase III Immunology 0 studies found, 0 recruiting [69]
182 lerdelimumab 7882 83
(2000)		 45
(2001)		 CAT-152,
Trabio		 IG Homo sapiens IgG4 - nd

TGFB2 (transforming growth factor beta2) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) Therapeutic Glaucoma surgery Phase III Ophthalmology 0 studies found, 0 recruiting [a] (42) [12]
183 lexatumumab 8753 95
(2006)		 57
(2007)		 HGS-ETR2 IG Homo sapiens IgG1 - lambda

8753 TNFRSF10B (tumor necrosis factor receptor (TNFR) superfamily member 10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAILR2, TRAIL-R2, TR-2, CD262) [Homo sapiens] Homo sapiens Human Genome Sciences Inc. (HGSI) (Rockville MD USA) Therapeutic Cancers Phase I Oncology 1 studies found, 0 recruiting NCI: C64621

 [p]
263 libivirumab 8481 91
(2004)		 53
(2005)		 17.1.41,
HepeX-B™ (combination of exbivirumab and libivirumab)		 IG Homo sapiens IgG1 - kappa

HBV (hepatitis B virus) [Hepatitis B virus] Cubist Pharmaceuticals, Inc. (Lexington MA USA) / XTL Biopharmaceuticals (Herzliya Israel) Therapeutic Hepatitis B reinfection in liver transplant patients
(Prevention)
Phase II FDA Orphan drug April 08, 2003 Infectiology 0 studies found, 0 recruiting [93]
423 lirilumab 9415 107
(2011)		 69
(2013)		 BMS-986015,
IPH2102		 IG Homo sapiens IgG4 - kappa

9415 KIRD2 subgroup (killer cell Immunoglobulin-like Receptor subgroup, including KIR2DL1 (nkat1/CD158A), KIR2DL2 (nkat6/CD158B1), KIR2DL3 (nkat2/CD158B2), KIR2DS1 (CD158H) and KIR2DS2 -nkat5/CD158J-) [Homo sapiens] Bristol-Myers Squibb (Princeton NJ USA) / Innate Pharma (Marseille France) Acute myeloid leukemia (AML) Phase II Hematology, Oncology 3 studies found, 3 recruiting (120)
Innate Pharma (Marseille France) Multiple myeloma (MM) Phase I Hematology, Immunology, Oncology
176 lucatumumab 8887 98
(2007)		 60
(2008)		 CHIR-12,12,
HCD122		 IG Homo sapiens IgG1 - nd

8887 CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5, p50) [Homo sapiens] Homo sapiens Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Xoma (Berkeley CA USA) Therapeutic Multiple myeloma (MM) Phase I Hematology, Immunology, Oncology 4 studies found, 0 recruiting [p]
Therapeutic Chronic lymphocytic leukemia (CLL) Phase I Hematology, Oncology
184 mapatumumab 8635 93
(2005)		 55
(2006)		 HGS-ETR1,
TRM-1		 IG Homo sapiens IgG1 - nd

TNFRSF10A (tumor necrosis factor receptor (TNFR) superfamily member 10A, death receptor 4, DR4, TNF-related apoptosis-inducing ligand receptor 1, TRAILR1, TRAIL-R1, TR-1, CD261) agonistic antibody [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Human Genome Sciences Inc. (HGSI) (Rockville MD USA) Therapeutic Lung cancers, Lung cancers (non small-cell) Phase II Oncology 7 studies found, 1 recruiting NCI: C61502
Therapeutic Non-Hodgkin's lymphoma (NHL) Phase II Oncology
Therapeutic Colorectal cancers Phase II Oncology
335 mavrilimumab 9234 102
(2009)		 64
(2010)		 CAM-3001 IG Homo sapiens IgG1 - lambda

9234 CSF2RA (colony stimulating factor 2 (granulocyte-macrophage) receptor alpha subunit, GM-CSF-R-alpha, CD116) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Rheumatoid arthritis (RA) Phase II Immunology 5 studies found, 3 recruiting
186 metelimumab 8087 86
(2002)		 48
(2002)		 CAT-192 IG Homo sapiens IgG4 - kappa

TGFB1 (transforming growth factor beta1, TGF beta) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Genzyme Corp. (Cambridge MA USA) Therapeutic Diffuse scleroderma Phase I/II Dermatology 1 studies found, 0 recruiting (42) [12]
Therapeutic Fibrotic diseases Phase I/II Dermatology
Therapeutic Scarring Phase I/II Dermatology
264 mirococept 8412 91
(2004)		 53
(2005)		 Mirococept Mirococept® RPI Homo sapiens CR1 (complement receptor type 1, C3b/C4b receptor, C3BR, Knops blood group, KN, CD35)

complement C3b, C4b [Homo sapiens] pET04-01 Inflazymme Pharmaceuticals Therapeutic Transplantation Phase II Immunology 0 studies found, 0 recruiting (44)
Therapeutic Acute myocardial infarction Phase II Cardiology
311 morolimumab 7646 79
(1998)		 41
(1999)		 IG Homo sapiens IgG1 - nd

RHD (Rhesus blood group D antigen, RhD, CD240D) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
367 namilumab 9382 104
(2010)		 66
(2011)		 MT203 IG Homo sapiens IgG1 - kappa

9382 CSF2 (colony stimulating factor 2 -granulocyte-macrophage-, granulocyte-macrophage colony stimulating factor, GM-CSF) [Homo sapiens] Micromet Inc. (Munich Germany) / Nycomed (Zurich Switzerland) Therapeutic Multiple sclerosis (MS) Phase I Immunology 1 studies found, 1 recruiting [74]
Therapeutic Rheumatoid arthritis (RA) Phase I Immunology
381 narnatumab 9447 105
(2011)		 67
(2012)		 IMC RON-8,
IMC-RON8,
RON8		 IG Homo sapiens IgG1 - kappa

9447 MST1R (macrophage stimulating 1 receptor, macrophage stimulating protein receptor, MSP receptor, c-met-related tyrosine kinase, protein- tyrosine kinase 8, PTK8, RON, p185-Ron, CD136) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Solid tumors Phase I Oncology 1 studies found, 1 recruiting
193 nebacumab 6658 66
(1991)		 32
(1992)		 centoxin,
HA-1A,
septomonab		 IG Homo sapiens IgM - kappa

Homo sapiens heteromyeloma A6(H4C5) CSL Behring (King of Prussia PA USA) Therapeutic Septic shock, MSS (meningococcal septic shock) Withdrawn Infectiology 0 studies found, 0 recruiting (57) (95) (96)
Therapeutic Gram-negative sepsis Infectiology
294 necitumumab 9083 100
(2008)		 62
(2009)		 11F8,
IMC-11F8,
LY3012211		 IG Homo sapiens IgG1 - kappa

9083 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Homo sapiens ImClone Systems Inc. (Somerville NJ USA) Therapeutic Solid tumors Phase I Oncology 10 studies found, 5 recruiting
Therapeutic Colorectal cancers, metastatic Phase II Oncology
Therapeutic Non-small cell lung cancers (NSCLC) Phase III Oncology
452 nesvacumab 9688 108
(2012)		 REGN-910 IG Homo sapiens IgG1 - nd

9688 ANGPT2 (Ang2, angiopoietin 2) [Homo sapiens] Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic Solid tumors
(Treatment)
Phase I Oncology 2 studies found, 2 recruiting
424 nivolumab 9623 107
(2011)		 BMS-936558,
MDX-1106,
ONO-4538		 IG Homo sapiens IgG4 - kappa

9623 PDCD1 (programmed cell death 1, PD-1, PD1, CD279) [Homo sapiens] Bristol-Myers Squibb (Princeton NJ USA) Melanoma Phase II Oncology 23 studies found, 17 recruiting
Renal cell carcinoma (RCC) Phase II Oncology
Cancers Phase II Oncology
Ono Pharmaceutical Co., Ltd (Osaka Japan) Treatment Hepatitis C Phase I Infectiology
194 ofatumumab 8606 93
(2005)		 55
(2006)		 HuMax-CD20® ARZERRA™ IG Homo sapiens IgG1 - kappa

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / GlaxoSmithKline (Brentford UK) Therapeutic Non-Hodgkin's lymphoma (NHL) (combination study) Phase III Oncology 92 studies found, 57 recruiting FDA: (BLA) 125326

ATC: L01XC10

NCI: C66952
Therapeutic Rheumatoid arthritis (RA) Phase III Immunology
Therapeutic Chronic lymphocytic leukemia (CLL) (Refractory) Phase M FDA approval October 26, 2009, sBLA April 01, 2009 Hematology, Oncology
352 olaratumab 9308 103
(2010)		 65
(2011)		 3G3,
IMC-3G3,
IMC3G3,
LY3012207		 IG Homo sapiens IgG1 - kappa

9308 PDGFRA (platelet-derived growth factor receptor alpha subunit, PDGFR2, CD140a) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Therapeutic Glioblastoma Phase II Oncology 12 studies found, 0 recruiting [66]
Therapeutic Ovarian cancers Phase II Oncology
284 onercept 7042 82
(1999)		 44
(2000)		 RPI Homo sapiens TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly 1A, TNF-RI, p55, CD120a) soluble form (TNF- binding protein 1)

TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Unknown Unknown Unknown 1 studies found, 0 recruiting
426 orticumab 9635 107
(2011)		 69
(2013)		 BI-204,
MLDL-1278A,
R-7418,
RG-7418		 IG Homo sapiens IgG1 - lambda

9635 oxLDL (oxidized low-density lipoprotein -LDL-, malondialdehyde (MDA) modified apolipoprotein -apo- B-100) [Homo sapiens] BioInvent (Lund Sweden) Acute coronary syndrome (ACS) Phase II Cardiology 2 studies found, 0 recruiting
Atherosclerosis Phase II Cardiovascular diseases
354 oxelumab 9320 103
(2010)		 65
(2011)		 huMAb OX40L,
R4930,
RO4989991		 IG Homo sapiens IgG1 - kappa

9320 TNFSF4 (tumor necrosis factor (TNF) superfamily member 4, OX40 ligand, OX-40L, TAX transcriptionally-activated glycoprotein 1, TXGP1, gp34, CD252) [Homo sapiens] Mus musculus F. Hoffmann-La Roche Ltd. (Basel Switzerland) Therapeutic Allergic rhinitis Phase I Immunology 2 studies found, 0 recruiting
Therapeutic Asthma Phase I Immunology
196 panitumumab 8499 91
(2004)		 53
(2005)		 ABX-EGF,
E7.6.3		 VECTIBIX™ IG Homo sapiens IgG2 - kappa

EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Therapeutic Colorectal cancers, metastatic Phase M FDA approval September 27, 2006 CHO (Chinese Hamster Ovary) cells Oncology 161 studies found, 79 recruiting FDA: (BLA) 125147

ATC: L01XC08

NCI: C1857

Drugnum: 933

 [b] [n] (11) (13) (41)
Therapeutic Head and Neck cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Colorectal cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
243 panobacumab 8888 100
(2008)		 62
(2009)		 Aerumab 11,
KBPA-101,
KBPA101		 IG Homo sapiens IgM - kappa

8888 serotype IATS O11 [Pseudomonas aeruginosa] ;
serotype IATS O11 [Gram negative bacteria] 		Homo sapiens Kenta Biotech Ltd (Berne Switzerland) Therapeutic Pseudomonas aeruginosa, hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa
(Treatment)
Phase II Infectiology 1 studies found, 0 recruiting (97)
407 patritumab 9549 106
(2011)		 68
(2012)		 AMG888,
U3-1287		 IG Homo sapiens IgG1 - kappa

9549 ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3) [Homo sapiens] Daiichi Sankyo Inc. (Edison NJ USA) / U3 Pharma (Martinsried Germany) Solid tumors Phase II Oncology 4 studies found, 2 recruiting
275 pegsunercept 8241 87
(2002)		 49
(2003)		 PEG sTNF-RI RPI Homo sapiens TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly 1A, TNF-RI, p55, CD120a) soluble form (TNF- binding protein 1)

TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Rheumatoid arthritis (RA) Phase II Immunology 3 studies found, 0 recruiting
429 placulumab 9567 107
(2011)		 69
(2013)		 ART621,
CEP-37247,
Dom-0200,
PN0621		 IG Homo sapiens [V kappa]2 - IGHG1 Fc

9567 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Teva Pharmaceutical Industries Ltd (Cephalon)0 (Frazer PA USA) Lombar radicular pain Immunology 3 studies found, 0 recruiting
Sciatica Phase II Immunology
270 pritumumab 8132 89
(2003)		 51
(2004)		 CLN G11 IG Homo sapiens IgG1 - nd

VIM (vimentin) [Homo sapiens] Unknown Cancers Oncology 0 studies found, 0 recruiting
370 radretumab 9340 104
(2010)		 66
(2011)		 L19-131 I ,
L19-SIP		 IG Homo sapiens [(scFv - heavy - kappa) - IGHE CH4]2

9340 fibronectin extra domain B (ED-B) [Homo sapiens] Phylogen (Sovicille Italy) Therapeutic Lymphoproliferative disease Phase II Oncology 4 studies found, 0 recruiting
Therapeutic Solid tumors Phase II Oncology
94 rafivirumab 9052 99
(2008)		 61
(2009)		 CR57 IG Homo sapiens IgG1 - lambda

9052 glycoprotein G (RVG) antigenic site I [Rabies virus] EBV immortalizaion Homo sapiens Crucell (CN Leiden Netherlands) Therapeutic Rabies post-exposure ( use in combination (Prophylaxis)) Phase II Immunology, Infectiology 0 studies found, 0 recruiting (27) [98]
446 ramatercept 9606 108
(2012)		 ACE-031 FPIA Homo sapiens ACVRL1 (activin A receptor type II-like 1, activin receptorlike kinase 1, ALK1, ALK-1, serine/threonine-protein kinase receptor R3, SKR3, transforming growth factor-beta superfamily receptor type I, TGF-B superfamily receptor type I, TSR-I, HHT2, ORW2) - IGHG1 Fc

9606 Acceleron Pharma, Inc (Cambridge UK) Muscle wasting Myology 0 studies found, 0 recruiting
295 ramucirumab 9098 100
(2008)		 62
(2009)		 1121B,
IMC-1121B,
LY3009806		 IG Homo sapiens IgG1 - kappa

9098 3s34
3s36
3s37		 KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309) [Homo sapiens] Homo sapiens Eli Lilly (Indianapolis IN USA) / ImClone Systems Inc. (Somerville NJ USA) Therapeutic Non-small cell lung cancers (NSCLC) Phase III Oncology 34 studies found, 10 recruiting [p]
ImClone Systems Inc. (Somerville NJ USA) Therapeutic Solid tumors Phase II Oncology
Therapeutic Gastric cancers Phase III Oncology
Therapeutic Colorectal cancers Phase III Oncology
Therapeutic Tumor vasculature Phase I Oncology
Therapeutic Breast cancers Phase II Oncology
260 raxibacumab 8580 92
(2004)		 54
(2005)		 ABthrax® IG Homo sapiens IgG1 - lambda

anthrax protective antigen (PA) [Bacillus anthracis] GlaxoSmithKline (Brentford UK) / Human Genome Sciences Inc. (HGSI) (Rockville MD USA) Anthrax inhalation
(Treatment)
Phase M FDA approval December 14, 2012 Infectiology 1 studies found, 0 recruiting (98) (122)
197 regavirumab 7250 71
(1994)		 35
(1995)		 C23,
MCA C23,
TI-23		 IG Homo sapiens IgG1 - kappa

HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human herpesvirus 5] Human hybridoma Homo sapiens Teijin Ltd. (Tokyo Japan) Therapeutic Cytomegalovirus (CMV) pneumonia in bone marrow transplantation Phase II Infectiology 3 studies found, 1 recruiting [e] (92)
Therapeutic Cytomegalovirus (CMV) retinitis in HIV individuals Phase II Infectiology
Therapeutic Cytomegalovirus (CMV) infections Phase II Infectiology
217 rilonacept 8750 95
(2006)		 57
(2007)		 ARCALYST™ FPIA Homo sapiens Interleukin-1 receptor accessory protein (IL1RAP)-type 1 interleukin-1 receptor-IGHG1 Fc

8750 IL1A (interleukin 1 alpha, IL-1A) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic Autoinflammatory diseases Immunology 18 studies found, 3 recruiting FDA: (BLA) 125249

ATC: L04AC04

 [p] (30)
Therapeutic Cryopyrin-Associated Periodic Syndromes (CAPS)
(Treatment)
(including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS))		 Phase M FDA approval February 27, 2008 Hereditary inflammatory diseases, Immunology
Therapeutic Osteoarthritis (OA) Immunology
Therapeutic Rheumatoid arthritis (RA) Immunology
302 rilotumumab 9123 101
(2009)		 63
(2010)		 IG Homo sapiens IgG2 - nd

9123 HGF (hepatocyte growth factor, scatter factor, SF, hepatopoeitin A) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Cancers Phase II Oncology 14 studies found, 7 recruiting
296 robatumumab 9092 100
(2008)		 62
(2009)		 19D12,
SCH 717454,
SCH717454		 IG Homo sapiens IgG1 - kappa

9092 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens Medarex (Princeton NJ USA) Therapeutic Colon sarcoma Phase II Oncology 4 studies found, 0 recruiting (74)
Therapeutic Blood cancers Preclinical Immunology, Oncology
355 roledumab 9335 103
(2010)		 65
(2011)		 LFB-R593 DMATRIA™ IG Homo sapiens IgG1 - kappa

9335 RHD (Rhesus blood group D antigen, RhD, CD240D) [Homo sapiens] Laboratoire Français du fractionnement et des Biotechnologies (LFB) (Courtabœuf France) Therapeutic prevention of feto-maternal allo-immunization in RhD- women Phase II Immunology 1 studies found, 0 recruiting [67]
393 romiplostim 8587 97
(2007)		 59
(2008)		 AMG531,
rINN,
USAN		 Nplate® CPCA Homo sapiens IGHG1 Fc - peptide 41 AA (dimer)

Amgen (Thousand Oaks CA USA) Idiopathic thrombocytopenic purpura
(Prevention)
Phase M FDA approval August 22, 2008 Immunology 49 studies found, 8 recruiting FDA: (BLA) 125268

REMS

ATC: B02BX04

 (71)
400 sarilumab 9476 106
(2011)		 68
(2012)		 REGN88,
SAR153191		 IG Homo sapiens IgG1 - kappa

9476 IL6R (interleukin 6 receptor, IL-6R, CD126) [Homo sapiens] Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) / Sanofi-Aventis (Paris France) Ankylosing spondylitis (AS) Phase II/III Immunology 12 studies found, 3 recruiting
Rheumatoid arthritis (RA) Phase II/III Immunology
326 secukinumab 9182 102
(2009)		 64
(2010)		 AIN457 IG Homo sapiens IgG1 - kappa

9182 IL17A (interleukin 17A, IL-17A) [Homo sapiens] Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Ankylosing spondylitis (AS) Phase III Immunology 49 studies found, 15 recruiting
Therapeutic Rheumatoid arthritis (RA) Phase III Immunology
Therapeutic Psoriasis Phase III Immunology
455 seribantumab 9710 108
(2012)		 MM121,
SAR256212		 IG Homo sapiens IgG2 - lambda

9710 ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3) [Homo sapiens] Sanofi-Aventis (Paris France) Therapeutic Non-small cell lung cancers (NSCLC)
(Treatment)
Phase II Oncology 9 studies found, 8 recruiting
Therapeutic Breast cancers
(Treatment)
Phase II Oncology
Therapeutic Solid tumors
(Treatment)
Phase I Oncology
Therapeutic Ovarian cancers
(Treatment)
Phase II Oncology
83 sevirumab 6560 66
(1991)		 32
(1992)		 EV2 7,
MSL 109,
MSL-109,
MSL109,
SDZ MSL 109		 PROTOVIR™ IG Homo sapiens IgG1 - kappa

HCMV (human cytomegalovirus) envelope glycoprotein H (gH) [Human herpesvirus 5] Mus musculus Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Cytomegalovirus (CMV) retinitis in HIV individuals Phase II Infectiology 6 studies found, 0 recruiting [a] (93)
Therapeutic Cytomegalovirus (CMV) pneumonia in bone marrow transplantation Phase II Infectiology
Therapeutic Cytomegalovirus (CMV) infections Phase II Infectiology
322 sifalimumab 9135 101
(2009)		 63
(2010)		 MDX-1103,
MEDI-545		 IG Homo sapiens IgG1 - kappa

9135 IFNA1 (interferon alpha1, IFN alpha, IFN alpha 1/13, IFN 13) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Therapeutic Polymyositis
(Treatment)
Phase I Immunology 8 studies found, 1 recruiting
Therapeutic Systemic lupus erythematosus (SLE)
(Treatment)
Phase II Immunology
Therapeutic Dermatomyositis
(Treatment)
Phase I Immunology
384 sirukumab 9431 105
(2011)		 67
(2012)		 CNTO 136 IG Homo sapiens IgG1 - kappa

9431 IL6 (interleukin 6, IL-6) [Homo sapiens] Centocor Inc. (Horsham PA USA) Lupus nephritis Phase II Immunology 8 studies found, 4 recruiting
Rheumatoid arthritis (RA) (Despite Methotrexate Therapy) Phase II Immunology
331 sotatercept 9188 102
(2009)		 64
(2010)		 ACE-011 FPIA Homo sapiens ACVR2A (activin receptor type 2a, activin receptor type IIA ) - IGHG1 Fc

9188 INHBA (inhibin beta A, activin A) [Homo sapiens] Acceleron Pharma, Inc (Cambridge UK) / Celgene corporation (Summit USA) Therapeutic Bone loss, in cancer Phase I Oncology 11 studies found, 6 recruiting NCI: C80038
Therapeutic Anemia, chemotherapy-induced (CIA) Phase II Hematology
Therapeutic Anemia, in chronic kidney disease-related (CKD) Phase II Hematology
192 stamulumab 8683 94
(2005)		 56
(2006)		 MYO-029 IG Homo sapiens IgG1 - nd

MSTN (myostatin, growth differentiation factor 8, GDF8) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Wyeth Pharmaceuticals (Madison NJ USA) Therapeutic Muscular dystrophy Phase I/II Myology 2 studies found, 0 recruiting
385 tabalumab 9430 105
(2011)		 67
(2012)		 LY2127399 IG Homo sapiens IgG4 - kappa

9430 TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] Eli Lilly (Indianapolis IN USA) Systemic lupus erythematosus (SLE) Phase III Immunology 20 studies found, 4 recruiting
Multiple myeloma (MM) Phase I Hematology, Immunology, Oncology
Connective tissue disease Phase III Immunology
Autoimmune diseases Phase III Immunology
336 teprotumumab 9107 101
(2009)		 63
(2010)		 IG Homo sapiens IgG1 - nd

9107 IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Unknown Unknown Unknown 0 studies found, 0 recruiting
392 torapsel 8337 91
(2004)		 53
(2005)		 42-89-glycoprotein,
pMT21:PL85,
WAY164339		 CPCA Homo sapiens SELPLG (selectin P glycoprotein ligand, PSGL-1, CD162) - IGHG1 Fc

SELP (P-selectin, CD62) [Homo sapiens] Homo sapiens Wyeth Pharmaceuticals (Madison NJ USA) Unknown Unknown 1 studies found, 0 recruiting (76)
171 tralokinumab 9235 102
(2009)		 64
(2010)		 CAT-354 IG Homo sapiens IgG1 - lambda

9235 IL13 (interleukin 13, IL-13) [Homo sapiens] Homo sapiens MedImmune Inc. (Gaithersburg MD USA) Therapeutic Asthma, severe
(Treatment)
Phase II Immunology 9 studies found, 2 recruiting (42)
408 trebananib 9468 106
(2011)		 68
(2012)		 2xCon4C,
AMG 386		 CPCA Homo sapiens IGHG1 Fc - (peptide 14-mer -peptide 14-mer) dimer

ANGPT2 (Ang2, angiopoietin 2) [Homo sapiens] Amgen (Thousand Oaks CA USA) Endometrial cancer Phase II Immunology 31 studies found, 17 recruiting (72) (73)
248 tremelimumab 8716 94
(2005)		 59
(2008)		 CP-675206 IG Homo sapiens IgG2 - nd

CTLA4 (cytotoxic T lymphocyte-associated antigen 4, CD152) [Homo sapiens] Homo sapiens 11.2.1 Abgenix (Fremont CA USA) / Pfizer (New York NY USA) Therapeutic Melanoma Oncology 10 studies found, 2 recruiting NCI: C49085
169 tuvirumab 6559 66
(1991)		 32
(1992)		 anti-hepatitis B IG Homo sapiens IgG1 - lambda

HBV (hepatitis B virus) [Hepatitis B virus] Homo sapiens PDL (Protein Design Labs) BioPharma (Fremont CA USA) Therapeutic Hepatitis B, chronic infection causing end-stage renal disease in liver transplant patients Phase I/II Infectiology 75 studies found, 7 recruiting [e]
Therapeutic Hepatitis B (Chronic active) Phase II Infectiology
373 urelumab 9365 104
(2010)		 66
(2011)		 IG Homo sapiens IgG4 - kappa

9365 TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137) [Homo sapiens] Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Tumors Phase II Oncology 7 studies found, 2 recruiting NCI: C62449
172 ustekinumab 8954 99
(2008)		 61
(2009)		 CNTO 1275,
TT-20		 STELARA™ IG Homo sapiens IgG1 - kappa

8954 IL12B (interleukin 12 beta, IL-12B, IL12 p40, CMLF2, NKSF2) p40 subunit common to IL12 and IL23 [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) / Medarex (Princeton NJ USA) Therapeutic Psoriasis Phase M FDA approval September 25, 2009, EMA approval January 16, 2009 Immunology 39 studies found, 14 recruiting FDA: (BLA) 125261

REMS

EMA: H-C-958

ATC: L04AC05

 (74)
Therapeutic Multiple sclerosis (MS) Phase II Immunology
Therapeutic Crohn's disease (CD) Phase III Immunology
Therapeutic Inflammation Phase III Immunology
398 vanutide cridificar 8947 100
(2008)		 62
(2009)		 ACC-001 CPCA Homo sapiens inactivated diphteria toxin CRM 197 (carrier) - β amyloid 42

Janssen Pharmaceuticals, inc. (Titusville NJ USA) / Pfizer (New York NY USA) Alzheimer's disease Phase II Neurology 9 studies found, 3 recruiting
374 vesencumab 9380 104
(2010)		 66
(2011)		 MNRP1685A IG Homo sapiens IgG1 - kappa

9380 NRP1 (neuropilin 1, NRP, vascular endothelial cell growth factor 165 receptor, VEGF165 receptor, VEGF165R, CD304) extracellular domain [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Therapeutic Solid tumors Phase I Oncology 2 studies found, 0 recruiting
199 votumumab 7165 70
(1993)		 34
(1994)		 Technetium (99mTc) votumumab HumaSPECT® IG Homo sapiens IgG3 - kappa

radiolabelled with Technetium-99m, Tc-99m		 carcinoma associated antigen CTAA16 (complex of cytokeratin polypeptides - 35-40kDa) [Homo sapiens] Homo sapiens 88-BV59 KS Biomedix Ltd (Guildford UK) / Organon Teknika Corp. (Durham NC USA) Therapeutic Colon cancers Withdrawn EC withdrawal (Not renewed by KS Biomedix) September 24, 2003, EC approval September 25, 1998 Oncology 0 studies found, 0 recruiting [d] (31) (39)
Therapeutic Rectal cancers Withdrawn EC withdrawal (Not renewed by KS Biomedix) September 24, 2003, EC approval September 25, 1998 Oncology
200 zalutumumab 8605 93
(2005)		 55
(2006)		 HuMax-EGFr HuMaX-EGFR™ IG Homo sapiens IgG1 - kappa

EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) Therapeutic Head and Neck cancers Phase III Oncology 10 studies found, 0 recruiting NCI: C64620
201 zanolimumab 8298 90
(2004)		 52
(2004)		 HuMax-CD4 HuMax-CD4® IG Homo sapiens IgG1 - kappa

CD4 (p55) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / TenX BioPharma (Philadelphia USA) Therapeutic Non-cutaneous T cell lymphoma (NCTCL) Phase II Oncology 7 studies found, 0 recruiting
Mycoisis fungoides or Sezary syndrome Phase III Infectiology
Therapeutic Cutaneous T cell lymphoma (CTCL) Phase III Oncology
8 ziralimumab 8061 84
(2000)		 46
(2001)		 ABX-RB2 IG Homo sapiens IgM - nd

BSG (basigin, Ok blood group, CD147) [Homo sapiens] Homo sapiens Abgenix (Fremont CA USA) Therapeutic Solid organ transplantation Preclinical Immunology 0 studies found, 0 recruiting (41)
Therapeutic Graft-versus-host disease (GvHD) Preclinical Immunology
Therapeutic Autoimmune diseases Preclinical Immunology
435 17C7 IG Homo sapiens IgG1 - nd

glycoprotein G (RVG) antigenic site III or minor site A [Rabies virus] transgenic HuMAb-Mouse® (Medarex) Mus musculus Massachusetts Biologic Laboratories (Jamaica Plain MA USA) Rabies post-exposure (Prophylaxis) Phase I Immunology, Infectiology [99]
99 4D5 and UCHT1,
trastuzumab coupled with UCHT1 F(ab')2		 IG Homo sapiens
Mus musculus
Hybrid		 IgG1 - kappa / F(ab')2

CD3E (CD3 epsilon) [Homo sapiens] ;
ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] ;
bispecific [Homo sapiens] 		Mus musculus Charing Cross Sunley Research Centre (UK) / Genentech Inc. (S. San Francisco CA USA) / ICRF (UK) Cancers (overexpressing ERBB2) Oncology [c] (36) [42]
444 AB65,
AbXTL65,
HepeX-C (AB68 only, or combination of AB68 and AB65)		 IG Homo sapiens IgG1 - nd

(HCV) envelope protein E2 [Hepatitis C virus] EBV immortalizaion XTL Biopharmaceuticals (Herzliya Israel) Hepatitis C reinfection in liver transplant patients
(Treatment)
Phase I Infectiology (107)
443 AB68,
AbXTL68,
HepeX-C (AB68 only, or combination of AB68 and AB65)		 IG Homo sapiens IgG1 - nd

(HCV) envelope protein E2 [Hepatitis C virus] Human hybridoma XTL Biopharmaceuticals (Herzliya Israel) Hepatitis C reinfection in liver transplant patients
(Treatment)
Phase I Infectiology (107)
Hepatitis C
(Treatment)
(chronic (Prophylaxis))		 Phase II Infectiology
163 ABX-IL8 IG Homo sapiens IgG2 - nd

IL8 (interleukin 8, IL-8) [Homo sapiens] Homo sapiens Abgenix (Fremont CA USA) Rheumatoid arthritis (RA) Phase II Immunology [a] [b] (11)
Psoriasis Phase II Immunology
Melanoma Preclinical Oncology
Angiogenesis Preclinical Oncology
166 AGS-PSCA,
MK-4721		 IG Homo sapiens IgG1 - kappa

PSCA (prostate stem cell antigen) [Homo sapiens] Homo sapiens Agensys (Santa Monica CA USA) / Merck & Co., Inc. (Whitehouse Station NJ USA) Bladder cancers Phase I Oncology [p] (59)
Pancreatic cancers Phase I Oncology
Prostate cancers Phase I Oncology
167 AL-901 IG Homo sapiens

IgE Fc [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) Allergic rhinitis Phase II Immunology [e]
Allergic asthma Phase II Immunology
442 CCR5mAb004,
HGS004		 IG Homo sapiens IgG4 - nd

CCR5 (chemokine (C-C) receptor 5, CD195) [Homo sapiens] Abgenix XenoMouse Human Genome Sciences Inc. (HGSI) (Rockville MD USA) Therapeutic HIV-1 infection, AIDS
(Treatment)
Phase I Infectiology (105)
438 CR3014 IG Homo sapiens IgG1 - nd

spike S1 fragment (318-510) receptor binding protein (RBD) [SARS coronavirus] Immune human scFv phage display library Crucell (CN Leiden Netherlands) SARS (severe acute respiratory syndrome) infection (use in combination) Infectiology [100]
439 CR3022 IG Homo sapiens IgG1 - nd

spike S1 fragment (318-510) receptor binding protein (RBD) [SARS coronavirus] Immune human scFv phage display library Crucell (CN Leiden Netherlands) SARS (severe acute respiratory syndrome) infection (use in combination) Infectiology [100]
437 CR4374 IG Homo sapiens IgG1 - nd

WNV (West Nile Virus) domain III [West Nile virus] Immune human Ab phage display library Crucell (CN Leiden Netherlands) West Nile Virus Infection Infectiology
445 HuMax-HepC,
LU54107		 IG Homo sapiens IgG1 - nd

(HCV) envelope protein E2 [Hepatitis C virus] EBV immortalizaion Genmab A/S (Copenhagen Denmark) Hepatitis C Preclinical Infectiology
177 HuMax-IL15 IG Homo sapiens

IL15 (interleukin 15, IL-15) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / Immunex Corporation Amgen (Thousand Oaks CA USA) Inflammatory arthritis diseases Phase I/II Immunology
Celiac disease Phase I/II Immunology
Psoriasis Phase I/II Immunology
228 HuMax-TAC™ Homo sapiens

IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) Transplant rejection Preclinical Immunology
Autoimmune disorders Preclinical Immunology
181 J695 IG Homo sapiens

IL12A (interleukin 12 alpha, IL-12A, IL12 p35, CMLF1, NKSF1) [Homo sapiens] Homo sapiens BASF (Ludwigshafen Germany) / Cambridge Antibody Technology (Cambridge UK) (US) Multiple sclerosis (MS) Immunology [12]
Crohn's disease (CD) Immunology
Rheumatoid arthritis (RA) Immunology
185 MDX-33 Homo sapiens

FCGR1 (immunoglobulin G Fc receptor high affinity I, Fc gamma RI, CD64, encoded by human FCGR1A, FCGR1B, FCGR1C) [Homo sapiens] Homo sapiens CSL Behring (King of Prussia PA USA) / Medarex (Princeton NJ USA) Autoimmune diseases Phase I Immunology [a] [b] (74)
Idiopathic thrombocytopenic purpura Phase I Hematology
187 MOR101 IG Homo sapiens Fab - nd - nd

ICAM1 (intercellular adhesion molecule 1, ICAM-1, CD54) [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Deep dermal burn Preclinical Dermatology [n] (22)
188 MOR102 IG Homo sapiens Fab - G4 - nd

ICAM1 (intercellular adhesion molecule 1, ICAM-1, CD54) [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Psoriasis Preclinical Immunology [n] (22)
189 MOR103 Homo sapiens

Homo sapiens MorphoSys (Martinsried/Pla Germany) Rheumatoid arthritis (RA) Phase I Immunology [n] (22)
190 MOR202 IG Homo sapiens IgG1 - nd

CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10) [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Therapeutic Multiple myeloma (MM) Preclinical Hematology, Immunology, Oncology [n] (22)
191 MORAb-028 IG Homo sapiens IgM - nd

ganglioside GD2 a cell surface antigen glycolipid [Homo sapiens] CMC Biopharmaceuticals (Copenhagen Denmark) / Morphotek Inc. (Exton PA USA) Melanoma Oncology [p]
195 OST 577 OSTAVIR™ Homo sapiens

HBV (hepatitis B virus) [Hepatitis B virus] Homo sapiens Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Hepatitis B Phase II Infectiology [a]
82 PRO-542 (rCD4-IgG2) FPIA Homo sapiens

HIV-1 (human immunodeficiency virus) gp120 [Human immunodeficiency virus 1] Genzyme Corp. (Cambridge MA USA) / Progenics Pharmaceuticals Inc. (Tarrytown NY USA) HIV-1 infection, AIDS Phase I/II Infectiology (113)
440 TI-57,
TI57,
V3		 IG Homo sapiens IgG1 - nd

(VZV) envelope glycoprotein H (gH, gpIII, gp118) [Human herpesvirus 3] Human hybridoma Teijin Ltd. (Tokyo Japan) Varicella zoster Infectiology (103)
434 rsv13/19 IG Homo sapiens Fab - G1 - kappa

human G1-kappa Fab combinatorial phage display library Unknown Unknown Unknown [97]
340 Hu-Max-CD32b™ IG Homo sapiens IgG1 - kappa

FCGR2B (immunoglobulin G Fc receptor low affinity IIb, Fc gamma RIIb, CD32, CD32b) [Homo sapiens] Genmab A/S (Copenhagen Denmark) Lymphoma Oncology
Cancers Preclinical Oncology
Chronic lymphocytic leukemia (CLL) Hematology, Oncology

up

Antibodies and immunoadhesins approved for therapeutic or diagnostic use and on the market (in 2013)

Number of results: 40

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT receptor type Species IG class and subclass or IG format FPIA, RPI, CPCA chain identification Conjugated/ Radiolabelled IMGT/2Dstructure-DB IMGT/3Dstructure-DB Specificity target name
[species]		 Development Technology Origin clone species Origin clone name Company Application Clinical indication Development status Regulatory agency status and year Expression system Clinical domain Clinical trials FDA / EMA / NCI number or ATC code Citations/ Notes/ References Biosimilars
212 abatacept 8495 91
(2004)		 53
(2005)		 BMS-188667,
CTLA4-Ig		 ORENCIA® FPIA Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)-IGHG1 Fc

CD80 (B7-1, CD28LG1) [Homo sapiens] ;
CD86 (B7-2, CD28LG2) [Homo sapiens] 		Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval December 23, 2005 CHO (Chinese Hamster Ovary) cells Immunology 133 studies found, 43 recruiting FDA: (BLA) 125118

ATC: L04AA24

Drugnum: 888

 [j] [n] (16) (30)
Therapeutic Psoriasis Phase I CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Juvenile Idiopathic Arthitis Phase M sBLA August 01, 2008 Immunology
Therapeutic Graft-versus-host disease (GvHD) (solid organ transplant) Phase I CHO (Chinese Hamster Ovary) cells Immunology
146 abciximab 7200 70
(1993)		 34
(1994)		 c7E3 REOPRO® IG Chimeric Fab - G1 - kappa

ITGA2B_ITGB3 (integrin alpha2b_beta3, integrin αIIbβ3, GPIIbIIIa, fibrinogen receptor, CD41_CD61) [Homo sapiens] Mus musculus 7E3 Centocor Inc. (Horsham PA USA) / Eli Lilly (Indianapolis IN USA) Therapeutic Refractory unstable angina when percutaneous coronary intervention is planned Phase M FDA approval November 05, 1997 Sp2/0 mouse myeloma cells Cardiology 60 studies found, 9 recruiting FDA: (BLA) 103575

Drugnum: 332

 [a] [b] [e] [f] [j]
Therapeutic Anti-platelet prevention of blood clots in the setting of high risk percutaneous transluminal coronary angioplasty Phase M FDA approval December 16, 1993 Sp2/0 mouse myeloma cells Cardiology
165 adalimumab 7860 82
(1999)		 44
(2000)		 D2E7 HUMIRA® (EU/US)
TRUDEXA® (EU) 		IG Homo sapiens IgG1 - kappa

7860 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Abbott Laboratories (Abbott Park IL USA) Therapeutic Juvenile Idiopathic Arthitis Phase M FDA approval February 21, 2008 Immunology 304 studies found, 116 recruiting FDA: (BLA) 125057

REMS

EMA: H-C-481

ATC: L04AB04

Drugnum: 814

 [a] [j] (12)
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval August 28, 2006 Immunology
Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval January 18, 2008 Immunology
Abbott Laboratories (Abbott Park IL USA) (EU/US) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval December 31, 2002 CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval October 03, 2005 CHO (Chinese Hamster Ovary) cells Immunology
Abbott Laboratories (Abbott Park IL USA) Therapeutic Crohn's disease (CD) (if inadequate response to conventional therapy) Phase M FDA approval February 27, 2010 Immunology
214 aflibercept 8739 95
(2006)		 57
(2007)		 VEGF Trap,
VEGF Trap R1/R2,
VEGF-trapR1,
VEGF-TRAPR1R2		 ZALTRAP™
EYLEA® 		FPIA Homo sapiens FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1 VEGFR, FLT, RFT, vascular permeability factor receptor) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, FLK1, CD309) - IGHG1 Fc

8739 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic Age-related macular degeneration (AMD), neovascular (wet) Phase M FDA approval (EYLEA®) July 18, 2011 Ophthalmology 94 studies found, 40 recruiting FDA: (BLA) 125387 (Eylea®)


FDA: (BLA) 125418 (Zaltrap™)

 [p] (30)
Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) / Sanofi-Aventis (Paris France) Colorectal cancers, metastatic Phase M FDA approval (ZALTRAP®) August 03, 2012 Oncology
Therapeutic Ovarian cancers Phase II Oncology
215 alefacept 8059 84
(2000)		 46
(2001)		 CD58-Fc,
LFA3-Fc		 AMEVIVE® FPIA Homo sapiens CD58 (LFA3, lymphocyte function associated antigen 3)-IGHG1 Fc

CD2 (lymphocyte function-antigen 2, LFA-2) [Homo sapiens] Homo sapiens Biogen Canada Inc. (Mississauga ON Canada) Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval January 31, 2003 CHO (Chinese Hamster Ovary) cells Immunology 42 studies found, 3 recruiting FDA: (BLA) 125036

ATC: L04AA15

Drugnum: 820

 [j] [n] (30)
11 alemtuzumab 8005 83
(2000)		 45
(2001)		 Campath-1H,
LDP-03		 CAMPATH® (US)
MABCAMPATH® (EU)
LEMTRADA™ 		IG Humanized IgG1 - kappa

8005 1bey
1ce1		 CD52 [Homo sapiens] Rattus norvegicus YTH34.5HL Berlex Inc. (Wayne NJ USA) (US) / Genzyme Corp. (Cambridge MA USA) (EU) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) (EU/US) Therapeutic Multiple sclerosis (MS) Phase I/II CHO (Chinese Hamster Ovary) cells Immunology 285 studies found, 97 recruiting FDA: (BLA) 103948

ATC: L01XC04

NCI: C1681

Drugnum: 702

 [a] [b] [c] (109) [19] [75] [76] [77] [78] [79] [80] [81] [82] [83]
Therapeutic Kidney transplant rejection Phase I/II CHO (Chinese Hamster Ovary) cells Immunology
Therapeutic Chronic lymphocytic leukemia (CLL) Phase M FDA approval May 07, 2001 CHO (Chinese Hamster Ovary) cells Hematology, Oncology
Sanofi-Aventis (Paris France) Therapeutic Multiple sclerosis (MS) Phase III Immunology
148 basiliximab 7578 76
(1996)		 38
(1997)		 CHI621 SIMULECT® IG Chimeric IgG1 - kappa

3iu3
1mim		 IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, CD25) [Homo sapiens] Mus musculus CHI621 Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Organ transplant rejection, acute
(Prevention)
Phase M FDA approval May 12, 1998 Immunology 107 studies found, 42 recruiting FDA: (BLA) 103764

ATC: L04AC02

Drugnum: 440

 [a] [b] [d] [f] [j] (53) [56]
Therapeutic Kidney transplant rejection, acute
(Prevention)
Phase M FDA approval January 02, 2003 Immunology
266 belimumab 8381 89
(2003)		 51
(2004)		 hBlySmAb-1.1,
LymphoStat-B		 BENLYSTA® IG Homo sapiens IgG1 - lambda

TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, B cell activating factor, BAFF, TALL1, BLyS, B lymphocyte activator, CD257) [Homo sapiens] GlaxoSmithKline (Brentford UK) / Human Genome Sciences Inc. (HGSI) (Rockville MD USA) Therapeutic Systemic lupus erythematosus (SLE) Phase M FDA approval March 10, 2011 Immunology 34 studies found, 18 recruiting FDA: (BLA) 125370

ATC: L04AA26

 (82)
258 besilesomab 8451 92
(2004)		 54
(2005)		 BW250/183 SCINTIMUN® (EU) IG Mus musculus IgG1 - kappa

radiolabelled with Technetium-99m, Tc-99m		 CEACAM8 (carcinoembryonic antigen-related cell adhesion molecule 8, NCA-95, nonspecific cross-reacting antigen 95 kDa, granulocyte cell antigen, CGM6, CD66b) [Homo sapiens] Iba Molecular Imaging (Louvain-la-Neuve Belgium) Diagnostic Peripheral bone infections Phase M EMA approval January 11, 2010 Osteology 1 studies found, 1 recruiting EMA: H-C-001045
Diagnostic Diagnosis of ostomyelitis Phase M EMA approval January 11, 2010 Osteology
Diagnostic Bone marrow scintigraphy Phase M EMA approval January 11, 2010 Osteology
24 bevacizumab 8017 83
(2000)		 45
(2001)		 12-IgG1,
F(ab)-12 IgG1,
Fab-12 IgG1,
rhuMAb-VEGF		 AVASTIN® IG Humanized IgG1 - kappa

8017 1bj1 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) (EU) Therapeutic Colorectal cancers, metastatic Phase M FDA approval February 26, 2004 CHO (Chinese Hamster Ovary) cells Oncology 1591 studies found, 190 recruiting FDA: (BLA) 125085

ATC: L01XC07

Drugnum: 851

 [a] [b] (20)
Therapeutic Glioblastoma Phase M FDA approval February 08, 2011 Oncology
Therapeutic Non-small cell lung cancers, metastatic Phase M FDA approval October 11, 2006 CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Renal cell carcinoma (RCC) Phase M FDA approval July 31, 2009 Oncology
Therapeutic Breast cancers (metastatic ERB2 negative) Phase M FDA approval February 22, 2008 CHO (Chinese Hamster Ovary) cells Oncology
324 brentuximab vedotin 9144 103
(2010)		 65
(2011)		 cAC10-Val-Cit-MMAE,
SGN-35		 ADCETRIS™ IG Chimeric IgG1 - kappa conjugated with monomethyl auristatin E (MMAE)

 9144 TNFRSF8 (tumor necrosis factor receptor (TNFR) superfamily member 8, CD30) [Homo sapiens] Mus musculus AC10, mAC10 (IgG2b) Seattle genetics, Inc. (Bothell WA USA) Therapeutic Cutaneous T cell lymphoma (CTCL) with mycosis fungoides (MF) or Sezary syndrome Phase II Oncology 42 studies found, 24 recruiting FDA: (BLA) 125388


FDA: (BLA) 125399

 (79)
Therapeutic Hodgkin lymphoma Phase M FDA approval August 19, 2011 Oncology
Therapeutic Anaplastic large cell lymphoma (ALCL) Phase M FDA approval August 19, 2011 Oncology
244 canakinumab 8836 97
(2007)		 59
(2008)		 ACZ885 ILARIS® IG Homo sapiens IgG1 - kappa

8836 IL1B (interleukin 1 beta, IL-1B) [Homo sapiens] Homo sapiens Novartis (Basel Switzerland) Therapeutic Rheumatoid arthritis (RA) Immunology 59 studies found, 17 recruiting FDA: (BLA) 125319

ATC: L04AC08
Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Cryopyrin-Associated Periodic Syndromes (CAPS) (including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 4 and older) Phase M FDA approval June 17, 2009 Hereditary inflammatory diseases, Immunology
115 capromab 7201 70
(1993)		 34
(1994)		 7E11-C5.3 radiolabelled,
capromab pendetide,
Indium In1111 ProstaScint®		 PROSTASCINT® IG Mus musculus IgG1 - kappa conjugated with chelator pendetide (GYK-DPTA)

radiolabelled with Indium-111, In-111		 FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA) [Homo sapiens] Mus musculus 7E11-C5.3 EUSA Pharma (Doylestown PA USA) Diagnostic Prostate cancers Phase M FDA approval October 28, 1996 Oncology 5 studies found, 1 recruiting FDA: (BLA) 103608

 [b] [d] [n] (31)
218 catumaxomab 8406 93
(2005)		 55
(2006)		 Mus mus. anti-EPCAM (Ho-3/TP-A-01/TPBs01) G2a kappa / Rat sp. anti-CD3E (26/II/6-1.2/TPBs01) G2b lambda,
TPBs01		 REMOVAB® IG Mus musculus
Rattus sp.
Hybrid		 IgG2a - kappa / G2b - lambda

CD3E (CD3 epsilon) [Homo sapiens] ;
EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] ;
bispecific [Homo sapiens] 		Fresenius Biotech GmbH (Bad Homburg Germany) / TRION Pharma (Munich Germany) Therapeutic Gastric cancers Phase II/III EC Orphan drug November 03, 2006 Oncology 14 studies found, 5 recruiting ATC: L01XC09

 [o] (28) (36)
Therapeutic Malignant ascites Phase M EMA approval April 20, 2009 Oncology
Therapeutic Ovarian cancers Phase II/III Oncology
242 certolizumab pegol 8448 90
(2004)		 52
(2004)		 CDP870,
PHA-738144		 CIMZIA® IG Humanized Fab' - nd - nd conjugated with pegol

 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval May 13, 2009 Immunology 80 studies found, 26 recruiting FDA: (BLA) 125160

REMS

ATC: L04AB05

 (80)
Therapeutic Crohn's disease (CD) Phase M FDA approval April 22, 2008 Immunology
151 cetuximab 7906 82
(1999)		 44
(2000)		 Fab C225,
IMC-225		 ERBITUX® IG Chimeric IgG1 - kappa

7906 1yy8
1yy9		 EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Mus musculus C225 ImClone Systems Inc. (Somerville NJ USA) (US) / Merck & Co., Inc. (Whitehouse Station NJ USA) (EU) Therapeutic Colorectal cancers, metastatic (EGFR positive) Phase M FDA approval February 12, 2004 Sp2/0 mouse myeloma cells Oncology 606 studies found, 183 recruiting FDA: (BLA) 125084

ATC: L01XC06

NCI: C1723

Drugnum: 850

 [a] [b] [e] [j]
37 eculizumab 8231 87
(2002)		 49
(2003)		 5G1.1,
h5G1.1,
h5G1.1HuG2/G4		 SOLIRIS™ IG Humanized IgG2 / G4 - kappa

C5 (complement 5) [Homo sapiens] Mus musculus Alexion Pharmaceuticals Inc. (New Haven CT USA) Therapeutic Paroxysmal nocturnal hemoglobinuria (PNH) Phase M FDA approval March 16, 2007 Hematology 45 studies found, 18 recruiting FDA: (BLA) 125166

REMS

ATC: L04AA25

NCI: C48386

Drugnum: 945

 [a] [b] (81)
Therapeutic Rheumatoid arthritis (RA) Phase II Immunology
Therapeutic Nephritis Phase II Urology
Therapeutic Psoriasis Phase I/II Immunology
Therapeutic Dermatomyositis Phase I/II Immunology
119 edrecolomab 7471 74
(1995)		 36
(1996)		 17-1A PANOREX® IG Mus musculus IgG2a - kappa

EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, EpCAM, CD326) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Colon cancers Phase M approval (Germany) January 01, 1995 Sp2/0 mouse myeloma cells Oncology 5 studies found, 2 recruiting ATC: L01XC01

NCI: C1554

 [a] [e] [90]
216 etanercept 7783 81
(1999)		 43
(2000)		 TNFR-immunoadhesin,
TNFRSF1B-Fc		 ENBREL® FPIA Homo sapiens TNFRSF1B (tumor necrosis factor receptor (TNFR) superfamily member 1B, TNFBR, p75, CD120b) - IGHG1 Fc

7783 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Immunex Corporation Amgen (Thousand Oaks CA USA) Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval February 15, 2002 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Immunology 315 studies found, 79 recruiting FDA: (BLA) 103795

REMS

ATC: L04AB01

Drugnum: 737

 [f] [j] [n] (15) (30)
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval November 02, 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Immunology
175 golimumab 8497 91
(2004)		 53
(2005)		 CNTO 148 SIMPONI™ IG Homo sapiens IgG1 - kappa

TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval April 24, 2009 Immunology 45 studies found, 18 recruiting FDA: (BLA) 125289

REMS

ATC: L04AB06
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval April 24, 2009 Immunology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval April 24, 2009 Immunology
122 ibritumomab tiuxetan 7873 81
(1999)		 43
(2000)		 In-111 Zevalin,
Y-90 Zevalin		 ZEVALIN® IG Mus musculus IgG1 - kappa conjugated with chelator tiuxetan

radiolabelled with Yttrium-90, Y-90 (Therapeutic) and Indium-111, In-111 (Diagnostic)		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus IDEC-Y2B8 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Schering AG (Berlin Germany) Therapeutic Non-Hodgkin's lymphoma (NHL) Phase M FDA approval February 19, 2002 CHO (Chinese Hamster Ovary) cells Oncology 99 studies found, 32 recruiting FDA: (BLA) 125019

 [j] [n] (31)
156 infliximab 7602 77
(1997)		 39
(1998)		 cA2,
TA-650		 REMICADE® IG Chimeric IgG1 - kappa

7602 TNF (tumor necrosis factor TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA) [Homo sapiens] Mus musculus A2 Janssen Biotechn Inc. (Horsham PA USA) Therapeutic Psoriasis, severe chronic plaque Phase M FDA approval September 26, 2006 Immunology 332 studies found, 100 recruiting FDA: (BLA) 103772

REMS

ATC: L04AB02

NCI: C1789

Drugnum: 703

Drugnum: 759

 [a] [b] [d] [f] [j] (83) (84) [53] [54] REMSIMA™, developed by Celltrion, Inc. (Incheon Korea), (CT-P13, biosimilar of REMICADE®), approved by KFDA on July 23, 2012, same clinical indications as REMICADE®
Therapeutic Ulcerative colitis (UC) Phase M FDA approval September 15, 2005 Immunology
Therapeutic Psoriatic arthritis (PSA) Phase M FDA approval May 18, 2005 Immunology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval November 10, 1999 Immunology
Therapeutic Ankylosing spondylitis (AS) Phase M FDA approval December 17, 2004 Immunology
Therapeutic Crohn's disease (CD)
(Treatment)
Phase M FDA approval August 24, 1998 Immunology
366 mogamulizumab 9374 104
(2010)		 66
(2011)		 AMG-761,
KM8761,
KW-0761		 POTELIGEO® IG Humanized IgG1 - kappa

9374 CCR4 (chemokine C-C motif receptor 4, chemokine CC receptor 4, CCR-4, CKR4, k5-5, CD194) [Homo sapiens] Amgen (Thousand Oaks CA USA) Therapeutic Asthma Phase I Immunology 10 studies found, 3 recruiting NCI: C62510

 (51) (90) [73]
Kyowa Hakko Kirin (Tokyo Japan) Therapeutic Peripheral T/NK cell lymphoma Phase II Hematology, Oncology
Therapeutic Adult T cell leukemia / lymphoma Phase M MHLW approval March 30, 2012 Hematology, Oncology
Therapeutic Peripheral T cell lymphoma and cutaneous T cell lymphoma Phase I/II Oncology
132 muromonab-CD3 6281 59
(1988)		 29
(1989)		 OKT3 ORTHOCLONE OKT3® IG Mus musculus IgG2a - kappa

1sy6 CD3E (CD3 epsilon) [Homo sapiens] Mus musculus Centocor Ortho Biotech Products LP (Raritan NJ USA) Therapeutic Heart transplant rejection (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology 46 studies found, 7 recruiting FDA: (BLA) 103463

ATC: L04AA02

NCI: C1321

 [a] [b] [d] [j] [n]
Therapeutic Liver transplantation (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology
Therapeutic Acute kidney transplant rejection (reversal) Phase M FDA approval September 14, 1992 Murine ascites, hybridoma Immunology
75 natalizumab 7716 79
(1998)		 41
(1999)		 AN100226 TYSABRI®
ANTEGREN® (formerly) 		IG Humanized IgG4 - nd

ITGA4 (integrin alpha4 subunit, CD49d) [Homo sapiens] Mus musculus AN100226m, MAb 21.6 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Elan Pharmaceuticals International Ltd. (Dublin Ireland) Therapeutic Colitis Phase II Immunology 65 studies found, 21 recruiting FDA: (BLA) 125104

ATC: L04AA23

Drugnum: 869

 [a] [b] [c] [e] [j] [k] (3) (4) [7]
Therapeutic Crohn's disease (CD) Phase M FDA approval January 14, 2008 NSO mouse myeloma cells Immunology
Therapeutic Multiple sclerosis (MS) Phase M FDA SBLA reintroduced June 05, 2006, Market suspension (three patients developed progressive multifocal leukoencephalopathy (PML)) February 28, 2005, FDA approval November 23, 2004 NSO mouse myeloma cells Immunology
Therapeutic Inflammatory conditions, acute and chronic COS cells transient expression Immunology
76 nimotuzumab 8545 94
(2005)		 56
(2006)		 hR3,
Theraloc		 THERACIM® (India, China, Cuba, Argentina, Columbia) IG Humanized IgG1 - kappa

3gkw EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Mus musculus YM BioSciences Inc. (Mississauga Canada) Therapeutic Pancreatic cancers, metastatic Phase II Oncology 38 studies found, 22 recruiting NCI: C2733

 [n]
Therapeutic Pancreatic cancers Phase M EMA Orphan drug June 03, 2008 NSO mouse myeloma cells Oncology
Therapeutic Lung cancers Phase II Oncology
Therapeutic Gastric cancers Phase II Oncology
Therapeutic Glioma cancers Phase M EMA withdrawal December 04, 2008, EMA Orphan drug September 02, 2004 NSO mouse myeloma cells Oncology
Therapeutic Head and Neck cancers Phase M NSO mouse myeloma cells Oncology
194 ofatumumab 8606 93
(2005)		 55
(2006)		 HuMax-CD20® ARZERRA™ IG Homo sapiens IgG1 - kappa

MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / GlaxoSmithKline (Brentford UK) Therapeutic Non-Hodgkin's lymphoma (NHL) (combination study) Phase III Oncology 92 studies found, 57 recruiting FDA: (BLA) 125326

ATC: L01XC10

NCI: C66952
Therapeutic Rheumatoid arthritis (RA) Phase III Immunology
Therapeutic Chronic lymphocytic leukemia (CLL) (Refractory) Phase M FDA approval October 26, 2009, sBLA April 01, 2009 Hematology, Oncology
77 omalizumab 8039 84
(2000)		 46
(2001)		 IGE25,
olizumab,
pSVIE26,
rhuMab-E25		 XOLAIR® IG Humanized IgG1 - kappa

8039 IgE Fc [Homo sapiens] Mus musculus MaE11 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) Therapeutic Asthma, severe persistent (allergic asthma) Phase M FDA approval (for subcutaneous use) June 20, 2003 CHO (Chinese Hamster Ovary) cells Immunology 111 studies found, 26 recruiting FDA: (BLA) 103976

REMS

NCI: C29299

 [a] [b] [l]
79 palivizumab 7753 79
(1998)		 41
(1999)		 MEDI-493 SYNAGIS® IG Humanized IgG1 - kappa

glycoprotein F RSV [Respiratory syncytial virus] Mus musculus Abbott Laboratories (Abbott Park IL USA) (EU) / MedImmune Inc. (Gaithersburg MD USA) (US) Therapeutic Respiratory Syncytial Virus (RSV) disease
(Treatment)
(Prophylaxis in high risk infants)		 Phase M AMM Market authorization (Abbott) August 01, 1999, FDA approval June 19, 1998 NSO mouse myeloma cells Infectiology, Pulmonary, Respiratory diseases 23 studies found, 5 recruiting FDA: (BLA) 103770

NCI: C2625

Drugnum: 447

 [a] [b] [d] [j] [49]
196 panitumumab 8499 91
(2004)		 53
(2005)		 ABX-EGF,
E7.6.3		 VECTIBIX™ IG Homo sapiens IgG2 - kappa

EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Therapeutic Colorectal cancers, metastatic Phase M FDA approval September 27, 2006 CHO (Chinese Hamster Ovary) cells Oncology 161 studies found, 79 recruiting FDA: (BLA) 125147

ATC: L01XC08

NCI: C1857

Drugnum: 933

 [b] [n] (11) (13) (41)
Therapeutic Head and Neck cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
Therapeutic Colorectal cancers Phase III CHO (Chinese Hamster Ovary) cells Oncology
80 pertuzumab 8380 89
(2003)		 51
(2004)		 OMNITARG™,
rhuMAB 2C4		 PERJETA™ IG Humanized IgG1 - kappa

8380 1l7i
1s78		 ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Therapeutic Prostate cancers Phase II Oncology 41 studies found, 21 recruiting FDA: (BLA) 125409

NCI: C38692
Therapeutic Breast cancers Phase M FDA approval June 08, 2012 Oncology
84 ranibizumab 8313 90
(2004)		 52
(2004)		 Fab-12 variant Y0317,
RhuFab		 LUCENTIS® IG Humanized Fab - G1 - kappa

8313 1cz8 VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Therapeutic Age-related macular degeneration (AMD), neovascular (wet) Phase M FDA approval June 30, 2006 E.coli (Escherichia coli) Ophthalmology 316 studies found, 104 recruiting FDA: (BLA) 125156

Drugnum: 904
260 raxibacumab 8580 92
(2004)		 54
(2005)		 ABthrax® IG Homo sapiens IgG1 - lambda

anthrax protective antigen (PA) [Bacillus anthracis] GlaxoSmithKline (Brentford UK) / Human Genome Sciences Inc. (HGSI) (Rockville MD USA) Anthrax inhalation
(Treatment)
Phase M FDA approval December 14, 2012 Infectiology 1 studies found, 0 recruiting (98) (122)
217 rilonacept 8750 95
(2006)		 57
(2007)		 ARCALYST™ FPIA Homo sapiens Interleukin-1 receptor accessory protein (IL1RAP)-type 1 interleukin-1 receptor-IGHG1 Fc

8750 IL1A (interleukin 1 alpha, IL-1A) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Therapeutic Autoinflammatory diseases Immunology 18 studies found, 3 recruiting FDA: (BLA) 125249

ATC: L04AC04

 [p] (30)
Therapeutic Cryopyrin-Associated Periodic Syndromes (CAPS)
(Treatment)
(including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS))		 Phase M FDA approval February 27, 2008 Hereditary inflammatory diseases, Immunology
Therapeutic Osteoarthritis (OA) Immunology
Therapeutic Rheumatoid arthritis (RA) Immunology
161 rituximab 7609 77
(1997)		 39
(1998)		 IDEC-C2B8 MABTHERA®
RITUXAN® (US, Canada and Japan) 		IG Chimeric IgG1 - kappa

7609 1l6x
2osl		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus IDEC-C2B8 CureTech (Yavne Israel) / IDEC Pharmaceuticals, Inc. (San Diego USA CA) Therapeutic Chronic lymphocytic leukemia (CLL) (CD20-positive, in combination with fludaraline and cyclophosphamide (FC) ) Phase M FDA approval (orphan drug) February 18, 2010 Hematology, Oncology 1275 studies found, 187 recruiting FDA: (BLA) 103705


FDA: (BLA) 103737

ATC: L01XC02

NCI: C1702

Drugnum: 349

 [a] [b] [d] [f] [j] [q] (18) (49) [55]
Genentech Inc. (S. San Francisco CA USA) / IDEC Pharmaceuticals, Inc. (San Diego USA CA) Therapeutic Non-Hodgkin's lymphoma (NHL)
(Treatment)
(follicular, CD20 positive, relapsed or refractory low grade)		 Phase M FDA approval November 01, 1997 Oncology
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval February 28, 2006 Immunology
Therapeutic Wegener's Granulomatosis (WG) and Microscopic Polygamiitis (MPA), in combination with glucocorticoides Phase M FDA approval April 19, 2011 Hematology
393 romiplostim 8587 97
(2007)		 59
(2008)		 AMG531,
rINN,
USAN		 Nplate® CPCA Homo sapiens IGHG1 Fc - peptide 41 AA (dimer)

Amgen (Thousand Oaks CA USA) Idiopathic thrombocytopenic purpura
(Prevention)
Phase M FDA approval August 22, 2008 Immunology 49 studies found, 8 recruiting FDA: (BLA) 125268

REMS

ATC: B02BX04

 (71)
96 tocilizumab 8394 90
(2004)		 52
(2004)		 atlizumab,
MRA,
rhPM-1		 ACTEMRA™
RoACTEMRA® (EU) 		IG Humanized IgG1 - kappa

8394 IL6R (interleukin 6 receptor, IL-6R, CD126) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Tokyo Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) Therapeutic Multiple myeloma (MM) CHO (Chinese Hamster Ovary) DHFR cells Hematology, Immunology, Oncology 292 studies found, 123 recruiting FDA: (BLA) 125276

REMS

EMA: H-C-955

ATC: L04AC07

 [c] (5) [38] [84] [85]
Therapeutic Rheumatoid arthritis (RA) Phase M FDA approval January 08, 2010, EMA approval January 16, 2009, Approval (by Japan) April 17, 2008 CHO (Chinese Hamster Ovary) DHFR cells Immunology
Diagnostic, Therapeutic Systemic juvenile idiopathic athritis (SJIA) Phase M FDA approval (sBLA) April 15, 2011 Immunology
Therapeutic Lymphoproliferative disorder giant lymph node hyperplasia (Castleman's disease) Phase III Approval (by Japan) June 01, 2005, NDA approval April 01, 2005 CHO (Chinese Hamster Ovary) DHFR cells Oncology
142 tositumomab 7827 80
(1998)		 42
(1999)		 BEXXAR® IG Mus musculus IgG2a - lambda

radiolabelled with Iodine-131, I-131		 MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20) [Homo sapiens] Mus musculus Corixa Corp. (Seattle WA USA) / GlaxoSmithKline (Brentford UK) Therapeutic Non-Hodgkin's lymphoma (NHL) (follicular, CD20 positive, following chemotherapy relapse) Phase M FDA approval June 27, 2003 Hybridoma Oncology 98 studies found, 21 recruiting FDA: (BLA) 125011

NCI: C2543

Drugnum: 834

 [j] [n] (31)
97 trastuzumab 7637 78
(1997)		 40
(1998)		 4D5V8,
Herceptin		 HERCEPTIN® IG Humanized IgG1 - kappa

7637 1n8z ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] Mus musculus 4D5 F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Genentech Inc. (S. San Francisco CA USA) (US) Therapeutic Breast cancers overexpressing ERBB2, metastatic Phase M AMM Market authorization (Roche) August 01, 2000, FDA approval September 01, 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Oncology 554 studies found, 174 recruiting FDA: (BLA) 103792

ATC: L01XC03

NCI: C1647

Drugnum: 485

 [a] [b] [d] [e] [j] [48]
Genentech Inc. (S. San Francisco CA USA) Therapeutic Gastric cancers Phase M FDA approval October 20, 2010 Oncology
172 ustekinumab 8954 99
(2008)		 61
(2009)		 CNTO 1275,
TT-20		 STELARA™ IG Homo sapiens IgG1 - kappa

8954 IL12B (interleukin 12 beta, IL-12B, IL12 p40, CMLF2, NKSF2) p40 subunit common to IL12 and IL23 [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) / Medarex (Princeton NJ USA) Therapeutic Psoriasis Phase M FDA approval September 25, 2009, EMA approval January 16, 2009 Immunology 39 studies found, 14 recruiting FDA: (BLA) 125261

REMS

EMA: H-C-958

ATC: L04AC05

 (74)
Therapeutic Multiple sclerosis (MS) Phase II Immunology
Therapeutic Crohn's disease (CD) Phase III Immunology
Therapeutic Inflammation Phase III Immunology

up

IMGT citations:
[a] Mike's Immunoglobulin Structure/Function: Antibodies for Therapeutic Applications.
[b] PhRMA: New Medicines in Development: Biotechnology: A 2000Survey.
[c] José Saldanha http://people.cryst.bbk.ac.uk/~ubcg07s/selhum.html
[d] Biopharmaceutical Benchmarks, Nature Biotechnology,18, 831-833 (2000).
[e] The antibodies, vol 6, ed. Zanetti M. and Capra J.D., Harwood academic publishers, Amsterdam, The Netherlands, pp 4-8 (2000).
[f] Information provided by Mitchell Reff, IDEC Pharmaceuticals.
[g] Schopf, R.E., Curr. Opin. Investig. Drugs, 2, 635-638 (2001).
[h] CLL Topics .
[i] Rosenwasser, L.J. et al., J. Allergy Clin. Immunol., 112, 563-570 (2003).
[j] Marie-Paule Lefranc, IMGT (26/12/2005).
[k] Information provided by Tarran Jones (08/02/2002) and from the AERES Biomedical web site (08/01/2004).
[l] Information from the Tanox Inc. web site (08/01/2004).
[m] Krietman RJ et al. PNAS 87, 8291-8295 (1990).
[n] Yan Wu and Marie-Paule Lefranc, IMGT (20/12/2006).
[o] Yan Wu and Marie-Paule Lefranc, IMGT, following information from Christian Behrens. (20/04/2007).
[p] Yan Wu and Marie-Paule Lefranc, IMGT (29/06/2007).
[q] Flavio Forrer, Highlights 2003 Medecine nucleaire:177Lu-DOTA-rituximab
[r] Correlation of TweakR Expression with Her2+ Ductal Breast Cancer and the Preclinical Therapeutic Effect of PDL192, a Humanized anti-TweakR antibody
[s] mAb BT-061
[t] Results from a Phase I Study of MLTA3698A, a Novel Anti-Lymphotoxin-a Monoclonal Antibody: Safety, Tolerability and Biologic Activity in Patients with Active Rheumatoid Arthritis.
[u] The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
[v] ALX-0081 a Novel Anti-Thrombotic: Results of a Single-Dose Phase 1 Study in Healthy Volunteers and Further Development in Patients with Stable Angina Undergoing PCI
IMGT glossary:
AMM: Autorisation de Mise sur le Marché (Market authorization)
ATC: Anatomical Therapeutic Chemical code
Drugnum: Database contains a listing of drugs approved by the Food and Drug Administration (FDA)
EC: European Commission
EMA: European Medicines Agency for the Evaluation of Medical Products
FDA: Food and Drug Administration
MHLW: Japan Ministry of Health, Labour and Welfare
NCI: National Cancer Institute
NDA: New Drug Application
NDC code: National Drug Code
REMS: Risk Evaluation and Mitigation Strategy
sBLA: Supplemental Biologics License Application
IMGT notes:
(1) Since the monoclonal antibody is type-specific it will be limited to certain patients.
(2) A different epitope is recognized by YFC51.1 and 60.3.
(3) Later Celltech produced IgG4.
(4) Stable expressing cell line made at Celltech (UK).
(5) A different epitope is recognized by PM-1.
(6) IgG4 has an amino acid change S241>P to allow complete disulfide bridge formation at the hinge.
(7) HMFG (Human Milk Fat Globule).
(8) Original mouse mAb from Tanox, Inc. (TX).
(9) BEC2 is an anti-idiotypic mAb. By mimicking the GD3 tumour associated antigen, BEC2 appears to stimulate a stronger immune response than natural GD3.
(10) Surface granulocyte nonspecific cross-reacting antigen.
(11) Human Ig from transgenic XenoMouse (Abgenix).
(12) Human antibodies derived from phage display human antibody libraries.
(13) Biopharmaceuticals in the U.S. and European Markets New entries in the 4th edition.
(14) No more information on 23/02/02. Development seems halted.
(15) Fusion protein of the soluble ligand-binding domain of the tumor necrosis factor receptor p75 (TNFrp75) and of the Fc of a human IgG1.
(16) Cytotoxin T lymphocyte-associated antigen 4-Immunoglobulin G1 fragment fusion protein.
(17) Calicheamicin is a cytotoxin antitumor antibiotic, isolated from fermentation of a bacterium, Micromonospora echino spora, ssp. calichensis .
(18) Rituximab proprietary name is RITUXAN® in the USA, Canada and Japan, and MABTHERA® in the other countries.
(19) Previously Techniclone Corp.
(20) The VH domain of ranibizumab (1cz8) differs from the VH domain of bevacizumab (1bj1) by four amino acid changes: VH [CDR1-IMGT: T29>D, N36>H, CDR3-IMGT: H109>Y, S112.2>T] and the V-KAPPA domain by one amino acid change M4>L.
(21) Clenoliximab derives from keliximab. The two antibodies share the same variable domains. In June 1997, IDEC and SmithKline Beecham suspended a clinical trial of a different anti-CD4 antibody (PRIMATIZED? IDEC-CE9.1). In that trial, CD4 cell depletion was noted in a subset of patients, though no serious side effects were reported. The constant human IGHG1 from keliximab has been changed to human IGHG4. Moreover the IGHG4 contains two amino acid changed S10>P (hinge) and L1.2>E (CH2), according to the IMGT unique numbering [57].
(22) Generated from HuCAL? (Human Combinatorial Antibody Library).
(23) J591 is a deimmunized antibody (Biovation, Ltd., Lonza Biologics, Plc.), chelated with DOTA (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) (BZL biologics, Inc., Framingham, MA, USA) for allowing labelling with 177Lu, 90Y and 111In (Vallabhajosula S. et al., J Nucl Med., 46, 634-641 (2005))
(24) US patent 5863745.
(25) mAb covalently linked to 2-3 molecules of calicheamicin.
(26) motavizumab derived from palivizumab.
(27) used with foravirumab/rafivirumab in cocktail.
(28) Hybrid: A hybrid antibody is one in which one-half of the antibody (one heavy chain and one light chain) is from one species origin whereas the other half is from another species origin.
An hybrid antibody is identified by a pre-stem made of each species pre-stem separated by the letter 'x' in the INN. For example, a rat-murine hybrid antibody is identified by the pre-stem -axo-.
(29) Immunotoxin: An immunotoxin is an antibody linked to a toxin.
(30) Immunoadhesin: An immunoadhesin is a protein constituted of binding domain(s) (usually from a receptor, ligand, or cell-adhesion molecule) linked to immu